en Chris mungall Erica Marcos Ningxian Fan Paul Fabry Randi Vita Ryan R. Brinkman Shunzhou Deng Alan Ruttenburg Alexander D. Diehl Amogh Madireddi Anna Maria Masci Anthony Huffman Barry Smith Bjoern Peters Edison Ong Ellen Zhang Hong Yu Jason Hu Jie Zheng Kallan Roan Khadeejah Khan Lindsay Cowell Melanie Courtot Ningxian Fan Omar Tibi Philip Huang Randi Vita Rebecca Racz Richard H. Scheuermann Rohit Goru Ronak Sutariya Samantha G. Sayers (SGS) Taiyu Lin Thomas Todd Xingxian Li Yongqun "Oliver" He (YH) Yu Lin (YL) Yuanyi (Penny) Pan Yuping Zheng Zuoshuang "Allen" Xiang A view of Vaccine Ontology (VO) with a focus on the modeling and representation of various cancer vaccines. OWL-DL Vaccine Ontology Cancer Vaccine View 2024-09-22 Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification. Really of interest to developers only BFO OWL specification label Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2 Person:Alan Ruttenberg Really of interest to developers only BFO CLIF specification label editor preferred term The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> editor preferred term example of usage A phrase describing how a term should be used and/or a citation to a work which uses it. May also include other kinds of examples that facilitate immediate understanding, such as widely know prototypes or instances of a class, or cases where a relation is said to hold. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> example of usage has curation status PERSON:Alan Ruttenberg PERSON:Bill Bug PERSON:Melanie Courtot has curation status definition The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. 2012-04-05: Barry Smith The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. Can you fix to something like: A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. Alan Ruttenberg Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. On the specifics of the proposed definition: We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with. 2012-04-05: Barry Smith The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. Can you fix to something like: A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. Alan Ruttenberg Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. On the specifics of the proposed definition: We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> definition editor note An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. PERSON:Daniel Schober GROUP:OBI:<http://purl.obofoundry.org/obo/obi> editor note term editor Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people 20110707, MC: label update to term editor and definition modified accordingly. See https://github.com/information-artifact-ontology/IAO/issues/115. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> term editor alternative label A label for a class or property that can be used to refer to the class or property instead of the preferred rdfs:label. Alternative labels should be used to indicate community- or context-specific labels, abbreviations, shorthand forms and the like. OBO Operations committee PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> Consider re-defing to: An alternative name for a class or property which can mean the same thing as the preferred name (semantically equivalent, narrow, broad or related). alternative label definition source Formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 PERSON:Daniel Schober Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w GROUP:OBI:<http://purl.obolibrary.org/obo/obi> definition source curator note An administrative note of use for a curator but of no use for a user PERSON:Alan Ruttenberg curator note term tracker item the URI for an OBI Terms ticket at sourceforge, such as https://sourceforge.net/p/obi/obi-terms/772/ An IRI or similar locator for a request or discussion of an ontology term. Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg The 'tracker item' can associate a tracker with a specific ontology term. term tracker item ontology term requester The name of the person, project, or organization that motivated inclusion of an ontology term by requesting its addition. Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg The 'term requester' can credit the person, organization or project who request the ontology term. ontology term requester imported from For external terms/classes, the ontology from which the term was imported PERSON:Alan Ruttenberg PERSON:Melanie Courtot GROUP:OBI:<http://purl.obolibrary.org/obo/obi> imported from elucidation person:Alan Ruttenberg Person:Barry Smith Primitive terms in a highest-level ontology such as BFO are terms which are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms elucidation has associated axiom(nl) Person:Alan Ruttenberg Person:Alan Ruttenberg An axiom associated with a term expressed using natural language has associated axiom(nl) has associated axiom(fol) Person:Alan Ruttenberg Person:Alan Ruttenberg An axiom expressed in first order logic using CLIF syntax has associated axiom(fol) has axiom id Person:Alan Ruttenberg Person:Alan Ruttenberg A URI that is intended to be unique label for an axiom used for tracking change to the ontology. For an axiom expressed in different languages, each expression is given the same URI has axiom label ISA alternative term An alternative term used by the ISA tools project (http://isa-tools.org). Requested by Alejandra Gonzalez-Beltran https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891&atid=886178 Person: Alejandra Gonzalez-Beltran Person: Philippe Rocca-Serra ISA tools project (http://isa-tools.org) ISA alternative term IEDB alternative term An alternative term used by the IEDB. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IEDB alternative term A GeneID in the NCBI Gene database Oliver He, Yue Liu NCBI GeneID An assertion that holds between an OWL Object Property and a temporal interpretation that elucidates how OWL Class Axioms that use this property are to be interpreted in a temporal context. temporal interpretation S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX in_taxon: <http://purl.obolibrary.org/obo/RO_0002162> PREFIX present_in_taxon: <http://purl.obolibrary.org/obo/RO_0002175> CONSTRUCT { in_taxon: a owl:ObjectProperty . ?witness rdfs:label ?label . ?witness rdfs:subClassOf ?x . ?witness rdfs:subClassOf [ a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom ?taxon ] . } WHERE { ?x present_in_taxon: ?taxon . BIND(IRI(CONCAT( "http://purl.obolibrary.org/obo/RO_0002175#", MD5(STR(?x)), "-", MD5(STR(?taxon)) )) as ?witness) BIND(CONCAT(STR(?x), " in taxon ", STR(?taxon)) AS ?label) } The SPARQL expansion for this relation introduces new named classes into the ontology. For this reason it is likely that the expansion should only be performed during a QC pipeline; the expanded output should usually not be included in a published version of the ontology. present in taxon An annotation property that represents a matched vaccine identifier used in the VIOLIN database. Oliver He Omar Tibi VIOLIN vaccine ID An annotation property that refers to a specific CVX ID. Oliver He Penny Pan https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx CVX code An annotation property that shows the status of vaccine developmeint including: clinical trial, research, licensed, or Emergency Use Authorization (EUA). Anthony Huffman Jie Zheng Oliver He Penny Pan status of vaccine development An annotation property that represents an identifier of RxNorm or RxNorm extension concept assigned by OMOP. OMOP concept ID An annotation property that refers to full vaccine name in CVX code set. CVX full vaccine name An annotation property that refers to short description in CVX code set. CVX short description is part of my brain is part of my body (continuant parthood, two material entities) my stomach cavity is part of my stomach (continuant parthood, immaterial entity is part of material entity) this day is part of this year (occurrent parthood) a core relation that holds between a part and its whole Everything is part of itself. Any part of any part of a thing is itself part of that thing. Two distinct things cannot be part of each other. Occurrents are not subject to change and so parthood between occurrents holds for all the times that the part exists. Many continuants are subject to change, so parthood between continuants will only hold at certain times, but this is difficult to specify in OWL. See http://purl.obolibrary.org/obo/ro/docs/temporal-semantics/ Parthood requires the part and the whole to have compatible classes: only an occurrent can be part of an occurrent; only a process can be part of a process; only a continuant can be part of a continuant; only an independent continuant can be part of an independent continuant; only an immaterial entity can be part of an immaterial entity; only a specifically dependent continuant can be part of a specifically dependent continuant; only a generically dependent continuant can be part of a generically dependent continuant. (This list is not exhaustive.) A continuant cannot be part of an occurrent: use 'participates in'. An occurrent cannot be part of a continuant: use 'has participant'. A material entity cannot be part of an immaterial entity: use 'has location'. A specifically dependent continuant cannot be part of an independent continuant: use 'inheres in'. An independent continuant cannot be part of a specifically dependent continuant: use 'bearer of'. part_of part of http://www.obofoundry.org/ro/#OBO_REL:part_of has part my body has part my brain (continuant parthood, two material entities) my stomach has part my stomach cavity (continuant parthood, material entity has part immaterial entity) this year has part this day (occurrent parthood) a core relation that holds between a whole and its part Everything has itself as a part. Any part of any part of a thing is itself part of that thing. Two distinct things cannot have each other as a part. Occurrents are not subject to change and so parthood between occurrents holds for all the times that the part exists. Many continuants are subject to change, so parthood between continuants will only hold at certain times, but this is difficult to specify in OWL. See http://purl.obolibrary.org/obo/ro/docs/temporal-semantics/ Parthood requires the part and the whole to have compatible classes: only an occurrent have an occurrent as part; only a process can have a process as part; only a continuant can have a continuant as part; only an independent continuant can have an independent continuant as part; only a specifically dependent continuant can have a specifically dependent continuant as part; only a generically dependent continuant can have a generically dependent continuant as part. (This list is not exhaustive.) A continuant cannot have an occurrent as part: use 'participates in'. An occurrent cannot have a continuant as part: use 'has participant'. An immaterial entity cannot have a material entity as part: use 'location of'. An independent continuant cannot have a specifically dependent continuant as part: use 'bearer of'. A specifically dependent continuant cannot have an independent continuant as part: use 'inheres in'. has_part has part realized in this disease is realized in this disease course this fragility is realized in this shattering this investigator role is realized in this investigation is realized by realized_in [copied from inverse property 'realizes'] to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003]) Paraphrase of elucidation: a relation between a realizable entity and a process, where there is some material entity that is bearer of the realizable entity and participates in the process, and the realizable entity comes to be realized in the course of the process realized in realizes this disease course realizes this disease this investigation realizes this investigator role this shattering realizes this fragility to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003]) Paraphrase of elucidation: a relation between a process and a realizable entity, where there is some material entity that is bearer of the realizable entity and participates in the process, and the realizable entity comes to be realized in the course of the process realizes has_specified_input see is_input_of example_of_usage The inverse property of is_specified_input_of 8/17/09: specified inputs of one process are not necessarily specified inputs of a larger process that it is part of. This is in contrast to how 'has participant' works. PERSON: Alan Ruttenberg PERSON: Bjoern Peters PERSON: Larry Hunter PERSON: Melanie Coutot has_specified_input is_specified_input_of some Autologous EBV(Epstein-Barr virus)-transformed B-LCL (B lymphocyte cell line) is_input_for instance of Chromum Release Assay described at https://wiki.cbil.upenn.edu/obiwiki/index.php/Chromium_Release_assay A relation between a planned process and a continuant participating in that process that is not created during the process. The presence of the continuant during the process is explicitly specified in the plan specification which the process realizes the concretization of. Alan Ruttenberg PERSON:Bjoern Peters is_specified_input_of has_specified_output The inverse property of is_specified_output_of PERSON: Alan Ruttenberg PERSON: Bjoern Peters PERSON: Larry Hunter PERSON: Melanie Courtot has_specified_output is_manufactured_by http://www.affymetrix.com/products/arrays/specific/hgu133.affx is_manufactered_by http://www.affymetrix.com/ (if we decide to use these URIs for the actual entities) c is_manufactured_by o means that there was a process p in which c was built in which a person, or set of people or machines did the work(bore the "Manufacturer Role", and those people/and or machines were members or of directed by the organization to do this. Alan Ruttenberg Liju Fan has_make has_manufacturer is_manufactured_by is_specified_output_of A relation between a planned process and a continuant participating in that process. The presence of the continuant at the end of the process is explicitly specified in the objective specification which the process realizes the concretization of. Alan Ruttenberg PERSON:Bjoern Peters is_specified_output_of achieves_planned_objective A cell sorting process achieves the objective specification 'material separation objective' This relation obtains between a planned process and a objective specification when the criteria specified in the objective specification are met at the end of the planned process. BP, AR, PPPB branch PPPB branch derived modified according to email thread from 1/23/09 in accordince with DT and PPPB branch achieves_planned_objective objective_achieved_by This relation obtains between an objective specification and a planned process when the criteria specified in the objective specification are met at the end of the planned process. OBI OBI objective_achieved_by inheres in this fragility is a characteristic of this vase this red color is a characteristic of this apple a relation between a specifically dependent continuant (the characteristic) and any other entity (the bearer), in which the characteristic depends on the bearer for its existence. inheres_in Note that this relation was previously called "inheres in", but was changed to be called "characteristic of" because BFO2 uses "inheres in" in a more restricted fashion. This relation differs from BFO2:inheres_in in two respects: (1) it does not impose a range constraint, and thus it allows qualities of processes, as well as of information entities, whereas BFO2 restricts inheres_in to only apply to independent continuants (2) it is declared functional, i.e. something can only be a characteristic of one thing. characteristic of bearer of this apple is bearer of this red color this vase is bearer of this fragility Inverse of characteristic_of A bearer can have many dependents, and its dependents can exist for different periods of time, but none of its dependents can exist when the bearer does not exist. bearer_of is bearer of has characteristic participates in this blood clot participates in this blood coagulation this input material (or this output material) participates in this process this investigator participates in this investigation a relation between a continuant and a process, in which the continuant is somehow involved in the process participates_in participates in has participant this blood coagulation has participant this blood clot this investigation has participant this investigator this process has participant this input material (or this output material) a relation between a process and a continuant, in which the continuant is somehow involved in the process Has_participant is a primitive instance-level relation between a process, a continuant, and a time at which the continuant participates in some way in the process. The relation obtains, for example, when this particular process of oxygen exchange across this particular alveolar membrane has_participant this particular sample of hemoglobin at this particular time. has_participant http://www.obofoundry.org/ro/#OBO_REL:has_participant has participant A journal article is an information artifact that inheres in some number of printed journals. For each copy of the printed journal there is some quality that carries the journal article, such as a pattern of ink. The journal article (a generically dependent continuant) is concretized as the quality (a specifically dependent continuant), and both depend on that copy of the printed journal (an independent continuant). An investigator reads a protocol and forms a plan to carry out an assay. The plan is a realizable entity (a specifically dependent continuant) that concretizes the protocol (a generically dependent continuant), and both depend on the investigator (an independent continuant). The plan is then realized by the assay (a process). A relationship between a generically dependent continuant and a specifically dependent continuant, in which the generically dependent continuant depends on some independent continuant in virtue of the fact that the specifically dependent continuant also depends on that same independent continuant. A generically dependent continuant may be concretized as multiple specifically dependent continuants. is concretized as A journal article is an information artifact that inheres in some number of printed journals. For each copy of the printed journal there is some quality that carries the journal article, such as a pattern of ink. The quality (a specifically dependent continuant) concretizes the journal article (a generically dependent continuant), and both depend on that copy of the printed journal (an independent continuant). An investigator reads a protocol and forms a plan to carry out an assay. The plan is a realizable entity (a specifically dependent continuant) that concretizes the protocol (a generically dependent continuant), and both depend on the investigator (an independent continuant). The plan is then realized by the assay (a process). A relationship between a specifically dependent continuant and a generically dependent continuant, in which the generically dependent continuant depends on some independent continuant in virtue of the fact that the specifically dependent continuant also depends on that same independent continuant. Multiple specifically dependent continuants can concretize the same generically dependent continuant. concretizes this catalysis function is a function of this enzyme a relation between a function and an independent continuant (the bearer), in which the function specifically depends on the bearer for its existence A function inheres in its bearer at all times for which the function exists, however the function need not be realized at all the times that the function exists. function_of is function of This relation is modeled after the BFO relation of the same name which was in BFO2, but is used in a more restricted sense - specifically, we model this relation as functional (inherited from characteristic-of). Note that this relation is now removed from BFO2020. function of this red color is a quality of this apple a relation between a quality and an independent continuant (the bearer), in which the quality specifically depends on the bearer for its existence A quality inheres in its bearer at all times for which the quality exists. is quality of quality_of This relation is modeled after the BFO relation of the same name which was in BFO2, but is used in a more restricted sense - specifically, we model this relation as functional (inherited from characteristic-of). Note that this relation is now removed from BFO2020. quality of this investigator role is a role of this person a relation between a role and an independent continuant (the bearer), in which the role specifically depends on the bearer for its existence A role inheres in its bearer at all times for which the role exists, however the role need not be realized at all the times that the role exists. is role of role_of This relation is modeled after the BFO relation of the same name which was in BFO2, but is used in a more restricted sense - specifically, we model this relation as functional (inherited from characteristic-of). Note that this relation is now removed from BFO2020. role of this enzyme has function this catalysis function (more colloquially: this enzyme has this catalysis function) a relation between an independent continuant (the bearer) and a function, in which the function specifically depends on the bearer for its existence A bearer can have many functions, and its functions can exist for different periods of time, but none of its functions can exist when the bearer does not exist. A function need not be realized at all the times that the function exists. has_function has function this apple has quality this red color a relation between an independent continuant (the bearer) and a quality, in which the quality specifically depends on the bearer for its existence A bearer can have many qualities, and its qualities can exist for different periods of time, but none of its qualities can exist when the bearer does not exist. has_quality has quality this person has role this investigator role (more colloquially: this person has this role of investigator) a relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence A bearer can have many roles, and its roles can exist for different periods of time, but none of its roles can exist when the bearer does not exist. A role need not be realized at all the times that the role exists. has_role has role a relation between an independent continuant (the bearer) and a disposition, in which the disposition specifically depends on the bearer for its existence has disposition inverse of has disposition This relation is modeled after the BFO relation of the same name which was in BFO2, but is used in a more restricted sense - specifically, we model this relation as functional (inherited from characteristic-of). Note that this relation is now removed from BFO2020. disposition of is location of my head is the location of my brain this cage is the location of this rat a relation between two independent continuants, the location and the target, in which the target is entirely within the location Most location relations will only hold at certain times, but this is difficult to specify in OWL. See http://purl.obolibrary.org/obo/ro/docs/temporal-semantics/ location_of location of located in my brain is located in my head this rat is located in this cage a relation between two independent continuants, the target and the location, in which the target is entirely within the location Location as a relation between instances: The primitive instance-level relation c located_in r at t reflects the fact that each continuant is at any given time associated with exactly one spatial region, namely its exact location. Following we can use this relation to define a further instance-level location relation - not between a continuant and the region which it exactly occupies, but rather between one continuant and another. c is located in c1, in this sense, whenever the spatial region occupied by c is part_of the spatial region occupied by c1. Note that this relation comprehends both the relation of exact location between one continuant and another which obtains when r and r1 are identical (for example, when a portion of fluid exactly fills a cavity), as well as those sorts of inexact location relations which obtain, for example, between brain and head or between ovum and uterus Most location relations will only hold at certain times, but this is difficult to specify in OWL. See http://purl.obolibrary.org/obo/ro/docs/temporal-semantics/ located_in http://www.obofoundry.org/ro/#OBO_REL:located_in located in This is redundant with the more specific 'independent and not spatial region' constraint. We leave in the redundant axiom for use with reasoners that do not use negation. This is redundant with the more specific 'independent and not spatial region' constraint. We leave in the redundant axiom for use with reasoners that do not use negation. 2017-11-05T03:26:47Z disease has basis in An object property that specifies a relation between a vaccine and a vaccinate route vaccinated in route A shortcut relation that is equivalent to: 'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine host role' and (role_of some 'organism' and has_disposition some disease)))))))). The domain of this relation is a vaccine. The range of this relation is a disease. Asiyah Yu Lin Oliver He immunization against disease vaccine immunization against disease immunizes against disease A shortcut relation that is equivalent to: 'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine recipient role' and (role_of some 'organism')))))))). The domain of this relation is a vaccine. The range of this relation is a organism. Anna Maria Masci Asiyah Yu Lin Barry Smith Jie Zheng Oliver He immunization for host immunization for recipient immunizes host vaccine immunization for host vaccine immunization for recipient immunizes recipient A shortcut relation that is equivalent to: processed material and (is_specified_output_of some vaccine preparation) and (has function some (vaccine function and (is realized by only (vaccine immunization and (realizes some ('immunization target role' and (role_of some 'pathogen')))))))) The domain of this relation is a vaccine. The range of this relation is a pathogen (a bacterium, a virus, a fungus, and a parasite) Ranges: organism and 'has role' some 'pathogen role' Oliver He immunization against pathogen immunizes against microbe vaccine immunization against pathogen https://github.com/vaccineontology/VO/issues/675 immunizes against pathogen continuant Continuant An entity that exists in full at any time in which it exists at all, persists through time while maintaining its identity and has no temporal parts. BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240 Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002]) if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001]) if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002]) if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002]) (forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] (forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] (forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] (forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] continuant Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002]) if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001]) if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002]) if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002]) (forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] (forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] (forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] (forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] occurrent Occurrent An entity that has temporal parts and that happens, unfolds or develops through time. BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players. Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process. Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame. An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002]) Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001]) b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001]) (forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] (forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] occurrent Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process. per discussion with Barry Smith Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame. An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002]) Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001]) b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001]) (forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] (forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] ic IndependentContinuant a chair a heart a leg a molecule a spatial region an atom an orchestra. an organism the bottom right portion of a human torso the interior of your mouth b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]) For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001]) For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002]) (forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] (forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] (iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] A continuant that is a bearer of quality and realizable entity entities, in which other entities inhere and which itself cannot inhere in anything. independent continuant b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]) For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001]) For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002]) (forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] (forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] (iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] s-region SpatialRegion BFO 2 Reference: Spatial regions do not participate in processes. Spatial region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn't overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional. A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001]) All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001]) (forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001] (forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001] spatial region Spatial region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn't overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional. per discussion with Barry Smith A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001]) All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001]) (forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001] (forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001] process Process a process of cell-division, \ a beating of the heart a process of meiosis a process of sleeping the course of a disease the flight of a bird the life of an organism your process of aging. p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war) (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] An occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. process p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] disposition Disposition an atom of element X has the disposition to decay to an atom of element Y certain people have a predisposition to colon cancer children are innately disposed to categorize objects in certain ways. the cell wall is disposed to filter chemicals in endocytosis and exocytosis BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type. b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002]) If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002]) (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] disposition b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002]) If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002]) (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] realizable RealizableEntity the disposition of this piece of metal to conduct electricity. the disposition of your blood to coagulate the function of your reproductive organs the role of being a doctor the role of this boundary to delineate where Utah and Colorado meet A specifically dependent continuant that inheres in continuant entities and are not exhibited in full at every time in which it inheres in an entity or group of entities. The exhibition or actualization of a realizable entity is a particular manifestation, functioning or process that occurs under certain circumstances. To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002]) All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002]) (forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] (forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] realizable entity To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002]) All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002]) (forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] (forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] quality Quality the ambient temperature of this portion of air the color of a tomato the length of the circumference of your waist the mass of this piece of gold. the shape of your nose the shape of your nostril a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001]) If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] quality a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001]) If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] sdc SpecificallyDependentContinuant Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key of one-sided specifically dependent continuants: the mass of this tomato of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates. the disposition of this fish to decay the function of this heart: to pump blood the mutual dependence of proton donors and acceptors in chemical reactions [79 the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction the pink color of a medium rare piece of grilled filet mignon at its center the role of being a doctor the shape of this hole. the smell of this portion of mozzarella b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]) Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc. (iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] A continuant that inheres in or is borne by other entities. Every instance of A requires some specific instance of B which must always be the same. specifically dependent continuant b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]) Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc. per discussion with Barry Smith (iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] role Role John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married. the priest role the role of a boundary to demarcate two neighboring administrative territories the role of a building in serving as a military target the role of a stone in marking a property boundary the role of subject in a clinical trial the student role A realizable entity the manifestation of which brings about some result or end that is not essential to a continuant in virtue of the kind of thing that it is but that can be served or participated in by that kind of continuant in some kinds of natural, social or institutional contexts. BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives. b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001]) (forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] role b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001]) (forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] site Site Manhattan Canyon) a hole in the interior of a portion of cheese a rabbit hole an air traffic control region defined in the airspace above an airport the Grand Canyon the Piazza San Marco the cockpit of an aircraft the hold of a ship the interior of a kangaroo pouch the interior of the trunk of your car the interior of your bedroom the interior of your office the interior of your refrigerator the lumen of your gut your left nostril (a fiat part – the opening – of your left nasal cavity) b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002]) (forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002] site b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002]) (forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002] gdc GenericallyDependentContinuant The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity. the pdf file on your laptop, the pdf file that is a copy thereof on my laptop the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule. b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]) (iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] A continuant that is dependent on one or other independent continuant bearers. For every instance of A requires some instance of (an independent continuant type) B but which instance of B serves can change from time to time. generically dependent continuant b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]) (iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] function Function the function of a hammer to drive in nails the function of a heart pacemaker to regulate the beating of a heart through electricity the function of amylase in saliva to break down starch into sugar BFO 2 Reference: In the past, we have distinguished two varieties of function, artifactual function and biological function. These are not asserted subtypes of BFO:function however, since the same function – for example: to pump, to transport – can exist both in artifacts and in biological entities. The asserted subtypes of function that would be needed in order to yield a separate monoheirarchy are not artifactual function, biological function, etc., but rather transporting function, pumping function, etc. A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001]) (forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] function A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001]) (forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] material MaterialEntity a flame a forest fire a human being a hurricane a photon a puff of smoke a sea wave a tornado an aggregate of human beings. an energy wave an epidemic the undetached arm of a human being An independent continuant that is spatially extended whose identity is independent of that of other entities and can be maintained through time. BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60 BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity. BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here. A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]) Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002]) every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]) (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] material entity A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]) Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002]) every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]) (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] immaterial ImmaterialEntity BFO 2 Reference: Immaterial entities are divided into two subgroups:boundaries and sites, which bound, or are demarcated in relation, to material entities, and which can thus change location, shape and size and as their material hosts move or change shape or size (for example: your nasal passage; the hold of a ship; the boundary of Wales (which moves with the rotation of the Earth) [38, 7, 10 immaterial entity A disease that is the consequence of the presence of pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, and aberrant proteins known as prions. infectious disease DOID:10115 DOID:11078 DOID:1304 DOID:1321 DOID:2040 DOID:2288 DOID:3099 DOID:4120 DOID:4620 DOID:5256 DOID:945 DOID:95 DOID:9532 DOID:9696 ICD9CM:079.0 UMLS_CUI:C0001485 infectious disease disease_ontology DOID:0050117 DO:wk disease by infectious agent An organ system cancer located_in the respiratory system that is characterized by uncontrolled cellular proliferation in the respiratory tract. disease_ontology DOID:0050615 respiratory system cancer A cancer that is classified based on the organ it starts in. snadendla 2011-06-13T03:28:33Z MESH:D009371 disease_ontology DOID:0050686 organ system cancer A cancer that is classified by the type of cell from which it is derived. snadendla 2011-06-13T03:28:50Z disease_ontology DOID:0050687 cell type cancer A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles. lschriml 2012-09-18T02:00:45Z GARD:6969 ICDO:9673/3 MESH:D020522 disease_ontology DOID:0050746 mantle cell lymphoma A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs. DOID:1033 DOID:353 ICD10CM:C85.9 ICDO:9590/3 MESH:D008223 NCI:C3208 NCI:C7065 SNOMEDCT_US_2023_03_01:118600007 SNOMEDCT_US_2023_03_01:414628006 UMLS_CUI:C0024299 UMLS_CUI:C0598798 lymphoid cancer disease_ontology DOID:0060058 lymphoma An immune system cancer that is located_in the lymphatic system and is characterized by uncontrolled cellular proliferation of lymphoid tissue. lschriml 2011-05-11T01:05:14Z disease_ontology DOID:0060073 lymphatic system cancer An organ system cancer located_in the immune system that is characterized by uncontrolled cellular proliferation in organs of the immune system. lschriml 2011-06-08T01:11:18Z ICDO:9392/3 disease_ontology DOID:0060083 immune system cancer An organ system cancer located_in the muscular and skeletal organs and characterized by uncontrolled cellular proliferation of the musculoskeletal organs. lschriml 2011-07-15T02:30:51Z DOID:0060124 skeletal system cancer disease_ontology DOID:0060100 musculoskeletal system cancer A disease of anatomical entity that is located_in the thoracic cavity. lschriml 2011-07-25T02:23:47Z disease_ontology DOID:0060118 thoracic disease A gastrointestinal system cancer that is located_in the pharynx. lschriml 2011-07-27T01:26:34Z MESH:D010610 NCI:C3325 SNOMEDCT_US_2023_03_01:126685009 UMLS_CUI:C0031347 pharyngeal neoplasm pharynx neoplasm disease_ontology pharyngeal cancer DOID:0060119 pharynx cancer A gastrointestinal system cancer that is located_in the hepatobiliary system. disease_ontology DOID:0080355 hepatobiliary system cancer An intestinal cancer that is located_in the small intestine. GARD:9385 ICD10CM:C17 ICD9CM:152.9 NCI:C7523 SNOMEDCT_US_2023_03_01:363509000 UMLS_CUI:C0153425 disease_ontology DOID:10154 small intestine cancer A gastrointestinal system cancer that is located_in the intestine. ICD10CM:C26.0 ICD9CM:159.0 MESH:D007414 NCI:C4572 SNOMEDCT_US_2023_03_01:93838000 UMLS_CUI:C0346627 malignant intestinal tumors malignant neoplasm of intestine disease_ontology DOID:10155 intestinal cancer A male reproductive organ cancer that is located_in the prostate. DOID:514 ICD10CM:C61 ICD9CM:185 KEGG:05215 MESH:D011471 MIM:176807 MIM:300147 MIM:300704 MIM:601518 MIM:602759 MIM:608656 MIM:608658 MIM:609299 MIM:609558 MIM:610321 MIM:610997 MIM:611100 MIM:611868 MIM:611928 MIM:611955 MIM:611958 MIM:611959 NCI:C3343 NCI:C7378 ORDO:1331 SNOMEDCT_US_2023_03_01:126906006 SNOMEDCT_US_2023_03_01:93974005 UMLS_CUI:C0033578 UMLS_CUI:C0376358 NGP - new growth of prostate hereditary prostate cancer malignant tumor of the prostate prostate cancer, familial prostate neoplasm prostatic cancer prostatic neoplasm tumor of the prostate disease_ontology DOID:10283 Xref MGI. OMIM mapping confirmed by DO. [SN]. prostate cancer A gastrointestinal system cancer that is located_in the stomach. DOID:10539 DOID:10542 DOID:10543 DOID:4713 GARD:7704 ICD10CM:C16 ICD10CM:C16.2 ICD10CM:C16.5 ICD10CM:C16.6 ICD9CM:151 ICD9CM:151.4 ICD9CM:151.5 ICD9CM:151.6 MESH:D013274 MIM:613659 NCI:C3387 NCI:C9331 SNOMEDCT_US_2023_03_01:126824007 SNOMEDCT_US_2023_03_01:269459004 SNOMEDCT_US_2023_03_01:269460009 SNOMEDCT_US_2023_03_01:93717002 SNOMEDCT_US_2023_03_01:94074003 UMLS_CUI:C0024623 UMLS_CUI:C0038356 UMLS_CUI:C0153421 UMLS_CUI:C0153422 UMLS_CUI:C0153423 gastric cancer gastric neoplasm disease_ontology DOID:10534 OMIM mapping confirmed by DO. [SN]. stomach cancer A female reproductive system disease that is located_in the ovary. MESH:D010049 NCI:C26841 SNOMEDCT_US_2023_03_01:5552004 UMLS_CUI:C0029928 disease_ontology DOID:1100 ovarian disease An urinary system cancer that results_in malignant growth located_in the urinary bladder. DOID:5428 GARD:12210 ICD10CM:C67 ICD9CM:188 KEGG:05219 MESH:D001749 MIM:109800 NCI:C2901 NCI:C9334 SNOMEDCT_US_2023_03_01:126885006 SNOMEDCT_US_2023_03_01:363455001 UMLS_CUI:C0005684 UMLS_CUI:C0005695 bladder cancer tumor of the bladder disease_ontology DOID:11054 OMIM mapping confirmed by DO. [SN]. urinary bladder cancer A cell type cancer that has_material_basis_in abnormally proliferating cells derives from embryonic mesoderm. DOID:3936 ICD10CM:C49 ICD9CM:171.9 ICDO:8800/3 SNOMEDCT_US_2023_03_01:93765001 UMLS_CUI:C0153519 connective and soft tissue neoplasm tumor of soft tissue and skeleton disease_ontology DOID:1115 sarcoma A viral infectious disease that has_material_basis_in human papillomaviruses, which establish productive infections only in the stratified epithelium of the skin or mucous membranes. These viruses cause warts and sometimes tumors. They are transmitted_by sexual contact. MESH:D030361 HPV disease_ontology DOID:11166 Human papillomavirus infectious disease A nervous system cancer that is located in the peripheral nervous system. DOID:3194 MESH:D010524 MESH:D018317 NCI:C3321 NCI:C4972 SNOMEDCT_US_2023_03_01:126980002 SNOMEDCT_US_2023_03_01:189946005 UMLS_CUI:C0031118 UMLS_CUI:C0206727 neoplasm of peripheral nerve nerve sheath neoplasm tumor of PNS disease_ontology DOID:1192 peripheral nervous system neoplasm An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. GARD:12425 MESH:D006258 NCI:C3077 SNOMEDCT_US_2023_03_01:255055008 UMLS_CUI:C0018671 head and neck neoplasm head and neck tumours head/neck neoplasm tumor of head and neck disease_ontology DOID:11934 head and neck cancer A reproductive organ cancer that is manifested in the female genitals. This includes organs such as the ovaries, fallopian tubes, uterus, cervix, vagina and vulva. DOID:1244 DOID:1281 ICD10CM:C57 ICD9CM:184 MESH:D005833 NCI:C3053 NCI:C4913 SNOMEDCT_US_2023_03_01:126907002 SNOMEDCT_US_2023_03_01:188207007 UMLS_CUI:C0017416 UMLS_CUI:C0153585 UMLS_CUI:C0699889 female reproductive cancer malignant Gynecologic tumor malignant neoplasm of female genital organ disease_ontology DOID:120 female reproductive organ cancer A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells. DOID:9145 ICD10CM:C95.90 ICD9CM:208 ICDO:9800/3 MESH:D007938 NCI:C3161 SNOMEDCT_US_2023_03_01:255049003 UMLS_CUI:C0023418 disease_ontology DOID:1240 leukemia A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain. DOID:2125 DOID:2126 DOID:3543 DOID:6649 DOID:911 ICD10CM:C71 ICD9CM:191 ICD9CM:239.6 MESH:D001932 NCI:C170814 NCI:C2907 NCI:C3568 NCI:C5115 NCI:C7710 SNOMEDCT_US_2023_03_01:126952004 SNOMEDCT_US_2023_03_01:428061005 SNOMEDCT_US_2023_03_01:93727008 UMLS_CUI:C0006118 UMLS_CUI:C0153633 UMLS_CUI:C0220624 UMLS_CUI:C0750974 UMLS_CUI:C0750979 UMLS_CUI:C1334557 BT - Brain tumour adult brain tumor adult malignant brain neoplasm brain neoplasm brain neoplasm, adult malignant brain tumour malignant primary brain neoplasm malignant primary brain tumor malignant tumor of Brain malignant tumor of adult brain neoplasm of brain primary brain neoplasm primary brain tumor primary malignant neoplasm of brain tumor of the Brain disease_ontology DOID:1319 brain cancer A respiratory system cancer that is located_in the lung. DOID:13075 DOID:1322 DOID:9881 ICD10CM:C34.1 ICD10CM:C34.2 ICD10CM:C34.3 ICD9CM:162.3 ICD9CM:162.4 ICD9CM:162.5 ICD9CM:162.8 MIM:211980 MIM:608935 MIM:612571 MIM:612593 MIM:614210 SNOMEDCT_US_2023_03_01:187860004 SNOMEDCT_US_2023_03_01:187864008 SNOMEDCT_US_2023_03_01:187868006 SNOMEDCT_US_2023_03_01:187874006 UMLS_CUI:C0024624 UMLS_CUI:C0153491 UMLS_CUI:C0153492 UMLS_CUI:C0153493 disease_ontology lung neoplasm DOID:1324 lung cancer A disease that is characterized by abnormally rapid cell division. neoplasm DOID:0000818 cell process disease neoplasm disease_ontology DOID:14566 disease of cellular proliferation A disease of anatomical entity that is located_in reproductive system organs. DOID:6309 NCI:C27613 UMLS_CUI:C1335037 genital system disease disease_ontology DOID:15 reproductive system disease A head and neck cancer that has_material_basis_in epithelial cells and is located in the upper aerodigestive tract, including the lip, oral cavity (mouth), nasal cavity, paranasal sinuses, pharynx, and larynx. NCI:C6077 UMLS_CUI:C1334927 carcinoma of the neck disease_ontology carcinoma of neck DOID:1542 head and neck carcinoma A disease of anatomical entity that located_in the respiratory system which extends from the nasal sinuses to the diaphragm. DOID:3226 ICD10CM:J98 ICD9CM:519 SNOMEDCT_US_2023_03_01:155603009 UMLS_CUI:C0029582 disease_ontology DOID:1579 respiratory system disease A thoracic cancer that originates in the mammary gland. DOID:1648 DOID:4241 ICD10CM:C50 MESH:D001943 MIM:114480 NCI:C9335 SNOMEDCT_US_2023_03_01:254837009 UMLS_CUI:C0006142 breast tumor malignant neoplasm of breast malignant tumor of the breast mammary cancer mammary tumor primary breast cancer disease_ontology mammary neoplasm DOID:1612 Xref MGI. OMIM mapping confirmed by DO. [SN]. breast cancer A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis. ICD10CM:C80.1 ICD9CM:199 ICDO:8000/3 MESH:D009369 NCI:C9305 SNOMEDCT_US_2023_03_01:269513004 UMLS_CUI:C0006826 malignant neoplasm malignant tumor primary cancer disease_ontology DOID:162 Updating out dated UMLS CUI. cancer A disease of anatomical entity that occurs in the muscular and/or skeletal system. MESH:D009140 NCI:C107377 SNOMEDCT_US_2023_03_01:268047003 UMLS_CUI:C0026857 disease_ontology DOID:17 musculoskeletal system disease An organ system cancer located_in endocrine system that is characterized by uncontrolled cellular proliferation of the hormone producing glands of the endocrine system. DOID:10009 ICD10CM:C75.9 ICD9CM:194.9 MESH:D004701 NCI:C3010 NCI:C3575 SNOMEDCT_US_2023_03_01:127015005 SNOMEDCT_US_2023_03_01:93780007 UMLS_CUI:C0014132 UMLS_CUI:C0153658 Endocrine tumor endocrine neoplasm malignant Endocrine tumor malignant neoplasm of endocrine gland malignant tumour of endocrine gland neoplasm of endocrine gland neoplasm of endocrine system disease_ontology DOID:170 endocrine gland cancer An endocrine gland cancer located_in the pancreas. DOID:14356 DOID:1797 DOID:3588 DOID:9859 GARD:9364 ICD10CM:C25.0 ICD10CM:C25.1 ICD10CM:C25.2 ICD9CM:157.0 ICD9CM:157.1 ICD9CM:157.2 ICD9CM:157.8 KEGG:05212 MESH:D010190 NCI:C3305 ORDO:1333 ORDO:217074 SNOMEDCT_US_2023_03_01:126859007 SNOMEDCT_US_2023_03_01:187796007 SNOMEDCT_US_2023_03_01:93715005 SNOMEDCT_US_2023_03_01:93823001 SNOMEDCT_US_2023_03_01:94082003 UMLS_CUI:C0030297 UMLS_CUI:C0153458 UMLS_CUI:C0153459 UMLS_CUI:C0153460 UMLS_CUI:C0153463 Ca body of pancreas Ca head of pancreas Ca tail of pancreas malignant neoplasm of body of pancreas malignant neoplasm of head of pancreas malignant neoplasm of tail of pancreas pancreas neoplasm pancreatic neoplasm pancreatic tumor disease_ontology DOID:1793 Xref MGI. pancreatic cancer A disease of anatomical entity that is located_in kidney, ureter, bladder and urethra. DOID:579 NCI:C27599 UMLS_CUI:C1335051 Non-neoplastic urinary tract disease urinary tract disease disease_ontology DOID:18 urinary system disease A connective tissue cancer that is located_in bone and is characterized by uncontrolled cellular proliferation that destroys normal bone tissue. DOID:3348 MESH:D001859 NCI:C9343 SNOMEDCT_US_2023_03_01:126537000 UMLS_CUI:C0005967 CA - bone cancer bone neoplasm bone tumour malignant bone neoplasm malignant bone tumour malignant neoplasm of bone malignant osseous tumor neoplasm of bone osseous tumor disease_ontology DOID:184 bone cancer A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from melanocytes which are found in skin, the bowel and the eye. EFO:0000756 ICDO:8720/3 KEGG:05218 MESH:D008545 NCI:C3224 SNOMEDCT_US_2023_03_01:2092003 UMLS_CUI:C0025202 Naevocarcinoma malignant melanoma disease_ontology DOID:1909 melanoma MESH:D008545 An organ system cancer that is manifested in the reproductive organs. DOID:1900 NCI:C3674 UMLS_CUI:C0178830 Reproductive tumor malignant reproductive system neoplasm disease_ontology cancer of reproductive system DOID:193 reproductive organ cancer A female reproductive organ cancer that is located_in fallopian tube. DOID:1961 GARD:9162 ICD10CM:C57.0 ICD9CM:183.2 MESH:D005185 NCI:C3032 NCI:C7480 SNOMEDCT_US_2023_03_01:126916003 SNOMEDCT_US_2023_03_01:93794008 UMLS_CUI:C0015558 UMLS_CUI:C0153579 fallopian tube neoplasm malignant neoplasm of uterine tube malignant tumor of fallopian tube malignant tumour of fallopian tube neoplasm of fallopian tube tumor of the fallopian tube tumor, fallopian tube, malignant disease_ontology DOID:1964 fallopian tube cancer A colorectal cancer that is located_in the rectum. DOID:1989 ICD10CM:C20 ICD9CM:154.1 MESH:D012004 NCI:C7418 NCI:C9382 SNOMEDCT_US_2023_03_01:254582000 SNOMEDCT_US_2023_03_01:93984006 UMLS_CUI:C0007113 UMLS_CUI:C0949022 carcinoma of rectum carcinoma of the rectum malignant Rectal tumor malignant neoplasm of rectum malignant rectum tumor malignant tumor of rectum rectal cancer disease_ontology cancer of rectum DOID:1993 rectum cancer A musculoskeletal system cancer that is located_in connective tissue. MESH:D009372 SNOMEDCT_US_2023_03_01:126598008 UMLS_CUI:C0027656 Tumour of connective tissue connective tissue neoplasm mesenchymal tissue malignant neoplasm neoplasm of connective tissues disease_ontology DOID:201 connective tissue cancer A colorectal cancer that is located_in the colon. ICD10CM:C18 ICD9CM:153 MESH:D003110 NCI:C9242 SNOMEDCT_US_2023_03_01:363406005 UMLS_CUI:C0007102 disease_ontology DOID:219 colon cancer A reproductive system disease that impairs the ability to reproduce and is located in the uterus, vagina, cervix, ovaries or fallopian tubes. ICD9CM:629.9 MESH:D005831 SNOMEDCT_US_2023_03_01:38233001 UMLS_CUI:C0017411 disease_ontology DOID:229 female reproductive system disease A female reproductive organ cancer that is located_in the ovary. DOID:0060070 DOID:2144 DOID:9595 GARD:7295 ICD10CM:C56 ICD9CM:183.0 MESH:D010051 MIM:167000 MIM:607893 NCI:C4984 NCI:C7431 ORDO:213500 ORDO:213517 SNOMEDCT_US_2023_03_01:123843001 SNOMEDCT_US_2023_03_01:372117006 SNOMEDCT_US_2023_03_01:93934004 UMLS_CUI:C0919267 UMLS_CUI:C1140680 UMLS_CUI:C1299247 malignant Ovarian tumor malignant tumour of ovary ovarian neoplasm ovary neoplasm primary ovarian cancer tumor of the Ovary disease_ontology DOID:2394 Xref MGI. OMIM mapping confirmed by DO. [SN]. ovarian cancer An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes. DOID:1034 DOID:2532 MESH:D019337 NCI:C27134 SNOMEDCT_US_2023_03_01:414388001 UMLS_CUI:C0376544 Hematologic malignancy Hematologic neoplasm Hematological tumors blood cancer hematopoietic and lymphoid system tumor hematopoietic cancer hematopoietic neoplasm hematopoietic tumors malignant hematopoietic neoplasm disease_ontology DOID:2531 hematologic cancer A urinary system cancer that is located_in the kidney. DOID:11834 DOID:3676 ICD10CM:C64 ICD9CM:189.0 MESH:D007680 NCI:C120456 NCI:C3150 NCI:C7548 SNOMEDCT_US_2023_03_01:126880001 SNOMEDCT_US_2023_03_01:93849006 UMLS_CUI:C0022665 UMLS_CUI:C0494158 UMLS_CUI:C0740457 malignant neoplasm of kidney except pelvis malignant tumour of kidney renal cancer disease_ontology DOID:263 kidney cancer A disease of anatomical entity that is located_in endocrine glands which secretes a type of hormone directly into the bloodstream to regulate the body. ICD10CM:E34.9 ICD9CM:259.9 MESH:D004700 NCI:C3009 SNOMEDCT_US_2023_03_01:67432001 UMLS_CUI:C0014130 disease_ontology DOID:28 endocrine system disease A disease of anatomical entity that is located_in the immune system. EFO:0000540 ICD10CM:D89.9 ICD9CM:279.9 SNOMEDCT_US_2023_03_01:154782004 UMLS_CUI:C0041806 disease_ontology DOID:2914 immune system disease A carcinoma that has_material_basis_in abnormally proliferating cells, derives_from epithelial cells, which originate in glandular tissue. ICDO:8140/3 MESH:D000230 NCI:C2852 SNOMEDCT_US_2023_03_01:35917007 UMLS_CUI:C0001418 disease_ontology DOID:299 adenocarcinoma MESH:D000230 A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. DOID:2428 DOID:6570 ICDO:8010/3 MESH:D002277 MESH:D009375 NCI:C2916 NCI:C3709 SNOMEDCT_US_2023_03_01:188083002 SNOMEDCT_US_2023_03_01:269513004 SNOMEDCT_US_2023_03_01:71298006 UMLS_CUI:C0007097 UMLS_CUI:C0553707 UMLS_CUI:C1368683 epithelial cancer epithelioma malignant Epithelioma disease_ontology DOID:305 carcinoma A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes. DOID:3075 DOID:3080 GARD:2491 ICDO:9440/3 MESH:D005909 NCI:C129295 NCI:C39750 NCI:C9094 SNOMEDCT_US_2023_03_01:63634009 UMLS_CUI:C0017636 UMLS_CUI:C0278878 UMLS_CUI:C1514422 GBM adult glioblastoma multiforme glioblastoma multiforme grade IV adult Astrocytic tumor primary glioblastoma multiforme spongioblastoma multiforme disease_ontology DOID:3068 glioblastoma A malignant glioma that is has_material_basis_in astrocyte cells, a type of star-shaped glial cell, located in the brain and spinal cord. DOID:4861 ICDO:9400/3 MESH:D001254 NCI:C4951 NCI:C60781 SNOMEDCT_US_2023_03_01:189914005 SNOMEDCT_US_2023_03_01:99131000119108 UMLS_CUI:C0004114 UMLS_CUI:C0750935 Astrocytic tumor astrocytoma of Cerebrum astrocytoma of brain astroglioma cerebral astrocytoma disease_ontology DOID:3069 malignant astrocytoma MESH:D001254 An organ system cancer located_in the nervous system that affects the central or peripheral nervous system. DOID:1193 DOID:3195 DOID:4695 ICD9CM:192.9 MESH:D009380 NCI:C35562 SNOMEDCT_US_2023_03_01:188306000 UMLS_CUI:C0027665 UMLS_CUI:C0153643 UMLS_CUI:C1334956 malignant neoplasm of nervous system neoplasm of nervous system nervous system neoplasm neural neoplasm neural tumor tumor of the nervous system disease_ontology DOID:3093 nervous system cancer A gastrointestinal system disease that is located_in the liver and/or biliary tract. MESH:D004066 NCI:C3959 UMLS_CUI:C0267792 liver and biliary tract disease disease_ontology DOID:3118 hepatobiliary disease An organ system cancer located_in gastrointestinal tract that is manifested in organs of the gastrointestinal system. DOID:4945 DOID:8377 ICD10CM:C26.9 ICD9CM:239.0 MESH:D004067 MESH:D005770 NCI:C3052 NCI:C4890 SNOMEDCT_US_2023_03_01:128348002 SNOMEDCT_US_2023_03_01:276806006 SNOMEDCT_US_2023_03_01:428905002 UMLS_CUI:C0012243 UMLS_CUI:C0017185 UMLS_CUI:C0685938 GI tumor digestive system cancer gastrointestinal tract cancer disease_ontology DOID:3119 gastrointestinal system cancer A bone sarcoma that is located_in bone that has_material_basis_in cells of mesenchymal origin. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). DOID:183 GARD:7284 ICDO:9180/3 MESH:D012516 MESH:D018213 MIM:259500 NCI:C9145 ORDO:668 SNOMEDCT_US_2023_03_01:189878003 UMLS_CUI:C0029463 UMLS_CUI:C0206639 Osteogenic sarcoma Skeletal sarcoma bone tissue neoplasm osteoid sarcoma disease_ontology DOID:3347 OMIM mapping confirmed by DO. [SN]. osteosarcoma A connective tissue cancer that has_material_basis_in neural crest cells derives_from undeveloped, undifferentiated neuroectoderm. DOID:0050607 DOID:4158 DOID:4390 DOID:4391 DOID:4392 DOID:4980 GARD:6390 ICDO:9364/3 MESH:C563168 MESH:D012512 MESH:D018241 MIM:612219 NCI:C27901 NCI:C27903 NCI:C4817 NCI:C7542 NCI:C7806 NCI:C9341 SNOMEDCT_US_2023_03_01:134210007 SNOMEDCT_US_2023_03_01:73676002 SNOMEDCT_US_2023_03_01:76909002 UMLS_CUI:C0553580 UMLS_CUI:C0684337 UMLS_CUI:C0796547 UMLS_CUI:C0863029 UMLS_CUI:C0877849 UMLS_CUI:C1334408 Ewing's family localized tumor Ewing's sarcoma/peripheral primitive neuroectodermal tumor Ewing's tumor Ewings sarcoma Ewings sarcoma-primitive neuroectodermal tumor PNET of Thoracopulmonary Region localized Ewing sarcoma localized Ewing's sarcoma localized Ewing's sarcoma/peripheral primitive neuroectodermal tumor localized Ewing's tumor localized peripheral primitive neuroectodermal tumor peripheral primitive neuroectodermal tumor disease_ontology DOID:3369 OMIM mapping confirmed by DO. [SN]. Ewing sarcoma A female reproductive system disease that is located_in the uterus. ICD10CM:N85.9 ICD9CM:621.9 MESH:D014591 NCI:C26907 SNOMEDCT_US_2023_03_01:237068005 UMLS_CUI:C0042131 disease_ontology DOID:345 uterine disease A hepatobiliary system cancer that is located_in the liver. DOID:12300 DOID:269 DOID:7330 DOID:915 DOID:919 ICD10CM:C22.0 ICD10CM:C22.9 ICD9CM:155.0 ICD9CM:155.2 MESH:D008113 NCI:C34803 NCI:C7692 SNOMEDCT_US_2023_03_01:126851005 SNOMEDCT_US_2023_03_01:187771009 SNOMEDCT_US_2023_03_01:93870000 UMLS_CUI:C0023903 UMLS_CUI:C0024620 UMLS_CUI:C0345904 UMLS_CUI:C0854795 Ca liver - primary Resectable malignant neoplasm of Liver hepatic cancer hepatic neoplasm malignant hepato-biliary neoplasm malignant neoplasm of liver malignant neoplasm of liver, not specified as primary or secondary malignant neoplasm of liver, primary malignant tumor of liver neoplasm of liver non-resectable primary hepatic malignant neoplasm primary liver cancer primary malignant neoplasm of liver resectable malignant neoplasm of the liver disease_ontology DOID:3571 liver cancer A nervous system cancer that is located_in the central nervous system. DOID:0060093 DOID:1318 EFO:0000326 ICD10CM:C72.9 MESH:D016543 NCI:C4627 NCI:C9293 SNOMEDCT_US_2023_03_01:126951006 SNOMEDCT_US_2023_03_01:93744007 UMLS_CUI:C0085136 UMLS_CUI:C0348374 CNS neoplasm central nervous system tumor central nervous system tumors malignant neoplasm of central nervous system malignant tumor of CNS neoplasm of central nervous system disease_ontology DOID:3620 central nervous system cancer A female reproductive organ cancer that is located_in the uterus. DOID:4363 ICD10CM:C55 ICD9CM:179 MESH:D014594 NCI:C3435 NCI:C3552 SNOMEDCT_US_2023_03_01:126908007 SNOMEDCT_US_2023_03_01:371973000 UMLS_CUI:C0042138 UMLS_CUI:C0153567 CA - cancer of uterus Tumour of uterus malignant neoplasm of uterus malignant uterine tumor neoplasm of uterus uterine tumor uterus neoplasm disease_ontology DOID:363 uterine cancer A stomach carcinoma that derives_from epithelial cells of glandular origin. NCI:C4004 SNOMEDCT_US_2023_03_01:408647009 UMLS_CUI:C0278701 adenocarcinoma of stomach stomach adenocarcinoma disease_ontology DOID:3717 gastric adenocarcinoma A reproductive organ cancer that is manifested in the male genital system. This includes organs such as the penis and scrotum. DOID:10284 ICD10CM:C63.9 ICD9CM:187.9 MESH:D005834 NCI:C3054 NCI:C8561 SNOMEDCT_US_2023_03_01:126895004 SNOMEDCT_US_2023_03_01:363515000 UMLS_CUI:C0017417 UMLS_CUI:C0153606 male genital cancer male reproductive system neoplasm malignant neoplasm of male genital organ malignant neoplasm of male genital organ or tract malignant neoplasm of male genital organs malignant tumor of male Reproductive system malignant tumor of male genital organ neoplasm of male genital organ tumor of male Reproductive system disease_ontology male genital neoplasm DOID:3856 male reproductive organ cancer A lung cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells and is located_in the lungs and has_symptom cough and has_symptom chest discomfort or pain and has_symptom weight loss and has_symptom hemoptysis. EFO:0001071 NCI:C4878 SNOMEDCT_US_2023_03_01:154485001 UMLS_CUI:C0684249 cancer of lung disease_ontology carcinoma of lung DOID:3905 OMIM mapping confirmed by DO. [SN]. lung carcinoma A lung carcinoma that is characterized as any type of epithelial lung cancer other than small cell lung carcinoma. EFO:0003060 KEGG:05223 MESH:D002289 NCI:C2926 SNOMEDCT_US_2023_03_01:254637007 UMLS_CUI:C0007131 NSCLC Non-small cell lung cancer non-small cell lung carcinoma disease_ontology DOID:3908 lung non-small cell carcinoma An organ system cancer that is located_in the kidneys, ureteres, bladder or urethra. ICD10CM:C68.9 ICD9CM:189.9 SNOMEDCT_US_2023_03_01:448233000 UMLS_CUI:C0348371 disease_ontology DOID:3996 urinary system cancer A disease is a disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism. MESH:D004194 NCI:C2991 SNOMEDCT_US_2023_03_01:64572001 UMLS_CUI:C0012634 disease_ontology DOID:4 disease A female reproductive organ cancer that is located_in the cervix. DOID:4361 ICD10CM:C53 ICD9CM:180 MESH:D002583 MIM:603956 NCI:C2940 NCI:C9311 SNOMEDCT_US_2023_03_01:123841004 SNOMEDCT_US_2023_03_01:254885005 UMLS_CUI:C0007847 UMLS_CUI:C0007873 cervical neoplasm cervix cancer cervix uteri cancer neoplasm of uterine cervix tumor of the Cervix Uteri uterine cervical neoplasm disease_ontology DOID:4362 cervical cancer A biliary tract cancer that is located_in the bile duct. DOID:10019 ICD10CM:C24.0 ICD9CM:156.1 MESH:D001650 NCI:C2898 NCI:C7483 SNOMEDCT_US_2023_03_01:93790004 UMLS_CUI:C0005396 UMLS_CUI:C0153453 Ca extrahepatic bile ducts bile duct tumor malignant neoplasm of the extrahepatic bile duct disease_ontology DOID:4606 bile duct cancer A bile duct carcinoma that derives_from epithelial cells of glandular origin. NCI:C27813 SNOMEDCT_US_2023_03_01:70179006 UMLS_CUI:C1370800 disease_ontology DOID:4896 bile duct adenocarcinoma A bile duct cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. MESH:D001650 NCI:C27814 SNOMEDCT_US_2023_03_01:70179006 UMLS_CUI:C0740277 disease_ontology DOID:4897 bile duct carcinoma A bile duct adenocarcinoma that has_material_basis_in bile duct epithelial cells. DOID:5249 ICD10CM:C22.1 ICDO:8160/3 MESH:D018281 NCI:C4436 NCI:C8265 SNOMEDCT_US_2023_03_01:70179006 UMLS_CUI:C0206698 UMLS_CUI:C0280725 adult primary Cholangiocarcinoma adult primary cholangiocellular carcinoma cholangiosarcoma disease_ontology DOID:4947 cholangiocarcinoma A hematopoietic cancer that derives_from the blood-forming stem cells of the bone marrow. DOID:2356 DOID:2761 EFO:0004251 ICD10CM:D47.1 MESH:D009196 SNOMEDCT_US_2023_03_01:128925001 UMLS_CUI:C0027022 bone Marrow tumor bone marrow neoplasm malignant bone Marrow tumor malignant neoplasm of bone marrow disease_ontology DOID:4960 bone marrow cancer A gastrointestinal system cancer that is located_in the esophagus. DOID:10291 DOID:10292 DOID:10448 DOID:1102 DOID:1104 GARD:6383 ICD10CM:C15.3 ICD10CM:C15.4 ICD10CM:C15.5 ICD9CM:150.2 ICD9CM:150.3 ICD9CM:150.4 ICD9CM:150.5 ICD9CM:150.8 MESH:D004938 MIM:133239 NCI:C3028 NCI:C3533 NCI:C3534 NCI:C3535 NCI:C4764 SNOMEDCT_US_2023_03_01:126817006 SNOMEDCT_US_2023_03_01:187729008 SNOMEDCT_US_2023_03_01:93656003 SNOMEDCT_US_2023_03_01:93877002 SNOMEDCT_US_2023_03_01:93895004 SNOMEDCT_US_2023_03_01:94119000 UMLS_CUI:C0014859 UMLS_CUI:C0153413 UMLS_CUI:C0153414 UMLS_CUI:C0153415 UMLS_CUI:C0153416 UMLS_CUI:C0496775 Ca lower third oesophagus Ca middle third oesophagus esophagus cancer malignant neoplasm of distal third of esophagus malignant neoplasm of lower third of oesophagus malignant neoplasm of middle third of oesophagus malignant neoplasm of proximal third of esophagus malignant neoplasm of upper third esophagus malignant tumor of Distal Third of esophagus malignant tumor of Proximal Third of esophagus malignant tumor of abdominal esophagus malignant tumor of the middle Third of the esophagus disease_ontology DOID:5041 esophageal cancer An organ system cancer located_in the thoracic cavity that develops in the different types of cells within the lungs, as well as less common cancers of the esophagus, the trachea, or the chest wall. DOID:3937 ICD10CM:C76.1 ICD9CM:195.1 MESH:D013899 NCI:C3406 NCI:C3576 SNOMEDCT_US_2023_03_01:188361007 SNOMEDCT_US_2023_03_01:255058005 UMLS_CUI:C0039981 UMLS_CUI:C0153661 Thoracic tumor thorax cancer thorax neoplasm tumor of thorax disease_ontology DOID:5093 thoracic cancer A gastrointestinal system disease that is located_in the intestine. DOID:10759 DOID:11222 DOID:11789 DOID:8531 DOID:8558 DOID:8591 ICD10CM:K63.9 ICD9CM:569.9 MESH:D007410 NCI:C26801 SNOMEDCT_US_2023_03_01:266483008 UMLS_CUI:C0021831 disease_ontology DOID:5295 intestinal disease A lung carcinoma that has_material_basis_in primitive-appearing cells that are smaller than normal cells and is located_in the lung. DOID:0050875 KEGG:05222 MESH:D055752 MIM:182280 NCI:C4917 SNOMEDCT_US_2023_03_01:254632001 UMLS_CUI:C0149925 disease_ontology DOID:5409 OMIM mapping confirmed by DO. [SN]. lung small cell carcinoma A stomach cancer that is located_in the stomach. EFO:0000178 NCI:C4911 SNOMEDCT_US_2023_03_01:154446008 UMLS_CUI:C0699791 cancer of the stomach carcinoma of stomach gastric carcinoma disease_ontology DOID:5517 stomach carcinoma A head and neck carcinoma that has_material_basis_in squamous cells that line the moist, mucosal surfaces inside the head and neck. GARD:8503 MESH:D000077195 MIM:275355 NCI:C34447 SNOMEDCT_US_2023_03_01:716659002 UMLS_CUI:C1168401 carcinoma of the head and neck squamous cell carcinoma of the head and neck squamous cell carcinomas of head and neck disease_ontology DOID:5520 OMIM mapping confirmed by DO. [SN]. head and neck squamous cell carcinoma A musculoskeletal system disease that affects tissues such as skin, tendons, and cartilage. MESH:D003240 NCI:C26729 SNOMEDCT_US_2023_03_01:201432001 UMLS_CUI:C0009782 connective tissue disorder disorder of connective tissue disease_ontology DOID:65 connective tissue disease A mature B-cell neoplasm that is composed of plasma cells. EFO:0000200 MESH:D010265 SNOMEDCT_US_2023_03_01:71390001 UMLS_CUI:C1136084 Plasma cell dyscrasia Plasma cell tumour Plasmacytic tumor disease_ontology DOID:6536 plasma cell neoplasm A liver carcinoma that has_material_basis_in undifferentiated hepatocytes and located_in the liver. DOID:5005 EFO:0000182 ICD10CM:C22.0 ICDO:8170/3 MESH:D006528 MIM:114550 NCI:C3099 ORDO:88673 SNOMEDCT_US_2023_03_01:154469006 UMLS_CUI:C2239176 Hepatoma disease_ontology DOID:684 OMIM mapping confirmed by DO. [SN]. hepatocellular carcinoma A liver cancer that has_material_basis_in epithelial cells. NCI:C7927 UMLS_CUI:C0279000 Liver and Intrahepatic bile duct carcinoma disease_ontology DOID:686 liver carcinoma A disease that manifests in a defined anatomical structure. DOID:1 DOID:2 DOID:5 DOID:71 DOID:72 DOID:8 disease_ontology DOID:7 disease of anatomical entity A non-Hodgkin lymphoma that has_material_basis_in B cells. GARD:5877 MESH:D016393 NCI:C3457 SNOMEDCT_US_2023_03_01:109979007 UMLS_CUI:C0079731 B-cell lymphocytic neoplasm disease_ontology DOID:707 B-cell lymphoma A disease of anatomical entity that has_material_basis_in hematopoietic cells. ICD10CM:D75.9 ICD9CM:289.9 MESH:D006402 NCI:C26323 SNOMEDCT_US_2023_03_01:154785002 UMLS_CUI:C0018939 Blood disease Blood dyscrasia DISEASE OF THE BLOOD AND BLOOD-FORMING ORGANS Hematological disease blood disorder disease of haematopoietic system disease of hematopoietic system haematopoietic system disease disease_ontology DOID:74 hematopoietic system disease An autonomic nervous system neoplasm that derives_from immature nerve cells. EFO:0000621 GARD:7185 ICDO:9500/3 MESH:D009447 NCI:C3270 ORDO:635 SNOMEDCT_US_2023_03_01:432328008 UMLS_CUI:C0027819 disease_ontology DOID:769 Xref MGI. OMIM mapping confirmed by DO. [SN]. neuroblastoma A disease of anatomical entity that is located_in the gastrointestinal tract. DOID:27 DOID:944 ICD10CM:K92.9 ICD9CM:520-579.99 MESH:D004066 SNOMEDCT_US_2023_03_01:53619000 UMLS_CUI:C0012242 GIT disease Gastroenteropathy alimentary system disease digestive system disorder gastrointestinal disease gastrointestinal disorder disease_ontology DOID:77 gastrointestinal system disease A pharynx cancer that is located_in the oropharynx. DOID:8684 DOID:8851 DOID:8949 DOID:9168 ICD10CM:C10 ICD10CM:C10.2 ICD10CM:C10.3 ICD10CM:C10.8 ICD9CM:146 ICD9CM:146.5 ICD9CM:146.6 ICD9CM:146.7 NCI:C7398 SNOMEDCT_US_2023_03_01:187686007 SNOMEDCT_US_2023_03_01:93933005 SNOMEDCT_US_2023_03_01:93971002 UMLS_CUI:C0153382 UMLS_CUI:C0153388 UMLS_CUI:C0153389 UMLS_CUI:C0153390 Oropharyngeal carcinoma malignant Oropharyngeal tumor malignant tumor of oropharynx malignant tumour of mesopharynx oropharyngeal cancer disease_ontology DOID:8557 oropharynx cancer A disease of anatomical entity that is located_in the central nervous system or located_in the peripheral nervous system. ICD10CM:G98 ICD9CM:349.9 MESH:D009422 NCI:C26835 SNOMEDCT_US_2023_03_01:155262005 UMLS_CUI:C0027765 disease_ontology DOID:863 nervous system disease A large intestine cancer that is located_in the colon and/or located_in the rectum. ICD10CM:C18.9 KEGG:05210 MESH:D015179 MIM:114500 NCI:C2956 NCI:C4978 SNOMEDCT_US_2023_03_01:126837005 SNOMEDCT_US_2023_03_01:93854002 UMLS_CUI:C0009404 UMLS_CUI:C0346629 disease_ontology DOID:9256 Xref MGI. OMIM mapping confirmed by DO. [SN]. colorectal cancer A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or throat, where the nasal passages and auditory tubes join the remainder of the upper respiratory tract. DOID:8813 DOID:8814 DOID:9057 DOID:9144 DOID:9197 DOID:9229 GARD:7163 ICD10CM:C11 ICD10CM:C11.0 ICD10CM:C11.1 ICD10CM:C11.2 ICD10CM:C11.3 ICD9CM:147 ICD9CM:147.0 ICD9CM:147.1 ICD9CM:147.2 ICD9CM:147.3 MESH:D009303 MIM:161550 MIM:607107 NCI:C9321 ORDO:150 SNOMEDCT_US_2023_03_01:187692001 SNOMEDCT_US_2023_03_01:187693006 SNOMEDCT_US_2023_03_01:187700006 SNOMEDCT_US_2023_03_01:363398003 SNOMEDCT_US_2023_03_01:93919005 SNOMEDCT_US_2023_03_01:94078000 UMLS_CUI:C0153392 UMLS_CUI:C0153393 UMLS_CUI:C0153394 UMLS_CUI:C0153395 UMLS_CUI:C0153396 UMLS_CUI:C0238301 Nasopharyngeal carcinoma malignant Nasopharyngeal tumor malignant neoplasm of nasopharynx nasopharynx cancer disease_ontology carcinoma of nasopharynx DOID:9261 Xref MGI. OMIM mapping confirmed by DO. [SN]. nasopharynx carcinoma A myeloid neoplasm that is located_in the plasma cells in bone marrow. EFO:0001378 GARD:7108 ICD10CM:C90.0 ICD9CM:203.0 MESH:D009101 MIM:254500 NCI:C3242 ORDO:29073 SNOMEDCT_US_2023_03_01:94705007 UMLS_CUI:C0026764 myeloma disease_ontology DOID:9538 OMIM mapping confirmed by DO. [SN]. multiple myeloma Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. biological_process GO:0006955 immune response A biological process is the execution of a genetically-encoded biological module or program. It consists of all the steps required to achieve the specific biological objective of the module. A biological process is accomplished by a particular set of molecular functions carried out by specific gene products (or macromolecular complexes), often in a highly regulated manner and in a particular temporal sequence. https://github.com/geneontology/go-ontology/issues/24968 jl 2012-09-19T15:05:24Z GO:0000004 GO:0007582 GO:0044699 Wikipedia:Biological_process biological process physiological process biological_process single organism process single-organism process GO:0008150 Note that, in addition to forming the root of the biological process ontology, this term is recommended for the annotation of gene products whose biological process is unknown. When this term is used for annotation, it indicates that no information was available about the biological process of the gene product annotated as of the date the annotation was made; the evidence code 'no data' (ND), is used to indicate this. biological_process Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism. GO:0051869 physiological response to stimulus biological_process GO:0050896 Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC. response to stimulus objective specification In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction. A directive information entity that describes an intended process endpoint. When part of a plan specification the concretization is realized in a planned process in which the bearer tries to effect the world so that the process endpoint is achieved. 2009-03-16: original definition when imported from OBI read: "objective is an non realizable information entity which can serve as that proper part of a plan towards which the realization of the plan is directed." 2014-03-31: In the example of usage ("In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction") there is a protocol which is the ChIP assay protocol. In addition to being concretized on paper, the protocol can be concretized as a realizable entity, such as a plan that inheres in a person. The objective specification is the part that says that some protein and DNA interactions are identified. This is a specification of a process endpoint: the boundary in the process before which they are not identified and after which they are. During the realization of the plan, the goal is to get to the point of having the interactions, and participants in the realization of the plan try to do that. Answers the question, why did you do this experiment? PERSON: Alan Ruttenberg PERSON: Barry Smith PERSON: Bjoern Peters PERSON: Jennifer Fostel goal specification OBI Plan and Planned Process/Roles Branch OBI_0000217 objective specification data item Data items include counts of things, analyte concentrations, and statistical summaries. An information content entity that is intended to be a truthful statement about something (modulo, e.g., measurement precision or other systematic errors) and is constructed/acquired by a method which reliably tends to produce (approximately) truthful statements. 2/2/2009 Alan and Bjoern discussing FACS run output data. This is a data item because it is about the cell population. Each element records an event and is typically further composed a set of measurment data items that record the fluorescent intensity stimulated by one of the lasers. 2009-03-16: data item deliberatly ambiguous: we merged data set and datum to be one entity, not knowing how to define singular versus plural. So data item is more general than datum. 2009-03-16: removed datum as alternative term as datum specifically refers to singular form, and is thus not an exact synonym. 2014-03-31: See discussion at http://odontomachus.wordpress.com/2014/03/30/aboutness-objects-propositions/ JAR: datum -- well, this will be very tricky to define, but maybe some information-like stuff that might be put into a computer and that is meant, by someone, to denote and/or to be interpreted by some process... I would include lists, tables, sentences... I think I might defer to Barry, or to Brian Cantwell Smith JAR: A data item is an approximately justified approximately true approximate belief PERSON: Alan Ruttenberg PERSON: Chris Stoeckert PERSON: Jonathan Rees data data item information content entity Examples of information content entites include journal articles, data, graphical layouts, and graphs. A generically dependent continuant that is about some thing. 2014-03-10: The use of "thing" is intended to be general enough to include universals and configurations (see https://groups.google.com/d/msg/information-ontology/GBxvYZCk1oc/-L6B5fSBBTQJ). information_content_entity 'is_encoded_in' some digital_entity in obi before split (040907). information_content_entity 'is_encoded_in' some physical_document in obi before split (040907). Previous. An information content entity is a non-realizable information entity that 'is encoded in' some digital or physical entity. PERSON: Chris Stoeckert OBI_0000142 information content entity An information content entity whose concretizations indicate to their bearer how to realize them in a process. 2009-03-16: provenance: a term realizable information entity was proposed for OBI (OBI_0000337) , edited by the PlanAndPlannedProcess branch. Original definition was "is the specification of a process that can be concretized and realized by an actor" with alternative term "instruction".It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term. 2013-05-30 Alan Ruttenberg: What differentiates a directive information entity from an information concretization is that it can have concretizations that are either qualities or realizable entities. The concretizations that are realizable entities are created when an individual chooses to take up the direction, i.e. has the intention to (try to) realize it. 8/6/2009 Alan Ruttenberg: Changed label from "information entity about a realizable" after discussions at ICBO Werner pushed back on calling it realizable information entity as it isn't realizable. However this name isn't right either. An example would be a recipe. The realizable entity would be a plan, but the information entity isn't about the plan, it, once concretized, *is* the plan. -Alan PERSON: Alan Ruttenberg PERSON: Bjoern Peters directive information entity curation status specification The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting) PERSON:Bill Bug GROUP:OBI:<http://purl.obolibrary.org/obo/obi> OBI_0000266 curation status specification data about an ontology part Data about an ontology part is a data item about a part of an ontology, for example a term Person:Alan Ruttenberg data about an ontology part plan specification PMID: 18323827.Nat Med. 2008 Mar;14(3):226.New plan proposed to help resolve conflicting medical advice. A directive information entity with action specifications and objective specifications as parts, and that may be concretized as a realizable entity that, if realized, is realized in a process in which the bearer tries to achieve the objectives by taking the actions specified. 2009-03-16: provenance: a term a plan was proposed for OBI (OBI_0000344) , edited by the PlanAndPlannedProcess branch. Original definition was " a plan is a specification of a process that is realized by an actor to achieve the objective specified as part of the plan". It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term. 2014-03-31: A plan specification can have other parts, such as conditional specifications. 2022-01-16 Updated definition to that proposed by Clint Dowloand, IAO Issue 231. Alternative previous definition: a plan is a set of instructions that specify how an objective should be achieved Alan Ruttenberg Clint Dowland OBI Plan and Planned Process branch OBI_0000344 2/3/2009 Comment from OBI review. Action specification not well enough specified. Conditional specification not well enough specified. Question whether all plan specifications have objective specifications. Request that IAO either clarify these or change definitions not to use them plan specification https://github.com/information-artifact-ontology/IAO/issues/231#issuecomment-1010455131 obsolescence reason specification The reason for which a term has been deprecated. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. The creation of this class has been inspired in part by Werner Ceusters' paper, Applying evolutionary terminology auditing to the Gene Ontology. PERSON: Alan Ruttenberg PERSON: Melanie Courtot obsolescence reason specification denotator type The Basic Formal Ontology ontology makes a distinction between Universals and defined classes, where the formal are "natural kinds" and the latter arbitrary collections of entities. A denotator type indicates how a term should be interpreted from an ontological perspective. Alan Ruttenberg Barry Smith, Werner Ceusters denotator type A part of an extended organism that itself has as part a population of one or more infectious agents and that (1) exists as a result of processes initiated by members of the infectious agent population and is (2) clinically abnormal in virtue of the presence of this infectious agent population, or (3) has a disposition to bring clinical abnormality to immunocompetent organisms of the same Species as the host (the organism corresponding to the extended organism) through transmission of a member or offspring of a member of the infectious agent population. Albert Goldfain Alexander Diehl Lindsay Cowell The organism corresponding to the extended organism is host to the infectious agents. By this definition, parts of the host can be considered part of the infection. infection A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos. mesothelioma A carcinoma arising in the lip or oral cavity. Most oral cavity carcinomas are squamous cell carcinomas of the tongue, buccal mucosa, or gums. Less frequent morphologic variants include mucoepidermoid carcinoma and adenocarcinoma. Lip carcinomas are usually basal cell or squamous cell carcinomas. lip and oral cavity carcinoma NCBITaxon:85055 GC_ID:1 house mouse mouse ncbi_taxonomy Mus musculus GC_ID:1 ncbi_taxonomy Vira Viridae viruses Viruses GC_ID:1 Human Papilloma Virus human papillomavirus HPV ncbi_taxonomy Human papillomavirus NCBITaxon:40673 GC_ID:1 bony vertebrates ncbi_taxonomy Euteleostomi GC_ID:1 PMID:11743200 PMID:11791233 ncbi_taxonomy Boreotheria Boreoeutheria GC_ID:1 PMID:20206957 Papillomavirus ncbi_taxonomy Papillomaviridae GC_ID:11 PMID:10425795 PMID:10425796 PMID:10425797 PMID:10490293 PMID:10843050 PMID:10939651 PMID:10939673 PMID:10939677 PMID:11211268 PMID:11321083 PMID:11321113 PMID:11411719 PMID:11540071 PMID:11542017 PMID:11542087 PMID:11760965 PMID:12054223 PMID:270744 PMID:32628106 PMID:36748408 PMID:7520741 PMID:8123559 PMID:8186100 PMID:8590690 PMID:9103655 PMID:9336922 eubacteria ncbi_taxonomy Bacteria (ex Cavalier-Smith 1987) Bacteria Woese et al. 2024 Bacteriobiota Monera Procaryotae Prokaryota Prokaryotae bacteria prokaryote prokaryotes Bacteria GC_ID:11 PMID:10425795 PMID:10425796 PMID:10425797 PMID:10490293 PMID:10843050 PMID:10939651 PMID:10939673 PMID:10939677 PMID:11211268 PMID:11321083 PMID:11321113 PMID:11411719 PMID:11540071 PMID:11541975 PMID:11542064 PMID:11542149 PMID:11760965 PMID:12054223 PMID:25527841 PMID:270744 PMID:32628106 PMID:36748408 PMID:8123559 PMID:8590690 PMID:9103655 PMID:9336922 ncbi_taxonomy Archaebacteria Archaebiota Mendosicutes Metabacteria Monera Procaryotae Prokaryota Prokaryotae archaea prokaryote prokaryotes Archaea GC_ID:1 ncbi_taxonomy Shotokuvirae GC_ID:1 ncbi_taxonomy Cossaviricota GC_ID:1 ncbi_taxonomy Papovaviricetes GC_ID:1 PMID:23020233 PMID:30257078 eucaryotes eukaryotes ncbi_taxonomy Eucarya Eucaryotae Eukarya Eukaryotae eukaryotes Eukaryota GC_ID:1 PMID:11214319 PMID:12082125 PMID:12878460 PMID:15522813 ncbi_taxonomy Euarchontoglires GC_ID:1 PMID:11214319 PMID:12082125 PMID:15522813 Rodents and rabbits ncbi_taxonomy Glires GC_ID:1 ncbi_taxonomy Anthropoidea Simiiformes GC_ID:1 amniotes ncbi_taxonomy Amniota GC_ID:1 ncbi_taxonomy Fungi/Metazoa group opisthokonts Opisthokonta GC_ID:1 ncbi_taxonomy Bilateria GC_ID:1 ncbi_taxonomy unclassified Papillomaviridae NCBITaxon:109679 GC_ID:1 ncbi_taxonomy Murinae GC_ID:1 mammals ncbi_taxonomy mammals Mammalia GC_ID:1 Vertebrata vertebrates ncbi_taxonomy vertebrates Vertebrata <vertebrates> GC_ID:1 primate ncbi_taxonomy Primata primates Primates GC_ID:1 ncbi_taxonomy Catarrhini GC_ID:1 human ncbi_taxonomy Homo sapiens GC_ID:1 rodent ncbi_taxonomy rodents Rodentia planned process Injecting mice with a vaccine in order to test its efficacy A process that realizes a plan which is the concretization of a plan specification. 'Plan' includes a future direction sense. That can be problematic if plans are changed during their execution. There are however implicit contingencies for protocols that an agent has in his mind that can be considered part of the plan, even if the agent didn't have them in mind before. Therefore, a planned process can diverge from what the agent would have said the plan was before executing it, by adjusting to problems encountered during execution (e.g. choosing another reagent with equivalent properties, if the originally planned one has run out.) We are only considering successfully completed planned processes. A plan may be modified, and details added during execution. For a given planned process, the associated realized plan specification is the one encompassing all changes made during execution. This means that all processes in which an agent acts towards achieving some objectives is a planned process. Bjoern Peters branch derived 6/11/9: Edited at workshop. Used to include: is initiated by an agent This class merges the previously separated objective driven process and planned process, as they the separation proved hard to maintain. (1/22/09, branch call) planned process processed material Examples include gel matrices, filter paper, parafilm and buffer solutions, mass spectrometer, tissue samples Is a material entity that is created or changed during material processing. PERSON: Alan Ruttenberg processed material material processing A cell lysis, production of a cloning vector, creating a buffer. A planned process which results in physical changes in a specified input material PERSON: Bjoern Peters PERSON: Frank Gibson PERSON: Jennifer Fostel PERSON: Melanie Courtot PERSON: Philippe Rocca Serra material transformation OBI branch derived material processing antigen role A role of a material entity that is being recognized in whole or in part by receptors of the immune system such as antibodies or T cell receptors. An antigen is a substance that prompts the generation of antibodies and can cause an immune response. Wikipedia http://en.wikipedia.org/wiki/Antigen. In the strict sense, immunogens are those substances that elicit a response from the immune system, whereas antigens are defined as substances that bind to specific antibodies. Not all antigens produce an immunogenic response, but all immunogens are antigens Role Branch OBI 9Mar09 waiting for discussion with immunology terms antigen role organization PMID: 16353909.AAPS J. 2005 Sep 22;7(2):E274-80. Review. The joint food and agriculture organization of the United Nations/World Health Organization Expert Committee on Food Additives and its role in the evaluation of the safety of veterinary drug residues in foods. An entity that can bear roles, has members, and has a set of organization rules. Members of organizations are either organizations themselves or individual people. Members can bear specific organization member roles that are determined in the organization rules. The organization rules also determine how decisions are made on behalf of the organization by the organization members. BP: The definition summarizes long email discussions on the OBI developer, roles, biomaterial and denrie branches. It leaves open if an organization is a material entity or a dependent continuant, as no consensus was reached on that. The current placement as material is therefore temporary, in order to move forward with development. Here is the entire email summary, on which the definition is based: 1) there are organization_member_roles (president, treasurer, branch editor), with individual persons as bearers 2) there are organization_roles (employer, owner, vendor, patent holder) 3) an organization has a charter / rules / bylaws, which specify what roles there are, how they should be realized, and how to modify the charter/rules/bylaws themselves. It is debatable what the organization itself is (some kind of dependent continuant or an aggregate of people). This also determines who/what the bearer of organization_roles' are. My personal favorite is still to define organization as a kind of 'legal entity', but thinking it through leads to all kinds of questions that are clearly outside the scope of OBI. Interestingly enough, it does not seem to matter much where we place organization itself, as long as we can subclass it (University, Corporation, Government Agency, Hospital), instantiate it (Affymetrix, NCBI, NIH, ISO, W3C, University of Oklahoma), and have it play roles. This leads to my proposal: We define organization through the statements 1 - 3 above, but without an 'is a' statement for now. We can leave it in its current place in the is_a hierarchy (material entity) or move it up to 'continuant'. We leave further clarifications to BFO, and close this issue for now. PERSON: Alan Ruttenberg PERSON: Bjoern Peters PERSON: Philippe Rocca-Serra PERSON: Susanna Sansone GROUP: OBI organization adding a material entity into a target Injecting a drug into a mouse. Adding IL-2 to a cell culture. Adding NaCl into water. is a process with the objective to place a material entity bearing the 'material to be added role' into a material bearing the 'target of material addition role'. Class was renamed from 'administering substance', as this is commonly used only for additions into organisms. BP branch derived adding a material entity into a target material to be added role drug added to a buffer contained in a tube; substance injected into an animal; A role of a material entity that is realized in an "adding a material entity into a target" process where the bearer of the role is added into another material entity (the target). Role Branch OBI 9 March 09 from discussion with PA branch material to be added role adding material objective creating a mouse infected with LCM virus is the specification of an objective to add a material into a target material. The adding is asymmetric in the sense that the target material largely retains its identity BP adding material objective target of material addition role peritoneum of an animal receiving an interperitoneal injection; solution in a tube receiving additional material; location of absorbed material following a dermal application. A role of a material entity that is realized in an "adding a material entity into a target" process where the bearer of the role (the target) receives the addition of another material entity. From Branch discussion with BP, AR, MC -- there is a need for the recipient to interact with the administered material. for example, a tooth receiving a filling was not considered to be a target role. GROUP: Role Branch OBI target of material addition role material transformation objective The objective to create a mouse infected with LCM virus. The objective to create a defined solution of PBS. an objective specifiction that creates an specific output object from input materials. PERSON: Bjoern Peters PERSON: Frank Gibson PERSON: Jennifer Fostel PERSON: Melanie Courtot PERSON: Philippe Rocca-Serra artifact creation objective GROUP: OBI PlanAndPlannedProcess Branch material transformation objective manufacturing A planned process with the objective to produce a processed material which will have a function for future use. A person or organization (having manufacturer role) is a participant in this process Manufacturing implies reproducibility and responsibility AR This includes a single scientist making a processed material for personal use. PERSON: Bjoern Peters PERSON: Frank Gibson PERSON: Jennifer Fostel PERSON: Melanie Courtot PERSON: Philippe Rocca-Serra GROUP: OBI PlanAndPlannedProcess Branch manufacturing manufacturing objective is the objective to manufacture a material of a certain function (device) PERSON: Bjoern Peters PERSON: Frank Gibson PERSON: Jennifer Fostel PERSON: Melanie Courtot PERSON: Philippe Rocca-Serra GROUP: OBI PlanAndPlannedProcess Branch manufacturing objective manufacturer role With respect to The Accuri C6 Flow Cytometer System, the organization Accuri bears the role manufacturer role. With respect to a transformed line of tissue culture cells derived by a specific lab, the lab whose personnel isolated the cll line bears the role manufacturer role. With respect to a specific antibody produced by an individual scientist, the scientist who purifies, characterizes and distributes the anitbody bears the role manufacturer role. Manufacturer role is a role which inheres in a person or organization and which is realized by a manufacturing process. GROUP: Role Branch OBI manufacturer role material combination Mixing two fluids. Adding salt into water. Injecting a mouse with PBS. is a material processing with the objective to combine two or more material entities as input into a single material entity as output. created at workshop as parent class for 'adding material into target', which is asymmetric, while combination encompasses all addition processes. bp bp material combination material combination objective is an objective to obtain an output material that contains several input materials. PPPB branch bp material combination objective pathogen role Pathogen: An agent of disease. A disease producer. The term pathogen most commonly is used to refer to infectious organisms. These include bacteria (such as staph), viruses (such as HIV), and fungi (such as yeast). Less commonly, pathogen refers to a noninfectious agent of disease such as a chemical. http://www.medterms.com/script/main/art.asp?articlekey=6383 pathogen role is a role which inheres in an organism and realized in the process of disease course in the organism bearing host role caused by the organism bearing pathogen role GROUP: Role Branch OBI 6 April 2009: from the Vaccine Community pathogen role manufacturer A person or organization that has a manufacturer role. manufacturer organism animal fungus plant virus A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. 10/21/09: This is a placeholder term, that should ideally be imported from the NCBI taxonomy, but the high level hierarchy there does not suit our needs (includes plasmids and 'other organisms') 13-02-2009: OBI doesn't take position as to when an organism starts or ends being an organism - e.g. sperm, foetus. This issue is outside the scope of OBI. GROUP: OBI Biomaterial Branch WEB: http://en.wikipedia.org/wiki/Organism organism administering substance in vivo Balb/c mice received an intracameral or subconjunctival injection of trinitrophenylated spleen cells injecting mice with 10 ug morphine intranasally, a patient taking two pills of 1 mg aspirin orally A process by which a substance is intentionally given to an organism resulting in exposure of the organism to that substance. 2009-11-10. Tracker: https://sourceforge.net/tracker/?func=detail&aid=2893050&group_id=177891&atid=886178 Different routes and means of administration should go as children underneath this Update the definition based on the discussion. Details see the tracker: https://sourceforge.net/p/obi/obi-terms/738/ needs roles such as perturber and perturbee (children of input role). Perturb is too strong. Host might be the name for one role. Others considered: Doner, Donated, Acceptor. Bjoern Peters Person:Bjoern Peters IEDB administering substance in vivo antigen A material entity that has the antigen role. IEDB IEDB antigen A gene is a material entity that represents the entire DNA sequence required for synthesis of a functional protein or RNA molecule. Oliver He WEB: http://www.ncbi.nlm.nih.gov/books/NBK21640/ gene The totality of all processes through which a given disease instance is realized. Albert Goldfain http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf creation date: 2009-06-23T11:55:44Z disease course A quality which inheres in a continuant. PATO:0001237 PATO:0001238 snap:Quality monadic quality of a continuant multiply inhering quality of a physical entity quality of a continuant quality of a single physical entity quality of an object quality of continuant monadic quality of an object monadic quality of continuant quality PATO:0001241 Relational qualities are qualities that hold between multiple entities. Normal (monadic) qualities such as the shape of a eyeball exist purely as a quality of that eyeball. A relational quality such as sensitivity to light is a quality of that eyeball (and connecting nervous system) as it relates to incoming light waves/particles. physical object quality A quality that inheres in an entire organism or part of an organism. quality PATO:0001995 organismal quality A quality inhering in a bearer by virtue of the severity of infectious disease caused by the bearer in a target organism. 2009-10-30T05:04:06Z quality PATO:0002146 virulence Anatomical entity that has mass. AAO:0010264 AEO:0000006 BILA:0000006 CARO:0000006 EHDAA2:0003006 FBbt:00007016 FMA:67165 HAO:0000006 TAO:0001836 TGMA:0001826 VHOG:0001721 uberon UBERON:0000465 material anatomical entity Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species. AAO:0010841 AEO:0000000 BFO:0000004 BILA:0000000 BIRNLEX:6 CARO:0000000 EHDAA2:0002229 FBbt:10000000 FMA:62955 HAO:0000000 MA:0000001 NCIT:C12219 TAO:0100000 TGMA:0001822 UMLS:C1515976 WBbt:0000100 XAO:0000000 ZFA:0100000 uberon UBERON:0001062 anatomical entity A pathogen component in vaccine that contains only a part of the pathogen organism instead of the whole organism. YH vaccine component part of pathogen organism in vaccine Material entity that is manufactured to realize the vaccine function. Many vaccines are developed to protect against infectious pathogens that causes infectious diseases. Many vaccines are also being developed against other diseases such as cancer, allergy, and autoimmune diseases. Anna Maria Masci Barry Smith Jie Zheng YH, BP, MC, LC, XZ, RS vaccine vaccine MeSH: D014612 A process of administering a vaccine in vivo to a recipient (e.g., human) with the intent to invoke a protective or therapeutic adaptive immune response. Anna Maria Masci Barry Smith Jie Zheng YH, BP vaccine administration process vaccination A vaccine that is composed of a plasmid vaccine vector (a circular double stranded DNA molecule) containing the whole of parts of genes encoding one or more vaccine antigen proteins. YH genetic vaccine naked DNA vaccine nucleic acid vaccine vaccine DNA vaccine Kallan Roan Oliver He BCG Live VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=351 351 TICE BCG For the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder. For the prophylaxis of primary or recurrent state Ta and/or T1 papillary tumors following transurethral resection (TUR). https://www.fda.gov/media/76396/download?attachment 102821 TICE BCG a vaccine component role that inheres in a recombinant vaccine vector as a vaccine component. The combination of a recombinant vaccine vector and a heterogenous protective antigen(s) inserted inside the vector for a recombinant vector vaccine. YH,YL role recombinant vaccine vector role A vaccine that targets against a bacterial disease. YH vaccine bacterial vaccine MeSH: D001428 a virulence of vaccine organism that shows an attenuated pheontype of the organism as the major component of a vaccine. YH quality vaccine organism live attenuated Vaccine that prevents or treats cancer. Anna Maria Masci Barry Smith Jie Zheng Oliver He neoplasm vaccine tumor vaccine MeSH:D019496 cancer vaccine a processed material that is output of the vaccine preparation and part of a vaccine. YH cardinal part of vaccine vaccine ingredient vaccine component vaccine component a USA licensed vaccine role that inheres ina vaccine approven to be by the US FDA to be used for humans in the USA. YH role FDA licensed vaccine role Conjugate vaccine is vaccine that conjugates/links antigens to the molecules that form the outer coat of disease-causing bacteria to promote an immune response. YH vaccine A conjugate vaccine is created by covalently attaching a poor (polysaccharide organism) antigen to a carrier protein (preferably from the same microorganism), thereby conferring the immunological attributes of the carrier on the attached antigen. --from wikipedia. conjugate vaccine To induce or modify protective or therapeutic immune response against a disease. PERSPN: Oliver He: There has been hot discussion about whether we use 'vaccine function' or 'vaccine role'. Vaccine role may not be the good term to use. Vaccine is designed to be 'vaccine', so it should be vaccine function. One special case is cowpox virus. The cowpox virus can be mixed with some liquid like water and used as a smallpox vaccine. In this case, people often say: the cowpox virus has a 'vaccine role'. However, the cowpox virus vaccine is a processed material of a mix of the virus with water. The virus is a virus, it is not a vaccine per se. Therefore, vaccine role may not be an accurate term. Anna Maria Masci Barry Smith Jie Zheng YH, MC, XZ, and AR disposition vaccine function A route of administration that inject the material(such as vaccines, allergens) directly into a muscle. YH,YL intramuscular injection route site intramuscular route A route of administration that located in the peritoneum. YL, YH site intraperitoneal route a licensed human vaccine that is licensed in the USA. YH FDA licensed vaccine https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm vaccine USA licensed human vaccine A vaccine that is licensed for commercial use. YH vaccine licensed vaccine A vaccine that is made from microbes that have been attenuated (weakened) in the laboratory so that they can't cause disease. YH attenuated vaccine vaccine live attenuated vaccine A route of administration that is located in the vein YH, Thom Todd site intravenous route a vaccine component that originates from an organism such as a pathogen or a modified organism. YH vaccine component pathogen organism component in vaccine A cancer vaccine that is used against melanoma, a malignant tumor of melanocytes. Oliver He WEB: http://en.wikipedia.org/wiki/Melanoma 68 40213171 melanoma vaccine melanoma SNOMEDCT:373869007 UMLS_CUI:C0796561 vaccine melanoma vaccine Mixed Bacterial Vaccine (MBV, Coley's Toxins) is a historical, vaguely defined preparation of heat-inactivated Streptococcus pyogenes and Serratia marcescens used as non-specific immunotherapy in the treatment of cancer. Oliver He PubMed:22847809 Mixed Bacterial Vaccine A vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to prevent a specific disorder. Jie Zheng YH prophylactic vaccine function disposition preventive vaccine function A vaccine that uses a modified virus or bacterium as the vector to deliver vaccine antigen(s) to the cells of the host body. YH vaccine recombinant vector vaccine A process that results in an adaptive immune response to one or more antigens. Anna Maria Masci Barry Smith Jie Zheng YH, XZ, BP WEB: http://en.wikipedia.org/wiki/Immunization process immunization An immunization that involves the introduction of foreign molecules into a recipient body, in a way which causes the recipient to actively induce adaptive immunity against the immunization target. Anna Maria Masci Barry Smith Jie Zheng Oliver He XZ WEB: http://en.wikipedia.org/wiki/Immunization process active immunization An immunization that is induced by a vaccine via vaccination process. Anna Maria Masci Barry Smith Jie Zheng YH, XZ artificial active immunization WEB: http://en.wikipedia.org/wiki/Immunization process vaccine immunization induction of adaptive immune response to antigen is an active immunization process that results in induction of adaptive immune response to some antigens, for example, in a vaccine. YH, XZ process induction of adaptive immune response to antigen disorder prevention is a processual entity that prevents a disorder that is the physical basis of a disease. YH, XZ process disorder prevention disorder treatment is a processual entity that leads to treat a disorder that is the physical basis of a disease. YH, XZ process disorder treatment an organism that is used as part of a vaccine Yongqun He organism vaccine organism A route of administration that is loacted in the hypodermis (subcutaneous tissue) region. YL, YH site subcutaneous route A vaccine that is composed of a purified protein(s) or other antigenic determinant(s) from a disease-causing organism. A subunit vaccine does not include the whole organism of a pathogen, so the subunits have less risk of causing adverse reactions. YH vaccine subunit vaccine A vaccine that is used for treatment for a disease. YH vaccine therapeutic vaccine A vaccine function realized the process of vaccination and leading to induction of an adaptive immune response to treat an existing specific disorder. Jie Zheng YH disposition therapeutic vaccine function A path that is located in gross anatomical part of an organism (e.g., human) and is used for administering a vaccine, a drug, fluid, poison, or other substance into the body. CDISC has a codelist: Rout of Administration. Desription from CDISC: The course by which a substance was administered in order to reach the site of action in the body. CDISC_SDTM_Route_of_Administration_Terminology YH,YL http://en.wikipedia.org/wiki/Route_of_administration site route of administration http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38114 http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66729 A subunit vaccine that uses small peptide(s) as immunoepitopes. Jie Zheng YH epitope vaccine peptide-based synthetic vaccine https://en.wikipedia.org/wiki/Peptide_vaccine vaccine peptide vaccine immunization objective is the specification of an objective to achieve immunization. YH, XZ WEB: http://en.wikipedia.org/wiki/Immunization information content entity immunization objective vaccine preparation is a manufacturing process to produce a vaccine. YH, BP vaccine generation vaccine production process vaccine preparation a vaccine component that uses a microbe (e.g., bacterium, virus, and parasitic organism) as a vector that is inserted with the DNA(s) of a heterologous protective antigen(s) to generate a "recombinant vector vaccine". The microorganism used as a vector generally has a stable non or low pathogenic phenotype for the species the vaccine is intended for. YH recombinant vector WEB: http://en.wikipedia.org/wiki/Vaccine WEB: http://www.biosafety.be/GT/Regulatory/Veterinary_vaccines/EMEA_000404en.pdf WEB: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003856.pdf vaccine component recombinant vaccine vector A vaccine that targets against a viral disease. YH vaccine viral vaccine MeSH: D014765 Role that inheres in a prepared material entity that is designed to induce protection or treatment for a disease or infection. YH role vaccine role A role that inheres in a material entity that becomes an ingredient of a vaccine. YH role vaccine component role A vaccine role that indicates the vaccine being a DNA vaccine. YH role DNA vaccine role A vaccine role that indicates the vaccine being a subunit vaccine. YH role subunit vaccine role A vaccine role that indicates the vaccine being a conjugate vaccine. YH role conjugate vaccine role A licensed vaccine role is a regulation-assigned role that indicates that a vaccine obtains official approval for commercial production and selling on the market. YH role licensed vaccine role a licensed vaccine with license for human use. YH vaccine licensed human vaccine A vaccine role that indicates the vaccine being a recombinant vector vaccine. YH role recombinant vector vaccine role a vaccine against human papillomavirus infection YH vaccine human papillomavirus vaccine SNOMEDCT: 424519000 UMLS_CUI: C1512511 A subunit vaccine role that indicates the vaccine being a peptide vaccine. Jie Zheng role peptide vaccine role a licensed vaccine role that indicates the vaccine occurs in USA. YH role USA licensed vaccine role A route of administration that located in the mouth YH site oral route A route of administration that inject the material(such as vaccines, allergens) into the skin itself. YH,YL intradermal injection route site intradermal route the vaccine component that is used as antigen to produce an immune responce protect against the specific pathogen or disease. This is a modified or partial form of the virus, bacteria or the toxin that causes the disease against which the vaccine protects. The vaccine antigen is altered from its original form so it no longer causes disease but it can produce an immune response.(Vaccine components FactSheet of NCIRS) YL, YH vaccine antigenic component vaccine component To create this term for cover some other vaccines such as cancer vaccine and so on. vaccine antigen a live attenuated quality of a bacterial vaccine strain. YH quality bacterial vaccine organism live attenuated a live attenuated quality of a virus vaccine strain. YH quality viral vaccine organism live attenuated PubMed:23969885 autologous dendritic cell melanoma vaccine a bacterial vaccine that is live and attenuated YH vaccine live attenuated bacterial vaccine a viral vaccine that is live attenuated YH vaccine This term has an equivalent class: 'viral vaccine' and ('has quality at some time' some 'vaccine organism live attenuated') However, running the reasoner takes time. As a way to reducing the time, I have tentatively made tern two subclasses instead of equivalent class. If needed, the equivalent class can be used in SPARQL or converted back in VO. --Oliver live attenuated viral vaccine Role that inheres in an organism that is the target of a vaccine administration (vaccination process). Allen Xiang Anna Maria Masci Barry Smith Jie Zheng Oliver He https://github.com/vaccineontology/VO/issues/677 role vaccine recipient role Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:8306370 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3066 https://github.com/vaccineontology/VO/issues/295 3066 Research B16 Vaccine adjuvanted by Loxoribine The objective that intends to produce vaccine via the vaccine preparation process. YH information content entity vaccine target specification A vaccine licensed in the USA Oliver He, Kallan Roan https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm vaccine USA licensed vaccine site intravesical route A cancer vaccine against non-small cell lung cancer (NSCLC) NSCLC vaccine non-small cell lung cancer vaccine A non-small cell lung cancer mRNA-derived vaccine that contains modified mRNAs encoding cancer-testis antigen NY-ESO-1, melanoma-associated antigens C1 (MAGE-C1/CT7) and C2 (MAGE-C2/CT10), survivin, and the oncofetal antigen 5T4 with potential antitumor and immunomodulatory activities. Oliver He Randi Vita https://www.cancer.gov/publications/dictionaries/cancer-drug/def/non-small-cell-lung-cancer-mrna-derived-vaccine-cv9201 CV9201 A vaccine that is used against an infection by a pathogen under Papillomaviridae. vaccine against Papillomaviridae https://en.wikipedia.org/wiki/Papillomaviridae vaccine Papillomaviridae vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:9725239 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3053 https://github.com/vaccineontology/VO/issues/369 1489079 3053 Clinical trial Gene name: E7 Cancer Vaccine using E7 protein of human papillomavirus 16 and Algammulin Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:10931134 PubMed:9725239 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3054 https://github.com/vaccineontology/VO/issues/370 1489079 3054 Licensed Gene name: E7 Cancer Vaccine using E7 protein of human papillomavirus 16 and Quil-A NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3074 3074 Recombinant Colorectal cancer antigen GA733 Vaccine NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3078 3078 Recombinant NY-ESO-1 Protein vaccine adjuvanted with Imiquimod Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:28706878 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3081 https://github.com/vaccineontology/VO/issues/241 1489079 3081 Clinical trial Gene name: E7 attenuated Listeria expressing cancer antigen vaccine NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3085 3085 Recombinant NY-ESO-1 ISCOMATRIX Vaccine NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3091 3091 Synthetic MUC1 Peptide Vaccine NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3617 3617 VO:0007471 Lymphoma DNA vaccine V-Alpha-V-Beta-V-Beta-FrC An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3643 https://github.com/vaccineontology/VO/issues/175 3643 Clinical trial Glypican-3-derived peptide vaccine for human hepatocellular carcinoma Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15879128 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3695 https://github.com/vaccineontology/VO/issues/316 8132375 3695 Research Gene name: Fragment C from tetanus toxin Cancer DNA vaccine p.DOM-AH1 encoding fragment C Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:18273615 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3696 https://github.com/vaccineontology/VO/issues/378 21423 3696 Research Gene name: E2A Carcinoma DNA vaccine pVAX/E2A Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12384547 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3698 https://github.com/vaccineontology/VO/issues/292 1945467 3698 Clinical trial Gene name: Immunoglobulin B-cell lymphoma DNA vaccine VCL-1642.XXX encoding a chimeric immunoglobulin molecule onsisting of tumor-specific variable (Id) regions Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12231517 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3699 https://github.com/vaccineontology/VO/issues/387 1048 128168861 3699 Research Gene name: S|CEA Colorectal cancer DNA vaccine pCEA/HBsAg encoding carcinoembryonic antigen and hepatitis B surface antigen Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12496961 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3700 https://github.com/vaccineontology/VO/issues/294 22178 7306 3700 Research Gene name: TYRP1|Gene name: Tyrp1 B16 melanoma DNA vaccine pSin-hTRP-1 encoding TRP-1 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12496961 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3701 https://github.com/vaccineontology/VO/issues/293 22178 7306 3701 Research Gene name: TYRP1|Gene name: Tyrp1 B16 melanoma DNA vaccine pCMV-hTRP-1 encoding TRP-1 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3705 3705 Melanoma DNA vaccine TA2M encoding tyrosinase peptides Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3713 https://github.com/vaccineontology/VO/issues/518 3713 Gene name: Survivin Melanoma DNA vaccine VR-S8/VR-IL2/AD-S8 encoding survivin Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3717 https://github.com/vaccineontology/VO/issues/512 2922 3717 Gene name: GRP Melanoma DNA vaccine pCR3.1-VS-HSP65-TP-GRP6-M2 encoding 6 tandem repeats of GRP Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3718 https://github.com/vaccineontology/VO/issues/514 12981 4100 3718 Gene name: GM-CSF|Gene name: MAGEA1 Melanoma DNA vaccine pNL3-MAGE-1-GM Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3719 https://github.com/vaccineontology/VO/issues/513 12981 4100 3719 Gene name: GM-CSF|Gene name: MAGEA1 Melanoma DNA vaccine pN4a-MAGE-1-GM Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3720 https://github.com/vaccineontology/VO/issues/516 84004 3720 Gene name: Mcam Melanoma DNA vaccine SINCp c-muMUC18 encoding MCAM/MUC18 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3723 https://github.com/vaccineontology/VO/issues/485 17829 4582 3723 Clinical trial Gene name: MUC1|Gene name: Muc1 Lung metastasis DNA vaccine pCEP4-MUC1 encoding MUC1 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3724 https://github.com/vaccineontology/VO/issues/511 6490 3724 Gene name: gp100 Melanoma DNA vaccine hugp100 encoding gp100 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3726 https://github.com/vaccineontology/VO/issues/519 20431 3726 Gene name: Pmel17 Melanoma DNA vaccine VR1012/mPmel17 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3727 https://github.com/vaccineontology/VO/issues/509 1067130 1638 3727 Gene name: HUMGP 75|Gene name: TRP-2 Melanoma DNA vaccine gp75 DNA encoding melanosomal membrane glycoproteins, gp75 Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3728 https://github.com/vaccineontology/VO/issues/521 22178 3728 Gene name: TRP-1 Melanoma recombinant vector vaccine rVVmTRP-1 encoding TRP-1 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3729 https://github.com/vaccineontology/VO/issues/510 6490 3729 Gene name: gp100 Melanoma DNA vaccine hTRP2 encoding TRP-2 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3730 https://github.com/vaccineontology/VO/issues/515 104042 55118 3730 Gene name: Ubiquitin|Gene name: Trp2 Melanoma DNA vaccine pUB-TRP-2 encoding a fusion protein linking murine ubiquitin (UB) to the N-terminus of the full-length mTRP-2 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3731 3731 Neuroblastoma DNA vaccine HuDsec NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3736 3736 Prostate cancer DNA vaccine pcDNA3-STEAP encoding six-transmembrane epithelial antigen NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3737 3737 Prostate cancer DNA vaccine hPSMAt encoding PSMA NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3738 3738 Prostate cancer DNA vaccine rPSMAt encoding PSMA NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3740 3740 Prostate cancer DNA vaccine pVax-PSA NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3742 3742 Prostate cancer DNA vaccine psig-3P-Fc encoding 3P(hPSM, hPAP, or hPSA)-Fc fusion protein NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3744 3744 Prostate cancer DNA vaccine PSCA-HSP encoding PSCA and HSP NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3745 3745 Prostate cancer DNA vaccine encoding PSCA NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3746 3746 Prostate cancer DNA vaccine pmPSCA encoding PSCA Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3768 https://github.com/vaccineontology/VO/issues/520 7299 3768 Gene name: Tyrosinase Melanoma DNA vaccine xenogeneic DNA encoding murine tyrosinase NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3869 3869 B16 melanoma DNA vaccine pSin-mTRP-1 A dendritic cell vaccine consisting of dendritic cells (DCs) electroporated with mRNA encoding three adjuvants, CD40 ligand (CD40L), a constitutively active TLR4, and CD70 (all together termed TriMix); coelectroporated with full-length mRNA encoding MAGE-A3, MAGE-C2, Tyrosinase and gp100; and linked to DC-LAMP, with potential immunostimulating activity. Upon vaccination, the DCs may stimulate the immune system to mount an antigen-specific cytotoxic T-lymphocyte (CTL) response against the melanoma antigens. This may decrease cellular proliferation of melanoma cells expressing these antigens. Electroporation with the adjuvants CD40L and TLR4 allows for the generation of mature and active DCs; electroporation with CD70 provides a costimulatory signal to CD27+ naive T cells thereby supporting T-cell proliferation and inhibiting T-cell apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5238 https://github.com/vaccineontology/VO/issues/286 4102 51438 6490 7099 7299 959 970 5238 Clinical trial Gene name: gp100 (PMEL)|Gene name: MAGEA3|Gene name: MAGEC2|Gene name: CD40LG|Gene name: Tyrosinase|Gene name: TLR4|Gene name: CD70 Autologous TriMix-DC Melanoma Vaccine NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3987 3987 pCR3.1-VS-HSP65-TP-GRP6-M2 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4001 4001 SRL172 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4019 4019 VMCL NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4025 4025 Newcastle disease virus lysate NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4044 4044 smallpox vaccine NF Oliver He RS Yuying Pan PubMed:22896657 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4054 4054 mRNA-electroporated dendritic cells encoding gp100 and tyrosinase as melanoma vaccine NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4057 4057 pcDNA3-MCC/ST The approach focuses on the use of five primary patient derived melanoma cells (MEL-2, MEL-V, 3MM, KFM, and GLM-2). These cells display differential in vitro migratory and invasive properties as well as have the ability to form solid tumors when implanted into BALB/c nude mice. The retention of the innate phenotype of these primary patient derived cells together with the expression of a multitude repertoire of melanoma associated antigens offers a novel opportunity to target melanoma so as to avoid immune evasion Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4064 https://github.com/vaccineontology/VO/issues/557 2315 6490 4064 Gene name: MLANA|Gene name: gp100 Multivalent immunotherapeutic vaccine NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4079 4079 short overlapping peptides and full-length recombinant protein NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4190 4190 Poliovirus vector expressing model antigen H2-Kb-restricted CTL epitope Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4193 https://github.com/vaccineontology/VO/issues/496 727897 4193 Gene name: MUC5B Maraba virus MG1 Vaccine NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4198 4198 rMeV- SCD NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4201 4201 rMCMV-TRP2 Several canarypox virus recombinants expressing human or murine p53 in wild-type or mutant form were constructed Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12006514 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4225 7157 4225 Clinical trial Gene name: TP53 (P53) ALVAC-P53 Vaccine NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4251 4251 rMVTT- HPV16-E6/E7 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4255 https://github.com/vaccineontology/VO/issues/527 4100 4255 Gene name: MAGEA1 MG1-hDCT Vaccine A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. In (H115D)VHL35 peptide, histidine is substituted for an aspartic acid in position 115. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5304 https://github.com/vaccineontology/VO/issues/77 5304 Clinical trial (H115D)VHL35 Peptide Vaccine A cancer vaccine that is used against prostate cancer. Oliver He Penny Pan https://www.hopkinsmedicine.org/health/conditions-and-diseases/prostate-cancer/immunotherapy-for-prostate-cancer prostate cancer vaccine A cancer vaccine that is used against colorectal cancer Oliver He Penny Pan PubMed:35990683 colorectal cancer vaccine A cancer vaccine that is used against lymphoma. Oliver He Penny Pan http://www.cancer.gov/news-events/cancer-currents-blog/2019/in-situ-vaccine-non-hodgkin-lymphoma lymphoma vaccine A cancer vaccine that is used against brain canceer. Oliver He Penny Pan https://www.criver.com/eureka/brain-cancer-vaccine-gliomas-moves-forward-clinic brain cancer vaccine A cancer vaccine that is used against liver canceer. Oliver He Penny Pan https://www.creative-biolabs.com/vaccine/liver-cancer-vaccines.htm liver cancer vaccine A cancer vaccine that is used against pancreatic canceer. Oliver He Penny Pan https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-vaccine pancreatic cancer vaccine A cancer vaccine that is developed against breast cancer. Oliver He breast cancer vaccine A cancer vaccine that is developed against bladder cancer. Oliver He bladder cancer vaccine A cancer vaccine that is developed against lung cancer. Oliver He lung cancer vaccine A cancer vaccine that is developed against leukemia. Oliver He leukemia cancer vaccine A cancer vaccine that is developed against cervical cancer. Oliver He cervical cancer vaccine A cancer vaccine that is developed against colon cancer. Oliver He colon cancer vaccine A cancer vaccine that is developed against gastric cancer Oliver He gastric cancer vaccine A cancer vaccine that is developed against mesothelioma cancer. Oliver He mesothelioma cancer vaccine A cancer vaccine that is developed against myeloma cancer. Oliver He myeloma cancer vaccine A cancer vaccine that is developed against ovarian cancer. Oliver He ovarian cancer vaccine A cancer vaccine that is developed against renal cancer. Oliver He renal cancer vaccine A cancer vaccine that is developed against sarcoma cancer. Oliver He sarcoma cancer vaccine A cancer vaccine that is developed against esophageal cancer. Jie Zheng Oliver He Xingxian Li Yuying Pan esophageal cancer vaccine A cancer vaccine that is developed against head and neck cancer. Jie Zheng Oliver He Xingxian Li Yuying Pan head and neck cancer vaccine A cancer vaccine that is developed against nasopharyngeal cancer. Jie Zheng Oliver He Xingxian Li Yuying Pan nasopharyngeal cancer vaccine A cancer vaccine that is developed against hepatocellular carcinoma. Jie Zheng Oliver He Xingxian Li Yuying Pan hepatocellular carcinoma vaccine a grouping class for vaccines for specific diseases Barry Smith, Oliver He, Jie Zheng, Charles Tapley Hoyt, Xingxian Li https://github.com/vaccineontology/VO/issues/619 vaccine vaccine against disease Vaccine against an infectious disease caused by specific pathogen(s). Note that all infectious diseases are caused by some pathogens, so 'infectious disease vaccine' and 'vaccine against pathogen infection' are basically synonyms. Barry Smith, Oliver He, Jie Zheng, Charles Tapley Hoyt, Xingxian Li infectious disease vaccine vaccine against pathogen vaccine against pathogen infection https://github.com/vaccineontology/VO/issues/619 https://github.com/vaccineontology/VO/issues/747 vaccine vaccine against infectious disease a grouping class for vaccines for specific platforms vaccine vaccine by platform type Gene expressing a protein which serves, either in whole or in part, as an antigen within a cancer vaccine. Yongqun He|Anna Maria Masci|Barry Smith|Jie Zheng https://github.com/vaccineontology/VO/issues/677 gene canvaxgen A recombinant oncolytic adenovirus encoding the immunohematopoietic cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cells lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus may promote a cytotoxic T cell response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48412 NCT: https://clinicaltrials.gov/ct2/show/NCT00109655 PubMed:28530155 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5475 https://github.com/vaccineontology/VO/issues/75 1437 5475 Clinical trial Gene name: CSF-2 Oncolytic Adenovirus Encoding GM-CSF Vaccine A non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the gene for interferon alpha-2b (IFN_2b) and the gene transfer enhancement agent Syn 3, with potential antineoplastic activity. Upon intravesical administration, recombinant adenovirus-interferon with Syn3 transfects both cancerous and normal bladder cells, and the adenovirus secretes interferon (IFN_2b) into the bladder. IFN exerts a direct antitumor killing effect and a bystander effect, thereby killing adjacent, non-transfected cancerous bladder cells. Syn 3 enhances the ability of the adenoviral vector to transfect cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C104743 NCT: https://clinicaltrials.gov/ct2/show/NCT02773849 PubMed:28834453 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5047 https://github.com/vaccineontology/VO/issues/322 3440 5047 Clinical trial Gene name: IFNA2 Recombinant Adenovirus-Interferon/Syn3 Vaccine A cancer vaccine adjuvant consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of recombinant fowlpox GM-CSF vaccine adjuvant may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2686 NCT: https://clinicaltrials.gov/ct2/show/NCT00072137 PubMed:15780740 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4994 https://github.com/vaccineontology/VO/issues/328 1437 4994 Clinical trial Gene name: GM-CSF Recombinant Fowlpox GM-CSF Vaccine Adjuvant A peptide vaccine derived from cytomegalovirus (CMV) antigens with potential immunostimulating activity. Intradermal administration of the PEP-CMV vaccine may stimulate the immune system to mount a specific helper and cytotoxic T-lymphocyte (CTL) response against CMV-infected tumor cells. Infection with the herpesvirus CMV may play a significant role in tumor cell initiation and progression as well as chemoresistance. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C107243 NCT: https://clinicaltrials.gov/ct2/show/NCT02864368 PubMed:31806885 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5259 https://github.com/vaccineontology/VO/issues/118 18826 5259 Clinical trial Gene name: pp65(Lcp 1) PEP-CMV Vaccine A cancer vaccine consisting of a human epidermal growth factor receptor variant III (EGFRvIIi)-specific peptide conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Vaccination with rindopepimut may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII. EGFRvIII, a functional variant of EGFR that is not expressed in normal tissues, was originally discovered in glioblastoma multiforme (GBM) and has also been found in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head and neck cancers. EGFRvIII contains an 83 amino acid deletion in its extracellular domain and has been shown to transform NIH/3T3 mouse embryonic fibroblast cells in vitro. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C69076 NCT: https://clinicaltrials.gov/ct2/show/NCT01498328 PubMed:28844499 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5032 https://github.com/vaccineontology/VO/issues/120 1956 5032 Clinical trial Gene name: EGFR PF-04948568 Vaccine Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29786 PubMed:21078216 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5192 https://github.com/vaccineontology/VO/issues/324 945006 5192 Clinical trial Gene name: lacZ Recombinant Adenovirus-LacZ Vaccine A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient‚Äö√†√∂‚àö√òs own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116332 NCT: https://clinicaltrials.gov/ct2/show/NCT02149225 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5086 5086 Clinical trial Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2 A personalized peptide-based cancer vaccine comprised of five to ten peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB tumor-associated peptides vaccine therapy APVAC1 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the tumor associated peptides, and results in decreased GB growth. The peptides are derived from a glioma actively-personalized vaccine consortium (GAPVAC) warehouse and are specifically selected based on the patient's expression of tumor-associated antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116331 NCT: https://clinicaltrials.gov/ct2/show/NCT02149225 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5231 1956 5231 Clinical trial Gene name: EGFR Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1 An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial growth factor receptor 2 (VEGFR-2) (VXM01), with potential immunomodulating, anti-angiogenic and antineoplastic activity. Upon oral administration and successful transduction, VEGFR-2 DNA vaccine VXM01 expresses VEGFR-2 in addition to inducing the expression of T-cell activation markers, such as CD25, interleukin-2, the early T-cell activation antigen CD69 and the lymphocyte function-associated antigen LFA-2. The immune response targets the fast growing VEGFR-2 expressing endothelial cells found in the tumor vasculature, thereby blocking angiogenesis which may ultimately inhibit tumor cell proliferation. VEGFR-2 is a receptor tyrosine kinase overexpressed on proliferating endothelial cells in the tumor vasculature. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C99378 NCT: https://clinicaltrials.gov/ct2/show/NCT02718443 PubMed:29632710 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5521 3791 5521 Clinical trial Gene name: KDR VEGFR-2 DNA Vaccine VXM01 A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the HER2 protein (E75 peptide) and combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activity. Upon intradermal injection, nelipepimut-S plus GM-CSF vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cell types. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF potentiates the antitumor immune response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C99228 NCT: https://clinicaltrials.gov/ct2/show/NCT02636582 PubMed:33485895 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5363 https://github.com/vaccineontology/VO/issues/54 2064 5363 Clinical trial Gene name: ERBB2 Nelipepimut-S Plus GM-CSF Vaccine A cancer vaccine consisting of one or more long, synthetic peptides derived from patient-specific breast cancer tumor-associated antigens (TAAs), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration of the personalized synthetic long peptide breast cancer vaccine, the peptides stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TAAs, which results in tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C121947 NCT: https://clinicaltrials.gov/ct2/show/NCT02427581 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5348 5348 Clinical trial Personalized Synthetic Long Peptide Breast Cancer Vaccine A plasmid DNA cancer vaccine encoding the intracellular domain (ICD) of the HER-2/neu proto-oncogene. Upon administration and after cellular uptake by skin or muscle cells, the pNGVL3-hICD vaccine plasmid expresses the HER-2/neu protein, which, after intracellular processing, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-2. The HER-2/neu ICD protein is highly immunogenic and, as a subdominant epitope, may be associated with decreased immune tolerance. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61146 NCT: https://clinicaltrials.gov/ct2/show/NCT05163223 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5040 https://github.com/vaccineontology/VO/issues/122 2064 5040 Clinical trial Gene name: ERBB2 pNGVL3-hICD Vaccine Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29785 PubMed:11590241 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5530 https://github.com/vaccineontology/VO/issues/320 5530 Clinical trial Recombinant Adenovirus-Cre Recombinase Vaccine An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116880 NCT: https://clinicaltrials.gov/ct2/show/NCT01220128 PubMed:30562862 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5297 https://github.com/vaccineontology/VO/issues/326 7490 5297 Clinical trial Gene name: WT1 Recombinant Anti-WT1 Immunotherapeutic GSK2302024A Vaccine A cancer vaccine consisting of a truncated recombinant HER2 peptide (dHER2) with potential antineoplastic activity. Upon administration, recombinant dHER2 vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. The HER2 protein is a tumor-associated antigen (TAA) that is overexpressed in a variety of cancers. dHER2 includes the extracellular domain (ECD) and a part of the intracellular domain (ICD) of the HER2 protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49177 NCT: https://clinicaltrials.gov/ct2/show/NCT00140738 PubMed:26975189 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5241 2064 5241 Clinical trial Gene name: ERBB2 Recombinant dHER2 Vaccine A cancer vaccine containing autologous dendritic cells pulsed with a fusion product of an epitope of human tumor-associated epithelial mucin 1 (MUC1) antigen and the vaccine adjuvant mannan (oxidized mannose), with potential antineoplastic activity. When the modified dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in tumor cell lysis. Addition of manna in this vaccine, enhances immune recognition. MUC1 antigen, a high-molecular-weight transmembrane glycoprotein, is overexpressed on many tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102782 NCT: https://clinicaltrials.gov/ct2/show/NCT00004156 PubMed:9656453 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5077 4582 5077 Clinical trial Gene name: MUC1 Recombinant Human MUC1-Oxidized Polymannose-pulsed Autologous Dendritic Cell Vaccine A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain incapable of virion assembly. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49087 NCT: https://clinicaltrials.gov/ct2/show/NCT00227474 PubMed:18990081 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5058 https://github.com/vaccineontology/VO/issues/337 7162 5058 Clinical trial Gene name: TPBG Recombinant Modified Vaccinia Ankara-5T4 Vaccine A vaccinia virus based vaccine expressing human tumor associated epithelial mucin (DF3 antigen; MUC1). MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in various tumors such as breast, prostate, and ovarian cancers. This vaccine could be used in development of immunotherapeutics against cancers expressing MUC1. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2510 NCT: https://clinicaltrials.gov/ct2/show/NCT00071942 PubMed:9101412 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5281 https://github.com/vaccineontology/VO/issues/338 354 4582 5281 Clinical trial Gene name: MUC1|Gene name: KLK3 Recombinant Vaccinia DF3/MUC1 Vaccine A vaccine containing a recombinant vaccinia virus that encodes the gene for human mucin-1, a tumor-associated antigen. Upon administration, recombinant vaccinia-MUC-1 vaccine may elicit a MUC-1-specific cytotoxic T cell response against tumor cells bearing MUC-1. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2732 NCT: https://clinicaltrials.gov/ct2/show/NCT00071942 PubMed:12898638 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5321 https://github.com/vaccineontology/VO/issues/347 4582 5321 Clinical trial Gene name: MUC1 Recombinant Vaccinia-MUC-1 Vaccine A vaccine containing a pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Sialylated Tn antigen (sTn) is a monosaccharide glycan usually O-linked to serine or threonine residues of mucins found on most epithelial cancers. Conjugation with KLH, a hapten carrier and an immunostimulant, improves host immune responses. Vaccination with sTn-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing sTn, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1690 NCT: https://clinicaltrials.gov/ct2/show/NCT00003638 PubMed:23983823 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5425 https://github.com/vaccineontology/VO/issues/361 5425 Clinical trial Gene name: sialyl-Tn Sialyl Tn-KLH Vaccine A vaccine comprised of a synthetic Sialyl-Tn antigen linked to the protein carrier, keyhole limpet hemocyanin (KLH), administered with immunostimulant, Detox. Vaccination with STn-KLH plus Detox may elicit an IgG-based anti-STn antibody response and ultimately a cytotoxic T-cell response against STn-expressing cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2501 NCT: https://clinicaltrials.gov/ct2/show/NCT00003638 PubMed:7690215 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5061 https://github.com/vaccineontology/VO/issues/363 5061 Clinical trial Gene name: sialyl-Tn STn-KLH plus Detox Vaccine A cancer vaccine comprised of multiple synthetic breast cancer peptides and the adjuvant tetanus toxoid helper peptide emulsified in the adjuvant Montanide ISA-51 with immunopotentiation activity. Vaccination with this cancer vaccine may elicit a specific cytotoxic T-lymphocyte response against breast cancer cells. Synthetic breast cancer peptides may stimulate the immune response against cells that produce breast cancer markers such as erbB2 (HER2/neu) while tetanus toxoid helper peptide binds to class II MHC molecules as a nonspecific vaccine helper epitope, resulting in a long-term immunopotentiation by increasing the helper T-cell response. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61076 NCT: https://clinicaltrials.gov/ct2/show/NCT00304096 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5271 6007 5271 Clinical trial Gene name: RHD Synthetic Breast Cancer Peptides-Tetanus Toxoid-Montanide ISA-51 Vaccine A vaccine containing a clustered pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Alpha-N-acetylgalactosamine (Tn) is a monosaccharide usually O-linked to serine or threonine residues of mucins found on most epithelial cancers with the highest expression on prostate cancer. This vaccine contains the Tn epitope cluster (c) that is synthesized by linking 3 copies of the Tn epitope on a threonine backbone to achieve the essential immunogenic structure. KLH is a hapten carrier and serves as an immunostimulant to improve immune recognition. Vaccination with Tn(c)-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing Tn antigen, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2474 NCT: https://clinicaltrials.gov/ct2/show/NCT00030823 PubMed:9579798 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5025 5025 Clinical trial Tn(c)-KLH Conjugate Vaccine A population of activated, immortalized, interleukin-2 (IL-2)-dependent, cytotoxic natural killer (NK) cells with potential antitumor activity. Natural killer cells ZRx101 are derived from NK-92 cells, having been modified to target tumor-associated antigens (TAAs) upregulated in certain types of cancer. The NK-92 cell line was originally isolated from a patient with large granular lymphocytic (LGL) leukemia/lymphoma. (NCIT_C85466). Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85466 NCT: https://clinicaltrials.gov/ct2/show/NCT00900809 PubMed:18425107 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5026 https://github.com/vaccineontology/VO/issues/50 107653060 5026 Clinical trial Gene name: IL12 Natural Killer Cells ZRx101 vaccine A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various tumors. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response to cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2657 NCT: https://clinicaltrials.gov/ct2/show/NCT05479045 PubMed:24397899 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5206 https://github.com/vaccineontology/VO/issues/55 1485 5206 Clinical trial Gene name: CTAG1B NY-ESO-1 peptide vaccine A plasmid DNA encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1 with potential immunostimulating and antitumor activities. Upon administration, NY-ESO-1 plasmid DNA cancer vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1 is a tumor associated antigen (TAA) found in normal testes and expressed on the surfaces of various tumor cells, including melanoma, breast, bladder, prostate, lung, ovarian, and hepatocellular tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62452 NCT: https://clinicaltrials.gov/ct2/show/NCT00199849 PubMed:15102697 PubMed:21900253 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5283 https://github.com/vaccineontology/VO/issues/56 https://github.com/vaccineontology/VO/issues/58 1485 5283 Clinical trial Gene name: CTAG1B NY-ESO-1 plasmid DNA cancer vaccine A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C113432 NCT: https://clinicaltrials.gov/ct2/show/NCT02015416 PubMed:31069460 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5445 https://github.com/vaccineontology/VO/issues/85 1485 7099 5445 Clinical trial Gene name: CTAG1B|Gene name: TLR4 NY-ESO-1/GLA-SE vaccine ID-G305AmN A recombinant nonapeptide used as an antineoplastic vaccine. NY-ESO-1b peptide vaccine contains the amino acid sequence SLLMWITQC, derived from the cancer-testis tumor antigen (NY-ESO-1), which is expressed on tumor cells of many different types, including melanomas. Vaccination with this peptide vaccine may elicit strong humoral and cellular immune responses to NY-ESO-1-expressing cancers. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C68999 NCT: https://clinicaltrials.gov/ct2/show/NCT00199836 PubMed:15501973 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5428 https://github.com/vaccineontology/VO/issues/112 1485 5428 Clinical trial Gene name: CTAG1B NY-ESO-1b peptide vaccine A tumor-associated antigen belonging to the family of immunogenic testicular proteins that are aberrantly expressed in human cancers in a lineage-nonspecific fashion. Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma; and restricted expression in normal tissues, with high-level mRNA expression found only in testis and ovary tissues. The gene for NY-ESO-1 maps to Xq28 and codes for an 18-kDa protein having no homology with any known protein. NY-ESO-1 elicits a strong, integrated humoral and cellular immune response in a high proportion of patients with NY-ESO-1-expressing tumors and is under investigation as a cancer immunotherapy agent. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26680 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5182 https://github.com/vaccineontology/VO/issues/76 1485 5182 Clinical trial Gene name: CTAG1B NY-ESO-B Vaccine An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells. After tumor cell lysis, released viruses infect neighboring tumor cells, tripping a chain of ONYX-015-mediated tumor cell cytotoxicity. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2830 NCT: https://clinicaltrials.gov/ct2/show/NCT00006106 PubMed:11892945 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5486 https://github.com/vaccineontology/VO/issues/73 7157 5486 Clinical trial Gene name: TP53 ONYX-015 Vaccine A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene. p53 peptide vaccine may elicit an HLA-A2.1-restricted cytotoxic T lymphocyte immune response against tumor cells that overexpress p53 protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1986 NCT: https://clinicaltrials.gov/ct2/show/NCT00001827 PubMed:24583792 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5255 7157 5255 Clinical trial Gene name: TP53 p53 Peptide Vaccine A peptide-based vaccine containing a pan HLA DR-binding epitope (PADRE) fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities. Upon administration, PADRE-CMV fusion peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against CMV in the CMV-infected host. The synthetic peptide PADRE is a universal helper T cell epitope. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78820 NCT: https://clinicaltrials.gov/ct2/show/NCT00722839 PubMed:22402037 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5441 5441 Clinical trial PADRE-CMV Fusion Peptide Vaccine A synthetic HIV-1 envelope peptide that was developed for use as a vaccine. Vaccination with PCLUS 3-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2786 NCT: https://clinicaltrials.gov/ct2/show/NCT00001386 PubMed:10546852 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5451 https://github.com/vaccineontology/VO/issues/115 5451 Clinical trial PCLUS 3-18MN Vaccine A synthetic HIV-1 envelope peptide that was developed for use as a vaccine. Vaccination with PCLUS 6.1-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2787 NCT: https://clinicaltrials.gov/ct2/show/NCT00001386 PubMed:10546852 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5443 https://github.com/vaccineontology/VO/issues/116 5443 Clinical trial PCLUS 6.1-18MN Vaccine A cancer vaccine consisting of Her2/neu peptides incorporated into microspheres of poly (lactide-co-glycolide) (PLGA), a biodegradable polymer. Poly microsphere encapsulated HER2/neu oral vaccine has been investigated for use in immunotherapy for tumors positive for HER-2/neu, a tumor associated antigen that is overexpressed in various cancers, including breast and ovarian cancer.‚Äö√†√∂‚àö¬ß Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2718 NCT: https://clinicaltrials.gov/ct2/show/NCT02795988 PubMed:29448628 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5176 2064 5176 Clinical trial Gene name: ERBB2 Poly Microsphere Encapsulated HER2/neu Oral Vaccine A cancer vaccine containing a RAS oncogene-encoded peptide with potential antineoplastic activity. RAS peptide cancer vaccine may stimulate a RAS peptide-specific antitumoral T-cell cytotoxic immune response, resulting in an inhibition of tumor cell proliferation and tumor cell death. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2438 NCT: https://clinicaltrials.gov/ct2/show/NCT00019006 PubMed:33016924 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5320 https://github.com/vaccineontology/VO/issues/189 3845 5320 Clinical trial Gene name: KRAS RAS Peptide Cancer Vaccine A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the stimulatory molecule transgene B7-1. Recombinant fowlpox-B7.1 (rF-B7.1) vaccine may enhance antigen presentation and activate antitumoral cytotoxic T-cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2666 NCT: https://clinicaltrials.gov/ct2/show/NCT00030693 PubMed:12969559 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5424 https://github.com/vaccineontology/VO/issues/329 941 5424 Clinical trial Gene name: CD80 Recombinant Fowlpox-B7.1 Vaccine A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). This agent may enhance CEA presentation to antigen presenting cells (APC) and activate cytotoxic T-cells against CEA-expressing tumors. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2620 NCT: https://clinicaltrials.gov/ct2/show/NCT00028496 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5049 https://github.com/vaccineontology/VO/issues/330 1048 5049 Clinical trial Gene name: CEACAM5 Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine A whole, heat-killed, recombinant Saccharomyces cerevisiae yeast-based vaccine genetically altered to express the carcinoembryonic antigen (CEA) peptide 610D with potential immunostimulating and antineoplastic activities. Upon administration, recombinant Saccharomyces cerevisia-CEA(610D) vaccine GI-6207 may stimulate a host cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells, which may result in tumor cell lysis. CEA, a tumor associated antigen, is overexpressed on a wide variety of human cancer cells including colorectal, gastric, lung, breast and pancreatic cancer cells. CEA 610D encodes for 9 amino acids (605-613) in which aspartate is substituted for asparagine at position 610 (610D) in order to strengthen the induction of the CTL response against CEA-expressing tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82371 NCT: https://clinicaltrials.gov/ct2/show/NCT00924092 PubMed:22862954 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5152 1048 5152 Clinical trial Gene name: CEACAM5 (CEA) Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207 A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1, and LFA-3; also called TRICOM). Vaccination with recombinant vaccinia-CEA(6D)-TRICOM vaccine stimulates the host immune system to mount a T-cell response against tumor cells expressing the CEA antigen. The use of TRICOM in the vaccine may elicit a greater antitumor cytotoxic T lymphocyte (CTL) immune response compared to the use of vaccinia-CEA alone. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2619 NCT: https://clinicaltrials.gov/ct2/show/NCT00217373 PubMed:27581603 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5037 https://github.com/vaccineontology/VO/issues/342 111518 5037 Clinical trial Gene name: Cea-Mouse Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine An admixture of recombinant vaccinia virus encoding MUC-1 and recombinant vaccinia virus encoding the murine T-cell co-stimulatory molecule B7.1. MUC-1 is a glycosylated mucin that is overexpressed in breast, lung, pancreatic, prostate, stomach, colon, and ovarian carcinomas. Vaccination with MUC-1 in combination with B7.1 may enhance the cytotoxic T cell (CTL) immune response to tumors expressing MUC-1, compared to vaccination with MUC-1 alone. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29409 PubMed:9101412 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5326 https://github.com/vaccineontology/VO/issues/348 12519 4582 5326 Clinical trial Gene name: MUC1|Gene name: Cd80 Recombinant Vaccinia-MUC1-B7 Vaccine A cancer vaccine consisting of a recombinant vaccinia viral vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with recombinant vaccinia- NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48419 NCT: https://clinicaltrials.gov/ct2/show/NCT00112957 PubMed:29773080 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5389 https://github.com/vaccineontology/VO/issues/349 1485 5389 Clinical trial Gene name: CTAG1B Recombinant Vaccinia-NY-ESO-1 Vaccine A replication-incompetent, pathotropic, tumor matrix (collagen)-targeted, retroviral vector encoding an N-terminal deletion mutant form of the cyclin G1 gene with potential antineoplastic activity. Under the control of a hybrid long-terminal repeat/cytomegalovirus (CMV) promoter, retrovector encoding mutant anti-cyclin G expresses the mutant cyclin G1 construct, resulting in disruption of tumor cell cyclin G1 activity and decreased cellular proliferation and angiogenesis. This agent preferentially targets collagen of the tumor matrix because of the incorporation of the collagen-binding domain of von Willebrand factor (vWF) on the retrovector surface. Exploiting the collagen-targeting mechanism of vWF permits delivery of the retrovector to tumor sites where angiogenesis and collagen matrix exposure occur. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49082 NCT: https://clinicaltrials.gov/ct2/show/NCT00505271 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5437 https://github.com/vaccineontology/VO/issues/355 900 5437 Clinical trial Gene name: CCNG1 Retrovector Encoding Mutant Anti-Cyclin G1 Vaccine An autologous dendritic cell (DC) vaccine loaded with tumor-associated antigens (TAAs) derived from survivin, p53 and human epidermal growth factor receptor 2 (HER2 or ERBB2), with immunostimulating and antineoplastic activities. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against tumor cells expressing these TAAs, resulting in tumor cell death. Survivin, p53 and HER2 are essential in neoplastic growth, and are considered to be universal tumor antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C114285 NCT: https://clinicaltrials.gov/ct2/show/NCT00978913 PubMed:16096014 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5180 2064 373110 7157 5180 Clinical trial Gene name: Survivin|Gene name: ERBB2|Gene name: p53 Survivin/p53/HER2 Antigen-loaded Autologous Dendritic Cell Vaccine A peptide vaccine containing a 15-mer peptide (DLAQMFFCFKELEGW), with C to M alteration at amino acid position 57, derived from the anti-apoptosis protein survivin, and conjugated with keyhole limpet hemocyanin (KLH), with potential immunopotentiating and antineoplastic activities. Upon subcutaneous administration of SVN53-67/M57-KLH peptide vaccine, this peptide is able to bind both HMC class I and II molecules and may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) as well as a T-helper cell response against survivin-expressing cancer cells. This may result in decreased tumor cell proliferation and ultimately tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family, expressed during embryonic development while absent in most normal adult cells, is upregulated in a variety of human cancers; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. KLH may enhance immune recognition and may promote an enhanced response. As SVN53-67 is weakly immunogenic in humans, the M57 alteration may lead to greater affinity towards HLA-A*0201 and thus an enhanced antitumor immune response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95705 NCT: https://clinicaltrials.gov/ct2/show/NCT02334865 PubMed:27576783 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5008 https://github.com/vaccineontology/VO/issues/405 373110 5008 Clinical trial Gene name: Survivin SVN53-67/M57-KLH Peptide Vaccine A DNA vaccine consisting of a plasmid encoding the full-length sequence of the tumor-associated antigen (TAA) human telomerase reverse transcriptase (hTERT), which is the catalytic subunit of human telomerase and synthesizes telomeric DNA at the chromosome ends, containing two immunogenic mutations, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT-encoding DNA vaccine INO-1400 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C120118 NCT: https://clinicaltrials.gov/ct2/show/NCT02960594 PubMed:34230114 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5171 https://github.com/vaccineontology/VO/issues/409 7015 5171 Clinical trial Gene name: TERT Synthetic hTERT DNA Vaccine INO-1400 A cancer vaccine consisting of E-PRA and E-PSM, two synthetic peptide analogs of PRAME (PReferential Antigen MElanoma) and PSMA (Prostate Specific Membrane Antigen), with potential immunostimulating activity. Upon direct administration into lymph nodes, synthetic peptides E-PRA and E-PSM vaccine may sitmulate a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing tumor cells. PRAME and PSMA are tumor-associated antigens upregulated and expressed on the cell surfaces of certain tumor cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C67098 NCT: https://clinicaltrials.gov/ct2/show/NCT00423254 PubMed:21760528 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5496 https://github.com/vaccineontology/VO/issues/412 6277 5496 Clinical trial Gene name: S100A6 Synthetic Peptides E-PRA And E-PSM Vaccine A peptide-based cancer vaccine, containing amino acid residues 27 through 35 of T cell receptor gamma alternate reading frame protein (TARP), with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 27-35 peptide vaccine may stimulate a host cytotoxic T-cell (CTL) response against TARP-expressing tumor cells, resulting in tumor cell cytotoxicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C85462 NCT: https://clinicaltrials.gov/ct2/show/NCT00972309 PubMed:27622067 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5448 https://github.com/vaccineontology/VO/issues/413 445347 5448 Clinical trial Gene name: TARP TARP 27-35 Peptide Vaccine A peptide-based cancer vaccine, consisting of amino acid residues 29 through 37 of T cell receptor gamma alternate reading frame protein (TARP) with a leucine-to-valine substitution at position 9, with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 29-37-9V peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against TARP-expressing tumor cells, which may result in decreased tumor cell proliferation. The leucine-to-valine substitution at position 9 of this peptide improves its immunogenicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C85463 NCT: https://clinicaltrials.gov/ct2/show/NCT02362464 PubMed:27622067 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5242 https://github.com/vaccineontology/VO/issues/414 445347 5242 Clinical trial Gene name: TARP TARP 29-37-9V Peptide Vaccine A cancer vaccine consisting of a recombinant vector encoding the tumor-associated carcinoembryonic antigen (CEA) that is‚Äö√†√∂‚àö¬ßcontaminated‚Äö√†√∂‚àö¬ßwith bovine viral diarrhea virus (BVDV). The carcinoembryonic antigen (CEA) is a prevalent tumor marker expressed by a number of different cancers such as colorectal, breast, lung and ovarian carcinomas; vaccination with vaccinia virus genetically engineered to express‚Äö√†√∂‚àö¬ßCEA‚Äö√†√∂‚àö¬ßmay generate antitumoral T-cell responses.‚Äö√†√∂‚àö¬ßBVDV‚Äö√†√∂‚àö¬ßis an RNA pestivirus that may contaminate vaccines due to its presence in fetal calf serum used as a growth supplement in the tissue culture of mammalian cells used in vaccine production. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29476 PubMed:35380920 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5295 https://github.com/vaccineontology/VO/issues/415 4153 5295 Clinical trial Gene name: MBL2 TBC-CEA-Contaminated W/ BVDV Vaccine A lipid-based multi-peptide cancer vaccine targeted against multiple cancers with immunopotentiating activity. Therapeutic breast/ovarian/prostate peptide cancer vaccine DPX-0907 is a lyophilized liposomal proprietary preparation comprised of 7 tumor-specific HLA-A2-restricted epitopes (TAAs): topoisomerase II alpha, B-cell receptor-associated protein 31 (CDM protein), TNF-alpha-converting enzyme (TACE/ADAM17), Abelson homolog 2 (Abl2), gamma catenin (Junction plakoglobin), epithelial discoidin domain receptor 1 (EDDR1) and integrin beta 8 subunit. Upon vaccination, the lyophilized antigen/adjuvant/liposome complex is re-suspended in Montanide 1SA51 VG to create a depot effect, thereby presenting the TAAs to the immune system for a prolonged period of time. This may stimulate a potent cytotoxic T-lymphocyte (CTL) immune response against cancer cells that express these 7 TAAs and share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. The 7 TAAs are overexpressed on the surface of breast/ovarian and prostate cancer cells and play an important role in tumor cell growth and survival. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C91077 NCT: https://clinicaltrials.gov/ct2/show/NCT01095848 PubMed:22862954 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5458 10134 27 3696 3728 6868 7153 780 5458 Clinical trial Gene name: BCAP31|Gene name: TOP2A|Gene name: ADAM17|Gene name: ABL2|Gene name: JUP|Gene name: DDR1|Gene name: IGTB8 Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907 A cancer vaccine containing URLC10 (up-regulated lung cancer 10) epitopes with potential immunostimulatory and antineoplastic activities. Upon administration, URL peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells. Up-regulated in lung and esophageal cancers, the function of URLC10 is unknown. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74087 NCT: https://clinicaltrials.gov/ct2/show/NCT00624182 PubMed:29568993 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5115 54742 5115 Clinical trial Gene name: LY6K URLC10 Peptide Vaccine A cancer vaccine containing five peptide epitopes with potential immunostimulatory and antitumor activity. Peptide epitopes in this vaccine are derived from: URLC10 (up-regulated lung cancer 10), TTK (TTK protein kinase), KOC1 (IGF II mRNA Binding Protein 3) and VEGFRs (vascular endothelial growth factor receptors) 1 and 2. Upon administration, URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK, KCO1, VEGFR 1 and 2 peptides, resulting in cell lysis and decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74088 NCT: https://clinicaltrials.gov/ct2/show/NCT00632333 PubMed:24708624 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5001 10643 54742 7422 5001 Clinical trial Gene name: LY6K|Gene name: VEGFA|Gene name: IGF2BP3 URLC10-TTK-KOC1-VEGFR1-VEGFR2 Multipeptide Vaccine A highly tumor-selective vaccinia virus (vv) with an engineered double deletion (DD) of the thymidine kinase (tk) and vaccinia growth factor genes and additions of both a cytosine deaminase (CD) gene and a somatostatin receptor (SR) gene with potential oncolytic viral activity. The tk and vaccinia growth factor gene deletions in intratumorally administered vaccinia virus (vvDD-CDSR) help to restrict its replication and cytolytic activity to tumor cells with large nucleotide pools and tumor cells with activation of the EGFR-Ras pathway. Addition of the CD gene to the viral genome allows control of oncolytic viral infection through the administration of the prodrug 5-fluorocytosine (5-FC), converted by CD to the antimetabolite 5-fluorouracil (5-FU) in cells infected with this agent. Addition of the SR gene allows anatomical localization of vaccinia virus (vvDD-CDSR) through the use of octreotide scintigraphy. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74089 NCT: https://clinicaltrials.gov/ct2/show/NCT00574977 PubMed:27203445 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5296 45091589 5296 Clinical trial Gene name: cdsR Vaccinia Virus DD-CDSR Vaccine A vaccine consisting of two plasmids encoding the human cytomegalovirus (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with immunostimulatory properties. Vaccination with VCL-CB01 may stimulate the host immune system to mount cellular and humoral immune responses against CMV positive cells, resulting in cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61327 NCT: https://clinicaltrials.gov/ct2/show/NCT00285259 PubMed:22237175 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5390 3077579 5390 Clinical trial Gene name: UL83 VCL-CB01 Vaccine A synthetic peptide vaccine consisting of a HLA-DR15-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 124 through 138, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 124-138 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C104738 PubMed:16220325 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5430 7490 5430 Clinical trial Gene name: WT1 WT1 124-138 Peptide Vaccine A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61442 NCT: https://clinicaltrials.gov/ct2/show/NCT01842139 PubMed:26492414 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5089 7490 5089 Clinical trial Gene name: WT1 WT1 126-134 Peptide Vaccine A synthetic peptide vaccine consisting of a HLA-A24-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 235 through 243, a MHC class I-restricted peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 235-243 peptide may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104734 PubMed:23225417 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5029 7490 5029 Clinical trial Gene name: WT1 WT1 235-243 Peptide Vaccine A synthetic peptide vaccine consisting of a HLA-DRw53-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 247 through 261, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 247-261 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104737 PubMed:16220325 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5468 7490 5468 Clinical trial Gene name: WT1 WT1 247-261 Peptide Vaccine A cancer vaccine consisting of the DNA plasmid pNGVL4a-A encoding calreticulin (CRT) linked to a detox form of human papillomavirus (HPV) type 16 E7 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, this vaccine may generate a potent cytotoxic T-lymphocyte (CTL) response against E7-expressing tumor cells, resulting in tumor cell death. For E7(detox), the amino acids in E7 at positions 24 (cysteine to glycine) and 26 (glutamic acid to glycine) were substituted. CRT, a 46 kDa protein located in the lumen of the cell's endoplasmic reticulum (ER), may potentiate MHC class I presentation of HPV-16 E7 to E7-specific CD8-positive T cells. In addition, pNGVL4a-A contains two short immunostimulatory DNA sequences (ISS) in the noncoding region, which may elicit the production of IFN- and IL-12 in transfected keratinocytes and dermal antigen presenting cells (APCs), resulting in a potent T helper cell type 1 response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C88289 NCT: https://clinicaltrials.gov/ct2/show/NCT00988559 PubMed:26616223 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5011 https://github.com/vaccineontology/VO/issues/123 1489079 5011 Clinical trial Gene name: HPV16 E7 pNGVL4a-CRT/E7(detox) DNA Vaccine An antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48418 NCT: https://clinicaltrials.gov/ct2/show/NCT00121173 PubMed:30296681 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5069 https://github.com/vaccineontology/VO/issues/124 1489079 5069 Clinical trial Gene name: HPV16 E7 pNGVL4a-Sig/E7(detox)/HSP70 DNA Vaccine A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) Types 6, 11, 16, and 18 with immunoprophylactic activity. The immunoprohylactic efficacy of L1 VLP vaccines, such as recombinant human papillomavirus quadrivalent vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61087 NCT: https://clinicaltrials.gov/ct2/show/NCT00411749 PubMed:35997582 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5406 25479185 5406 Clinical trial Gene name: L1 Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.‚Äö√†√∂‚àö¬ß Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119664 PubMed:26772631 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5342 25479185 7162 5342 Clinical trial Gene name: L1|Gene name: TPBG Recombinant Human Papillomavirus Nonavalent Vaccine A cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) strain encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) subtypes E6 and E7, and human interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Vaccination with MVA-HPV16E6/E7-IL2 vaccine TG4001 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against HPV16 E6- and E7-expressing tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C88326 NCT: https://clinicaltrials.gov/ct2/show/NCT01022346 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5208 https://github.com/vaccineontology/VO/issues/340 1489078 1489079 5208 Clinical trial Gene name: E6|Gene name: E7 Recombinant Vaccinia Viral Vector RO5217790 Vaccine A therapeutic peptide vaccine consisting of thirteen synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoproteins E6 and E7, with potential immunostimulating and antitumor activities. Upon administration, synthetic long E6/E7 peptides vaccine HPV-01 is taken up and degraded into small pieces by dendritic cells. The processed viral epitopes are presented by dendritic cells, which may stimulate the host immune system to mount both cytotoxic T-cell lymphocyte (CTL) and helper T cell responses against HPV E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The E6 and E7 oncoproteins are implicated in the tumorigenesis in a variety of cancers. The SLPs allow for optimal presentation by antigen-presenting cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C111037 NCT: https://clinicaltrials.gov/ct2/show/NCT02128126 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5186 https://github.com/vaccineontology/VO/issues/410 1489078 1489079 5186 Clinical trial Gene name: E6|Gene name: E7 Synthetic Long E6/E7 Peptides Vaccine HPV-01 A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2811 NCT: https://clinicaltrials.gov/ct2/show/NCT00493545 PubMed:16691066 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5542 1489079 3329 5542 Clinical trial Gene name: E7|Gene name: HSPD1 Verpasep Caltespen Vaccine A synthetic vaccine used for cancer immunotherapy also known as Ras(cis 12)-Vaccinia Vaccine, RASVAC-C is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29401 NCT: https://clinicaltrials.gov/ct2/show/NCT00019591 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5504 https://github.com/vaccineontology/VO/issues/190 3845 5504 Clinical trial Gene name: KRAS RASVAC-C Vaccine A synthetic vaccine used for cancer immunotherapy also known as Ras(val 12)-Vaccinia Vaccine, RASVAC-V is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 (valine instead of glycine) that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29402 NCT: https://clinicaltrials.gov/ct2/show/NCT00019591 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5497 https://github.com/vaccineontology/VO/issues/191 3845 5497 Clinical trial Gene name: KRAS RASVAC-V Vaccine A genetically-engineered adenovirus that contains the gene that encodes the human tumor-suppressor protein p53 with potential antineoplastic activity. Recombinant adenovirus-p53 SCH-58500 delivers p53 into tumor cells, which may result in p53-mediated cell cycle arrest and apoptosis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2423 NCT: https://clinicaltrials.gov/ct2/show/NCT00002960 PubMed:16082381 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5470 https://github.com/vaccineontology/VO/issues/325 4771 7157 7490 5470 Clinical trial Gene name: NF2|Gene name: WT1|Gene name: TP53 (P53) Recombinant Adenovirus-p53 SCH-58500 Vaccine An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. Upon adinistration, the L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C166939 NCT: https://clinicaltrials.gov/ct2/show/NCT01253837 PubMed:12810649 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5219 https://github.com/vaccineontology/VO/issues/336 100136034 5219 Clinical trial Gene name: tnf-alpha Recombinant Human Fusion Protein L19TNFalpha Vaccine A cancer vaccine containing multiple peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from, URLC10 (up-regulated lung cancer 10), CDCA1 (cell division cycle-associated protein 1), KOC1 (IGF II mRNA Binding Protein 3). Upon administration, URLC10-CDCA1-KOC1 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, CDCA1, KCO1 peptides, resulting in cell lysis and decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95212 NCT: https://clinicaltrials.gov/ct2/show/NCT00681577 PubMed:27720136 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5350 10643 54742 83540 5350 Clinical trial Gene name: LY6K|Gene name: NUF2|Gene name: IGF2BP3 URLC10-CDCA1-KOC1 Multipeptide Vaccine A fusion DNA vaccine containing the first domain of fragment C (FrC) of tetanus toxin (TT865-1120) (p.DOM) fused to the human Wilms' Tumor gene-1 (WT1)-derived MHC class I-binding epitope WT1.126, with potential antitumor activity. Upon vaccination with p.DOM-WT1-126 DNA and subsequent electroporation, this vaccine may induce a WT1 epitope-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing cancer cells. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. The FrC of tetanus toxin contains the MHC II-binding sequence, p30, which induces T-helper cell activation for long-lasting immunity. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96738 NCT: https://clinicaltrials.gov/ct2/show/NCT01334060 PubMed:27099895 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5165 https://github.com/vaccineontology/VO/issues/69 7490 5165 Clinical trial Gene name: WT1 p.DOM-WT1-126 DNA Vaccine A fusion DNA vaccine containing the first domain of fragment C (FrC) of tetanus toxin (TT865-1120) (p.DOM) fused to the human Wilms' Tumor gene-1 (WT1)-derived MHC class I-binding epitope WT1.37, with potential antitumor activity. Upon vaccination with p.DOM-WT1-37 DNA and subsequent electroporation, this vaccine may induce a WT1 epitope-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing cancer cells. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. The FrC of tetanus toxin contains the MHC II-binding sequence, p30, which induces T-helper cell activation for long-lasting immunity. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96737 NCT: https://clinicaltrials.gov/ct2/show/NCT01334060 PubMed:27099895 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5471 https://github.com/vaccineontology/VO/issues/61 https://github.com/vaccineontology/VO/issues/62 7490 5471 Clinical trial Gene name: WT1 p.DOM-WT1-37 DNA Vaccine A cancer vaccine containing PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3, with potential immunotherapeutic activity. Vaccination with PR1 leukemia peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Often overexpressed in leukemic cells, proteinase 3 is a serine proteinase that activates progelatinase A and is involved in angiogenesis and metastasis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2235 NCT: https://clinicaltrials.gov/ct2/show/NCT00004918 PubMed:27654852 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5140 https://github.com/vaccineontology/VO/issues/139 140738 5140 Clinical trial Gene name: TMEM37 PR1 Leukemia Peptide Vaccine A vaccine made of cancer cells, parts of cancer cells, or pure tumor antigens (substances isolated from tumor cells). A tumor antigen vaccine may stimulate the body's immune system to find and kill cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2341 NCT: https://clinicaltrials.gov/ct2/show/NCT00100971 PubMed:30348199 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5387 5387 Clinical trial Tumor Cell Derivative Vaccine A leukemia cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, WT1 peptide vaccine OCV-501 may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in some solid tumors. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C106257 NCT: https://clinicaltrials.gov/ct2/show/NCT01961882 PubMed:28321480 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5330 7490 5330 Clinical trial Gene name: WT1 WT1 Peptide Vaccine OCV-501 An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities. Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78865 NCT: https://clinicaltrials.gov/ct2/show/NCT00725283 PubMed:16117707 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5354 7490 5354 Clinical trial Gene name: WT1 WT1-A10/AS01B Immunotherapeutic GSK2130579A Vaccine A recombinant vaccinia virus encoding carcinoembryonic antigen (CEA). CEA is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung cancers. Attenuated vaccinia virus is a highly effective immunizing agent that evokes both humoral and cell-mediated responses. Vaccination with this agent may evoke a cytotoxic immune response to CEA-expressing cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2809 NCT: https://clinicaltrials.gov/ct2/show/NCT00081848 PubMed:7629885 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5401 https://github.com/vaccineontology/VO/issues/341 1048 5401 Clinical trial Gene name: CEACAM5 Recombinant Vaccinia-CEA Vaccine Human mesenchymal stem cells (MSCs) harvested from bone marrow of healthy adult donors and expanded ex vivo, with potential immunosuppressive activity. Remestemcel-L cells are hypo-immunogenic due to lack of major histocompatibility II (MHC II) molecule expression, eliciting little, if any, host immune response upon intravenous infusion. Infusion of allogeneic MSCs may result in: a) increased production of anti-inflammatory cytokines, such as interleukin-10, prostaglandin E, and hepatocyte growth factor; b) decreased mononuclear phagocyte expression of indoleamine 2,3,-dioxygenase, which catabolizes L-tryptophan into its pro-inflammatory metabolites; and c) modulated dendritic cell (DC)maturation and disrupted activities of natural killer (NK) cells and CD8+ and CD4+ T cells. In addition, pluripotent MSCs, upon administration, may be recruited to damaged tissue sites, differentiating along specific lineages when stimulated. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C67082 PubMed:32018062 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4993 https://github.com/vaccineontology/VO/issues/353 4993 Clinical trial Remestemcel-L Vaccine A replication-competent oncolytic, telomerase-specific adenovirus serotype 5 (Ad5), with potential antineoplastic activity. OBP-301 contains the human telomerase reverse transcriptase (hTERT) gene promoter sequence that drives the expression of the E1A and E1B genes, and is linked to an internal ribosomal entry site (IRES). Upon administration, OBP-301 selectively infects and replicates in cancer cells that are expressing telomerase, which causes cell lysis. This adenovirus does not infect or replicate in normal, healthy cells. OBP-301 may also potentially be used as a chemosensitizer. hTERT, which encodes for the catalytic protein subunit of telomerase, is overexpressed in a variety of cancer cell types but not in normal, healthy cells. The insertion of an IRES further improves selectivity towards telomerase-expressing cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C119617 NCT: https://clinicaltrials.gov/ct2/show/NCT02293850 PubMed:27673332 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5072 7015 5072 Clinical trial Gene name: TERT Telomerase-specific Type 5 Adenovirus OBP-301 Vaccine A proprietary cancer DNA vaccine that contains multiple natural and modified epitopes derived from the four tumor associated antigens, CEA, HER2/neu, p53, and MAGE 2/3. OSE 2101 also includes CAP1-6D, a heteroclitic CEA analog, and PADRE, a proprietary universal T-cell epitope that serves to enhance the immunogenicity of the epitopes. This agent has been shown to elicit cytotoxic T-lymphocyte responses against tumor cells expressing these multiple epitopes. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26645 NCT: https://clinicaltrials.gov/ct2/show/NCT02654587 PubMed:18382135 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5528 https://github.com/vaccineontology/VO/issues/72 1048 2064 4101 4102 7157 5528 Clinical trial Gene name: TP53|Gene name: CEACAM5|Gene name: ERBB2|Gene name: MAGEA2|Gene name: MAGEA3 EP-2101 Vaccine A tumor-specific peptide encoded by patient-specific mutant p53 oncogene with potential immunostimulatory properties. The peptide (LPTGQDL) contains a frame shift mutation at amino acid position 134. It was used to pulse dendritic cells, which are then used in the adoptive immunotherapy setting and may stimulate the host immune system to mount a specific cytotoxic T lymphocyte response against tumor cells expressing the p35 mutation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38121 NCT: https://clinicaltrials.gov/ct2/show/NCT00049218 PubMed:29301826 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5272 https://github.com/vaccineontology/VO/issues/125 https://github.com/vaccineontology/VO/issues/193 7157 5272 Clinical trial Gene name: TP53 PR-151 Peptide Vaccine An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95024 NCT: https://clinicaltrials.gov/ct2/show/NCT01598454 PubMed:26903265 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5201 https://github.com/vaccineontology/VO/issues/188 3265 3845 4893 5201 Clinical trial Gene name: HRAS|Gene name: NRAS|Gene name: KRAS Racotumomab Vaccine A replication-defective adenovirus containing a gene that encodes the human protein L523S with potential antineoplastic activity. Upon administration, recombinant adenovirus-L523S vaccine expresses L523S, which may stimulate antibody and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing L523S. L523S is an RNA-binding protein that belongs to the KOC (K homology domain containing protein over-expressed in cancer) family of proteins. As an oncofetal protein, L523S is normally expressed in early embryonic tissues and certain normal adult tissues such as colon, fallopian tube, gall bladder, and ovary tissues but may be overexpressed in squamous cell cancers of the lung. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49289 NCT: https://clinicaltrials.gov/ct2/show/NCT00062907 PubMed:16581300 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5074 https://github.com/vaccineontology/VO/issues/323 10643 5074 Clinical trial Gene name: IGF2BP3 Recombinant Adenovirus-L523S Vaccine A plasmid DNA encoding human L523S, an RNA-binding protein that belongs to the KOC (K homology domain containing protein overexpressed in cancer) family, with potential antineoplastic activity. Vaccination with L523S DNA may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express the L523S protein. As an oncofetal protein, L523S is normally expressed in early embryonic tissue, but is overexpressed in certain cancer cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49290 NCT: https://clinicaltrials.gov/ct2/show/NCT00062907 PubMed:12750279 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5156 https://github.com/vaccineontology/VO/issues/327 10643 5156 Clinical trial Gene name: IGF2BP3 Recombinant DNA-L523S Vaccine A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C70674 NCT: https://clinicaltrials.gov/ct2/show/NCT00516685 PubMed:29661145 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5190 25003478 5190 Clinical trial Gene name: LV28_RS26095 transcriptional regulator RegF Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine An allogeneic lung cancer vaccine with potential immunostimulating and antineoplastic activities. Derived from allogeneic lung tumor cells, tergenpumatucel-L is engineered to express the murine alpha-1,3-galactosyltransferase (GalT), an enzyme humans lack. GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes in glycoproteins and in glycolipids on the cell membranes of the allogeneic lung tumor cells present in the vaccine, essentially producing a 'xenograft'. The hyperacute rejection involves pre-existing human anti-alpha-gal antibodies that bind the foreign alpha-gal epitopes expressed by the vaccine tumor cell xenograft, resulting in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous lung tumor cells with unmodified carbohydrate epitopes. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C66985 NCT: https://clinicaltrials.gov/ct2/show/NCT02460367 PubMed:28238782 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5527 5527 Clinical trial Tergenpumatucel-L Vaccine A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential antineoplastic activity. Upon administration of viagenpumatucel-L, the irradiated live tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs) into the blood stream, thereby activating antigen presenting cells, natural killer cells and priming potent cytotoxic T lymphocytes (CTLs) to respond against TAAs on the endogenous tumor cells. Furthermore, this vaccine may induce long-lived memory T cells that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL retention sequence of gp96, normally an endoplasmatic reticulum-resident chaperone peptide, with the Fc portion of mouse and human IgG1. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61073 NCT: https://clinicaltrials.gov/ct2/show/NCT02439450 PubMed:27364122 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5513 7184 5513 Clinical trial Gene name: HSP90B1 Viagenpumatucel-L Vaccine A cancer vaccine consisting of a mixture of a murine lymphoma-derived idiotype and interleukin-2 (IL-2) encapsulated in dimyristoylphosphatidylcholine liposomes. The use of a liposomal carrier confers immunogenicity to the naturally non-immunogenic idiotype. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2783 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5541 https://github.com/vaccineontology/VO/issues/74 107653060 5541 Clinical trial Gene name: IL12 Oncovax-ID/IL-2 Vaccine A lipid depot-based therapeutic cancer vaccine composed of survivin epitopes, a universal T Helper peptide and a polynucleotide adjuvant encapsulated in liposomes and then formulated in the hydrophobic carrier Montanide ISA51 VG, with potential immunopotentiating and antineoplastic activities. Upon injection of the maveropepimut-S, a depot is created at the injection site from which the antigens and adjuvant are released. This vaccine may elicit a long lasting cellular response against survivin-expressing cancers, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C97951 NCT: https://clinicaltrials.gov/ct2/show/NCT02323230 PubMed:26405584 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5371 https://github.com/vaccineontology/VO/issues/364 373110 5371 Clinical trial Gene name: Survivin Survivin Antigen Vaccine DPX-Survivac A vaccine consisting of lymphoma-specific immunoglobulin that is not conjugated to a carrier molecule. Vaccination with unconjugated lymphoma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth.‚Äö√†√∂‚àö¬ß Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2821 PubMed:18715553 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5046 5046 Clinical trial Unconjugated Lymphoma Ig Id Vaccine A peptide cancer vaccine consisting of peptides derived from the melanoma antigen NA-17, the human leukocyte antigen HLA-A2-restricted human melanoma antigen 3 (MAGE-3.A2) and the cancer-testis antigen (NY-ESO-1), with potential immunostimulating and antineoplastic activities. Upon administration, the NA-17/MAGE-3.A2/NY-ESO-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing NA-17, MAGE-3.A2 and NY-ESO-1, resulting in tumor cell lysis. The tumor-associated antigens (TAAs) NA-17, MAGE-3.A2 and NY-ESO-1 are overexpressed in a variety of cancer cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96042 NCT: https://clinicaltrials.gov/ct2/show/NCT01308294 PubMed:25941588 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5305 https://github.com/vaccineontology/VO/issues/48 1485 4102 5305 Clinical trial Gene name: MAGEA3|Gene name: CTAG1B NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17. A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2680 NCT: https://clinicaltrials.gov/ct2/show/NCT01307618 PubMed:16133111 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5323 https://github.com/vaccineontology/VO/issues/49 107653060 2315 4102 6490 5323 Clinical trial Gene name: IL12|Gene name: MAGEA3|Gene name: MLANA|Gene name: PMEL NA17.A2 peptide vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1 (NY-ESO-1(157-165)), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount both an anti-tumoral cytotoxic T-lymphocyte (CTL) and an antibody-mediated immune response against NY-ESO-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C114380 NCT: https://clinicaltrials.gov/ct2/show/NCT00313508 PubMed:16311731 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5100 1485 2315 4102 6490 7299 5100 Clinical trial Gene name: MAGEA3|Gene name: MLANA|Gene name: PMEL|Gene name: CTAG1B|Gene name: TYR NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine composed of dendritic cells (DC) pulsed with peptides derived from the tumor-associated antigens human cancer/testis antigen NY-ESO-1 and melanoma antigen recognized by T-cells (MART-1/Melan-A), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1/MART-1 peptide-pulsed DC vaccine may stimulate the immune system to mount an anti-tumor cytotoxic T-lymphocyte (CTL) response against NY-ESO-1/MART-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells. MART-1 is expressed by melanoma cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C120129 NCT: https://clinicaltrials.gov/ct2/show/NCT00798629 PubMed:16311731 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5366 1485 2315 5366 Clinical trial Gene name: CTAG1B|Gene name: MLANA NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine A cancer vaccine consisting of PEP-3, a synthetic peptide encompassing a tumor-specific mutated segment of the epidermal growth factor receptor type vIII (EGFRvIII), conjugated to the naturally-occurring immunoadjuvant keyhole limpet hemocyanin (KLH) with potential immunostimulating and antineoplastic activities. Upon administration, PEP-3-KLH conjugate vaccine may induce a cytotoxic immune response against tumor cells that overexpress EGFRvIII; this antitumoral immune response may involve antibody-dependent cellular cytotoxicity (ADCC). Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74070 NCT: https://clinicaltrials.gov/ct2/show/NCT00626015 PubMed:14519652 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5480 https://github.com/vaccineontology/VO/issues/117 1956 5480 Clinical trial Gene name: EGFR PEP-3-KLH Conjugate Vaccine A whole cell vaccine derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology that exhibits immunomodulating activity. Plasmacytoid dendritic cells (pDCs) express a characteristic set of surface markers, such as CD123 (interleukin-3 receptor alpha chain), BDCA-2 (blood dendritic cell antigen 2; CD303) and BDCA-4 (CD304), as well as intracellular toll-like receptors 7 and 9. Upon stimulation, the activated pDCs produce substantial amounts of interferon (IFN) alpha, and to a lesser degree IFN-beta, as well as other cytokines and chemokines, such as tumor necrosis factor alpha and interleukins 1, 6 and 8. In addition, these pDCs, directly or indirectly stimulate T-cells, B-cells and natural killer cells. This may potentially lead to increased immunity against tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C103192 NCT: https://clinicaltrials.gov/ct2/show/NCT01690377 PubMed:30049538 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5006 https://github.com/vaccineontology/VO/issues/121 170482 3598 51284 54106 8829 5006 Clinical trial Gene name: IL13RA2|Gene name: CLEC4C|Gene name: NRP1|Gene name: TLR9|Gene name: TLR7 Plasmacytoid Dendritic Cell Vaccine rime/boost vaccination proved to be of no advantage or even detrimental in therapeutic settings in B16F1 and transgenic adenocarcinoma of the mouse prostate (TRAMP) models, respectively Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:23539449 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4074 https://github.com/vaccineontology/VO/issues/140 4074 Research prime/boost DC-TRP-2 melanoma vaccine A melanoma vaccine comprised of a recombinant fowlpox vector construct encoding a modified epitope of the melanoma antigen glycoprotein 100 (gp100), ES-2092M(gp100), containing an endoplasmic reticulum signal sequence targeted to the endoplasmic reticulum apparatus. Vaccination with recombinant fowlpox-gp100p209 vaccine may stimulate the host immune system more efficiently to mount a cytotoxic T lymphocyte response against tumor cells expressing the gp100 antigen. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2806 NCT: https://clinicaltrials.gov/ct2/show/NCT00080353 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5274 6490 5274 Clinical trial Gene name: gp100 (PMEL) Recombinant Fowlpox-gp100p209 Vaccine A cancer vaccine consisting of a replication-defective recombinant fowlpox virus that encodes for the murine melanoma antigen glycoprotein 100 (mgp100) with potential antineoplastic activity. Vaccination with recombinant fowlpox-mgp100 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2805 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5499 https://github.com/vaccineontology/VO/issues/332 5499 Clinical trial Recombinant Fowlpox-Mgp100 Vaccine A recombinant fowlpox virus vaccine with potential antineoplastic activity. Binding to the melanoma antigen tyrosinase, recombinant fowlpox-tyrosinase vaccine generates cellular immune responses against melanoma cells expressing the tyrosinase antigen; this effect is enhanced by the co-administration of interleukin 2 (IL-2). Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2807 NCT: https://clinicaltrials.gov/ct2/show/NCT00054535 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5518 https://github.com/vaccineontology/VO/issues/335 7299 5518 Clinical trial Gene name: Tyrosinase Recombinant Fowlpox-Tyrosinase Vaccine A recombinant chaperone-peptide complex-based vaccine composed of a complex between heat shock protein hsp110 and the human melanoma-associated antigen gp100, with potential antineoplastic activity. Upon vaccination, recombinant hsp110-gp100 chaperone complex activates the immune system to exert a cytotoxic T cell immune response and antigen-specific interferon-gamma production against gp100-overexpressing cancer cells. Gp100, is overexpressed in a variety of cancer cell types. Hsp110, binds to and chaperones full-length proteins during heat shock; as an immunoadjuvant it is able to enhance an immune response against antigen(s) and stimulate T-lymphocyte activation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C103830 NCT: https://clinicaltrials.gov/ct2/show/NCT01744171 PubMed:12750279 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5359 6490 5359 Clinical trial Gene name: gp100 (PMEL) Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine A recombinant vaccinia virus encoding a modified peptide of the gp100 melanoma-melanocyte antigen with potential use in cancer immunotherapy. gp100 human antigen is a wild type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. gp100p209 is a fragment epitope of gp100 in which the threonine in position 2 is replaced with methionine; this modification may stimulate tumor infiltrating lymphocytes (TIL) more efficiently.‚Äö√†√∂‚àö¬ß Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29566 NCT: https://clinicaltrials.gov/ct2/show/NCT00116597 PubMed:15133631 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5393 https://github.com/vaccineontology/VO/issues/344 6490 5393 Clinical trial Gene name: gp100 (PMEL) Recombinant Vaccinia-gp100:209-217 Vaccine A recombinant vaccinia virus encoding a modified peptide of the gp100 melanoma-melanocyte antigen with potential use in cancer immunotherapy. gp100 human antigen is a wild type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. This recombinant vaccinia Mgp100 encodes a fragment epitope of gp100 bearing 2 amino acids substitution; T->M at position 210 and 288 A ->V at position 210. This modification may stimulate tumor infiltrating lymphocytes (TIL) more efficiently. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C51978 PubMed:12912944 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5505 https://github.com/vaccineontology/VO/issues/346 6490 5505 Clinical trial Gene name: gp100 (PMEL) Recombinant Vaccinia-Mgp100 Vaccine A cancer vaccine consisting of an inactivated recombinant vaccinia virus encoding epitope peptides derived from melanoma-related HLA-A2-restricted tumor-associated antigens (TAAs), including Melan-A(27-35), gp100(280-288) and tyrosinase(1-9), and two co-stimulatory B7 proteins, B7.1 (CD80) and B7.2 (CD86). Upon administration, recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine may stimulate a cytotoxic T-lymphocyte response against melanoma cells that express TAAs which share epitopes with the epitope peptides expressed by the vaccine viral vector, resulting in tumor cell lysis; vaccine viral vector-expressed co-stimulatory proteins B7.1 and B7.2 may enhance the cytotoxic T-lymphocyte immune response to the TAAs. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48638 PubMed:30626434 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5232 12524 2315 6490 941 5232 Clinical trial Gene name: Cd86|Gene name: MLANA-Dupli|Gene name: CD80|Gene name: gp100 (PMEL) Recombinant Vaccinia-Multiepitope Melanoma Peptides-B7.1-B7.2 Vaccine A recombinant vaccinia virus encoding the melanocyte differentiation antigen tyrosinase-related protein-1 (TRP-1) with potential use in cancer immunotherapy. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29564 PubMed:19047169 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5063 https://github.com/vaccineontology/VO/issues/352 22178 5063 Clinical trial Gene name: TRP-1 Recombinant Vaccinia-TRP1 Vaccine A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (a granulocyte macrophage-colony stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered melanoma vaccine. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2430 NCT: https://clinicaltrials.gov/ct2/show/NCT01216436 PubMed:26241951 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5194 https://github.com/vaccineontology/VO/issues/360 1493 8784 5194 Clinical trial Gene name: CTLA4|Gene name: TNFRSF18 Sargramostim Plasmid DNA Melanoma Vaccine Adjuvant A recombinant plasmid DNA vaccine that encodes two peptides, tyrosinase 207-216 and tyrosinase 1-17, both of which are derived from human tyrosinase. Jie Zheng Jimmy Guo Oliver He Virginia He NCT: https://clinicaltrials.gov/ct2/show/NCT00023647 PubMed:12833467 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4002 https://github.com/vaccineontology/VO/issues/406 4002 Research Synchotrope TA2M Vaccine A recombinant plasmid DNA vaccine encoding epitopes of tyrosinase with potential antineoplastic activity. Synchrotope TA2M vaccine contains a plasmid encoding 2 epitopes, amino acid sequences 207-216 and 1-17 of tyrosinase, a protein frequently expressed by melanoma cells. Vaccination with the TA2M plasmid DNA vaccine may induce the production of anti-tyrosinase antibodies as well as elicit a cytotoxic T-lymphocyte (CTL) response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2650 NCT: https://clinicaltrials.gov/ct2/show/NCT00023647 PubMed:12833467 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5218 https://github.com/vaccineontology/VO/issues/407 7299 5218 Clinical trial Gene name: Tyrosinase Synchrotope TA2M Plasmid DNA Vaccine A bivalent DNA vaccine encoding epitopes for both Melan-A (MART-1) and tyrosinase with potential antineoplastic activity. Synchrovax SEM plasmid DNA vaccine contains a plasmid pSEM that encodes 4 epitopes: Melan-A (26-35), Melan-A (31-96), tyrosinase (1-9), and tyrosinase (369-377). Both Melan-A and tyrosinase are tumor antigens associated with melanoma. Vaccination with this plasmid DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) responses against cells expressing either or both of these antigens, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28549 NCT: https://clinicaltrials.gov/ct2/show/NCT00033228 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5506 https://github.com/vaccineontology/VO/issues/408 2315 7299 5506 Clinical trial Gene name: MLANA-Dupli|Gene name: Tyrosinase Synchrovax SEM Plasmid DNA Vaccine A cancer vaccine containing synthetic epitope peptides derived from melanoma tumor-associated antigens (TAAs), including melanoma-melanocyte antigen gp100(280-288), melanoma-associated antigen tyrosinase(1-9), and melanoma-associated antigen melan-A(27-35). Upon administration, synthetic melanoma-associated antigens vaccine may stimulate a cytotoxic T-lymphocyte immune response against melanoma cells that express TAAs which share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48639 NCT: https://clinicaltrials.gov/ct2/show/NCT00116597 PubMed:11874634 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5217 https://github.com/vaccineontology/VO/issues/411 6490 5217 Clinical trial Gene name: PMEL - obsolete Synthetic Melanoma-Associated Antigens Vaccine A RNA-lipoplex (RNA-LIP)-based cancer vaccine containing four naked ribonucleic acid (RNA)-drug products (DPs) RBL001.1, RBL002.2, RBL003.1, and RBL004.1 encoding the four melanoma-associated antigens (MAAs), the cancer-testis antigen NY-ESO-1, the human melanoma-associated antigen A3 (MAGE-A3), tyrosinase, and putative tyrosine-protein phosphatase (TPTE), encapsulated in liposomes, with potential antineoplastic activity. Upon intravenous administration of the tetravalent RNA-lipoplex cancer vaccine BNT111, the liposomes protect the RNA from degradation in the bloodstream, travel to the spleen and are taken up by antigen-presenting cells (APCs). The RNA is translocated to the cytoplasm and translated into the four tumor-associated proteins. The expressed proteins are processed and the human leukocyte antigen (HLA)-peptide complexes are presented to the immune system. This results in the production of various pro-inflammatory cytokines and induces antigen-specific CD8+ and CD4+ T-cell responses against the four selected MAAs NY-ESO-1, MAGE-A3, tyrosinase, and TPTE. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C122396 NCT: https://clinicaltrials.gov/ct2/show/NCT02410733 PubMed:21093980 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5114 416115 5114 Clinical trial Gene name: MAGE-1 Tetravalent RNA-lipoplex Cancer Vaccine Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:23090079 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4004 2315 6409 7299 4004 Research Gene name: MLANA|Gene name: PMEL|Gene name: Tyrosinase TLR-9/GM Vaccine Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:23509826 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4075 4075 Clinical trial TriMixDC-MEL Vaccine A recombinant peptide consisting of amino acid residues 180 to 188 of the tyrosinase-related protein 2 (TRP2). Expressed by cells of melanocyte origin, TRP2 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP-2: 180-188 peptide may induce cytotoxic T lymphocyte (CTL) responses to melanoma cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2815 NCT: https://clinicaltrials.gov/ct2/show/NCT00022438 PubMed:16906394 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5325 1638 5325 Clinical trial Gene name: TRP-2 TRP-2: 180-188 Peptide Vaccine A recombinant peptide consisting of amino acid residues 1 to 9 of the tyrosinase-related protein 1 (TRP1). Expressed by cells of melanocyte origin, TRP1 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP1(0RF3):1-9 may stimulate cytotoxic T cell responses to melanoma cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2816 NCT: https://clinicaltrials.gov/ct2/show/NCT00019383 PubMed:8027058 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5487 22178 5487 Clinical trial Gene name: TRP-1 TRP1(0RF3):1-9 Peptide Vaccine A peptide vaccine containing a tyrosinase epitope conjugated with keyhole lymphocyte hemocyanin (KLH) with potential antineoplastic activity. Tyrosinase, one of the melanoma differentiation antigens, is the rate-limiting enzyme for melanin synthesis. This tyrosine epitope is conjugated with KLH, which serves as an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with tyrosinase-KLH peptide vaccine may produce anti-tyrosinase antibodies as well as elicit a cytotoxic T lymphocyte (CTL) response against cells expressing tyrosinase antigen, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2384 NCT: https://clinicaltrials.gov/ct2/show/NCT00028431 PubMed:21143299 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5060 7299 5060 Clinical trial Gene name: Tyrosinase Tyrosinase-KLH Vaccine Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:14581425 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3999 tyrosinase240-251s, 368-376d vaccine 3999 Research tyrosinase240-251S, 368-376D Vaccine A cancer vaccine with VMCL was not associated with a statistically significant improvement in OS or RFS, with CIs not ruling out important gains from such treatment. Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:12377961 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4007 4007 Research vaccinia melanoma cell lysates (VMCL) vaccine Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:3155379 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4023 4023 Research Vaccinia Melanoma Oncolysates (VMO) Vaccine A recombinant vaccinia virus that encodes granulocyte-macrophage colony stimulating factor (GM-CSF). By activating T-cells and macrophages, vaccination with recombinant vaccinia GM-CSF may enhance the host immune system response to poorly immunogenic tumors, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2674 NCT: https://clinicaltrials.gov/ct2/show/NCT00002817 PubMed:8894677 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5508 12981 5508 Clinical trial Gene name: Csf2-Mouse Vaccinia-GM-CSF Vaccine A vaccine consisting of recombinant vaccinia virus, based on the modified vaccinia virus Ankara (MVA) that encodes the melanoma-associated antigen tyrosinase. Vaccination with vaccinia-tyrosinase may stimulate the host immune system to mount a cytotoxic T-cell response against tumor cells expressing tyrosinase. Tyrosinase is a melanoma-specific differentiation agent that catalyzes the synthesis of the melanin precursor L-3,4-dihydroxyphenylalanine (L-DOPA). Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2531 NCT: https://clinicaltrials.gov/ct2/show/NCT00019734 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5223 7299 5223 Clinical trial Gene name: Tyrosinase Vaccinia-Tyrosinase Vaccine A plasmid DNA vaccine, encoding an epitope of mouse tyrosinase, with potential antineoplastic activity. Administered via intramuscular electroporation, vaccination with xenogeneic tyrosinase DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) immune responses against melanoma cells that express tyrosinase, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C68839 NCT: https://clinicaltrials.gov/ct2/show/NCT00471133 PubMed:4019903 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5416 7299 5416 Clinical trial Gene name: Tyrosinase Xenogeneic Tyrosinase DNA Vaccine A recombinant replication-defective adenovirus which encodes the gene for the cytokine human interferon-beta (IFN-beta). Once inserted into and replicating in host tumor cells, recombinant adenovirus-hIFN-beta expresses human IFN-beta, which may stimulate an antiproliferative natural killer (NK) cell response against tumor cells and induce caspase-mediated tumor cell apoptosis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C28550 NCT: https://clinicaltrials.gov/ct2/show/NCT00066404 PubMed:19893592 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5510 https://github.com/vaccineontology/VO/issues/321 3456 5510 Clinical trial Gene name: IFNB1 Recombinant Adenovirus-hIFN-beta Vaccine A modified recombinant nonapeptide (LMLGEFLKL) derived from the anti-apoptosis protein survivin with potential immunopotentiating and antineoplastic activities. Upon administration, survivin Sur1M2 peptide vaccine may elicit humoral and cellular immune responses against survivin-expressing cancers, resulting in decreased tumor cell proliferation and tumor cell death. The survivin protein inhibits caspase activation and apoptosis; it is undetectable in normal adult tissues but is expressed by several human cancers including lung, colon, breast, pancreas, and prostate cancer as well as hematopoietic malignancies and skin cancers. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C71741 NCT: https://clinicaltrials.gov/ct2/show/NCT00499577 PubMed:29057249 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5265 https://github.com/vaccineontology/VO/issues/365 7015 5265 Clinical trial Gene name: TERT Survivin Sur1M2 Peptide Vaccine A vaccine consisting of myeloma-specific immunoglobulin that is not conjugated to a carrier molecule. Vaccination with unconjugated myeloma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against myeloma cells, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2822 NCT: https://clinicaltrials.gov/ct2/show/NCT00001561 PubMed:4108872 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5391 5391 Clinical trial Unconjugated Myeloma Ig Id Vaccine A peptide vaccine comprised of an epitope of human Wilms tumor 1 (WT-1) with potential antineoplastic activity. WT-1, a transcription factor, is overexpressed in most types of leukemia and in some solid cancers. Vaccination with the WT-1 analog peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against WT-1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64635 NCT: https://clinicaltrials.gov/ct2/show/NCT01827137 PubMed:25802083 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5341 7490 5341 Clinical trial Gene name: WT1 WT1 Analog Peptide Vaccine A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT2725 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in a vast number of non-hematological solid tumors. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C102751 NCT: https://clinicaltrials.gov/ct2/show/NCT01621542 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5027 7490 5027 Clinical trial Gene name: WT1 WT1 Peptide Vaccine WT2725 A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens. The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C103823 NCT: https://clinicaltrials.gov/ct2/show/NCT01718899 PubMed:30128502 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5415 22433 57823 6382 5415 Clinical trial Gene name: Xbp1|Gene name: SDC1|Gene name: SLAMF7 XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410 A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with autologous, lethally irradiated cancer cells and mixed with the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon vaccination, ovapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the repertoire of tumor associated antigens (TAAs) found in the irradiated cancer cells. GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C113651 NCT: https://clinicaltrials.gov/ct2/show/NCT02033616 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5481 https://github.com/vaccineontology/VO/issues/71 5481 Clinical trial Ovapuldencel-T Vaccine A cancer vaccine comprised of synthetic peptides corresponding to naturally-occurring peptides derived from ovarian cancer cell antigens. Ovarian cancer peptide vaccine may elicit a cytotoxic T-cell response against tumor cells expressing the related ovarian cancer cell antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48414 NCT: https://clinicaltrials.gov/ct2/show/NCT00091273 PubMed:20445345 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5502 5502 Clinical trial Ovarian Cancer Peptide Vaccine A cancer vaccine containing autologous dendritic cells (DCs) that are transfected with mRNAs extracted from amplified ovarian cancer stem cells, and mRNAs of the universal tumor antigens human telomerase reverse transcriptase (hTERT) and survivin with potential immunostimulatory and antineoplastic activities. Upon administration, ovarian cancer stem cell/hTERT/survivin mRNAs-loaded autologous DC-006 vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against ovarian cancer cells expressing hTERT, survivin, and specific ovarian cancer stem cell antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Ovarian cancer stem cells contain a specific range of antigens that are essential for the neoplastic growth and survival of ovarian cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96739 NCT: https://clinicaltrials.gov/ct2/show/NCT01334047 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5403 7015 5403 Clinical trial Gene name: TERT Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with an ovarian tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the ovarian tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells expressing ovarian tumor cell-specific antigens, which may result in ovarian tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C115105 NCT: https://clinicaltrials.gov/ct2/show/NCT02107950 PubMed:22862954 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5280 3696 3728 780 5280 Clinical trial Gene name: ITGB8|Gene name: JUP|Gene name: DDR1 Ovarian Tumor Antigen-activated Autologous Dendritic Cell Vaccine A peptide vaccine consisting of 10 synthetic long peptides (SLPs), 25-30 amino acids in size and derived from the middle portion of p53 (amino acids 70-251), mixed with the adjuvant Montanide ISA-51 with potential immunostimulatory and antitumor activities. Upon administration, p53 synthetic long peptide (70-251) vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against p53-expressing tumor cells. p53, a tumor associated antigen (TAA), may be overexpressed in variety of cancer cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C82420 NCT: https://clinicaltrials.gov/ct2/show/NCT00844506 PubMed:26334096 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5278 https://github.com/vaccineontology/VO/issues/59 7157 5278 Clinical trial Gene name: TP53 P53-Synthetic Long Peptides Vaccine A cell-based cancer vaccine with potential antineoplastic activity. PA-1-STK ovarian carcinoma vaccine is produced by transducing the ovarian cancer cell line, PA-1, with the herpes simplex thymidine kinase (HSV-tk) gene, resulting in a cell line, PA-1-STK, that permanently expresses the HSV tk gene. Upon transfection into malignant cells, this vaccine is capable of sensitizing tumor cells in response to an antiviral drug such as ganciclovir, which is readily phosphorylated by the TK enzyme to its active form. Administration of ganciclovir following PA-1 STK transfection results in enhanced cytotoxicity of the transfected tumor cells. Additionally, adjacent non-transfected cells are also killed by the activated antiviral drug, a phenomenon referred to as the bystander effect that occurs with this type of suicide-gene transfer technique. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2428 NCT: https://clinicaltrials.gov/ct2/show/NCT00006216 PubMed:7578411 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5245 https://github.com/vaccineontology/VO/issues/57 79447 5245 Clinical trial Gene name: PAGR1 PA-1-STK Ovarian Carcinoma Vaccine An oncolytic thymidine kinase (TK)-deleted vaccinia poxvirus expressing human GM-CSF (hGM-CSF) with antineoplastic activity. Upon intratumoral or intravenous administration, pexastimogene devacirepvec selectively infects and lyses tumor cells. While vaccinia displays a natural tumor cell tropism, deletion of the TK gene increases the tumor selectivity of vaccinia by limiting viral replication to cells expressing high levels of TK, such as certain cancer cells. hGM-CSF expression by this agent helps recruit antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, to virally infected tumor cells, thereby initiating an antitumoral immune response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71533 NCT: https://clinicaltrials.gov/ct2/show/NCT02562755 PubMed:31413923 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5078 https://github.com/vaccineontology/VO/issues/119 1437 5078 Clinical trial Gene name: hGM-CSF Pexastimogene-devacirepvec Vaccine A plasmid DNA vaccine containing mammalian expression vector pUMVC3, encoding epitopes of human insulin-like growth factor-binding protein 2 (hIGFBP-2) with potential immunostimulating and antineoplastic activities. Upon vaccination, pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against hIGFBP-2-expressing cells. The tumor associated antigen (TAA) hIGFBP-2, a member of the insulin like growth factor receptor family, is overexpressed in a number of cancer cell types and its expression has been associated with increased invasiveness. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95727 NCT: https://clinicaltrials.gov/ct2/show/NCT01322802 PubMed:17102977 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5365 https://github.com/vaccineontology/VO/issues/186 3484 5365 Clinical trial Gene name: hIGFBP-2 pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine A recombinant retrovirus containing the modified murine retroviral vector MFG-S encoding a chimeric construct, MOv18-gamma. MOv18 is a murine monoclonal antibody developed against epitope of human folate binding protein, which is overexpressed on more than 90% of non-mucinous epithelial ovarian neoplasms. The chimeric construct (MOv18-gamma) encodes the variable region of MOv18 antibody, and the gamma chain of human T-cell receptor. This virion might be used to transduce autologous T lymphocytes, and reintroduced back to the patient after expansion ex vivo to invoke specific immune response against ovarian cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29192 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5131 https://github.com/vaccineontology/VO/issues/356 2348 5131 Clinical trial Gene name: FOLR1 Retroviral Vector MFGS-MOv18-gamma Vaccine A fowlpox vaccine containing the tumor-associated antigen mucin-1 (MUC1), found in pancreatic tumor cells, and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; TRICOM), which is designed to enhance antigen presentation and activation of immune responses critical for tumor destruction. Vaccination with this agent may elicit a host immune response against MUC1-expressing tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29558 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5477 https://github.com/vaccineontology/VO/issues/357 4582 5477 Clinical trial Gene name: MUC1 rF-MUC1(DF3)/TRICOM Vaccine A whole cell vaccine comprised of irradiated allogenic pancreatic tumor cells transfected with a plasmid DNA encoding human sargramostim (GM-CSF). Vaccination results in expression of GM-CSF, which induces proliferation and differentiation hematopoietic lineage cells as well as stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Furthermore, administration of this pancreatic tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2445 NCT: https://clinicaltrials.gov/ct2/show/NCT00389610 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5340 100137216 5340 Clinical trial Gene name: GM-CSF Sargramostim Plasmid DNA Pancreatic Tumor Cell Vaccine A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor 1 (VEGFR1 or Flt-1) with potential immunostimulating, antiangiogenic, and antineoplastic activities. Upon vaccination, VEGFR1-1084 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR1-expressing endothelial cells of the tumor microvasculature, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR1, a receptor tyrosine kinase, may be overexpressed on endothelial cells of the tumor microvasculature and is associated with tumor cell proliferation, invasion and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenicity. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C77895 NCT: https://clinicaltrials.gov/ct2/show/NCT00655785 PubMed:26190488 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5214 2321 5214 Clinical trial Gene name: FLT1 VEGFR1-1084 Peptide Vaccine A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types; overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74090 NCT: https://clinicaltrials.gov/ct2/show/NCT00639925 PubMed:15930316 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5419 16542 5419 Clinical trial Gene name: Kdr VEGFR2-169 Peptide Vaccine A cancer vaccine containing HLA class I- and II-binding peptides derived from the NY-ESO-1/LAGE-1 cancer/testis antigen with potential immunostimulatory and antineoplastic activities. Upon administration, NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine may induce a cytotoxic immune response against tumor cells that over-express NY-ESO-1/LAGE-1. Rarely expressed by normal cells, the NY-ESO-1/LAGE-1 cancer/testis antigen has been shown to be preferentially expressed on the surface of some cancer cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74066 NCT: https://clinicaltrials.gov/ct2/show/NCT00616291 PubMed:21131422 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5379 https://github.com/vaccineontology/VO/issues/111 1485 30848 5379 Clinical trial Gene name: CTAG1B|Gene name: CTAG2 NY-ESO-1/LAGE-1 peptide vaccine An autologous dendritic cell (DCs) vaccine targeting prostate cancer with immunostimulating activity. The autologous DC vaccine is prepared via transfecting DCs with mRNAs extracted from primary prostate cancer tissue, and mRNAs of human telomerase reverse transcriptase (hTERT) and survivin. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against prostate cancer cells, resulting in tumor cell death. Both hTERT and survivin are essential in neoplastic growth, and are considered to be universal tumor antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95771 NCT: https://clinicaltrials.gov/ct2/show/NCT00345293 PubMed:30505813 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5205 7015 5205 Clinical trial Gene name: TERT Primary Prostate Cancer Tissue/hTERT/Survivin mRNA-loaded Autologous Dendritic Cell Vaccine This DNA vaccine expressed prostate-specific membrane antigen (PSMA) Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:22729556 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3710 3710 Research Prostate cancer DNA vaccine pDOM-PSMA27 encoding PSMA A cell-based vaccine derived from prostate cancer with potential immunopotentiating and antineoplastic activities. Prostate cancer vaccine ONY-P1 is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens. Upon administration, this vaccine may stimulate a host immune response against prostate cancer cells; in the vaccination schedule, the first two vaccinations are co-administered with bacillus Calmette-Guerin (BCG) as an adjuvant. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C71723 NCT: https://clinicaltrials.gov/ct2/show/NCT00514072 PubMed:22932804 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5351 https://github.com/vaccineontology/VO/issues/141 959 5351 Clinical trial Gene name: CD40 Prostate Cancer Vaccine ONY-P1 A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with a prostate tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the prostate tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against prostate cancer cells expressing prostate tumor cell-specific antigens, which may result in prostate tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C115106 NCT: https://clinicaltrials.gov/ct2/show/NCT02111577 PubMed:27683469 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5132 354 5132 Clinical trial Gene name: KLK3 Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine A vaccinia virus carrying a copy of the human gene encoding prostate-specific antigen (PSA), contaminated with bovine viral diarrhea virus (BVDV). Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29334 PubMed:27683469 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5260 https://github.com/vaccineontology/VO/issues/142 354 5260 Clinical trial Gene name: KLK3 PROSTVAC-Contaminated W/ BVDV vaccine A peptide vaccine containing the prostate specific antigen (PSA) with potential antineoplastic activity. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. Vaccination with PSA peptide vaccine may produce anti-PSA antibodies as well as elicit a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2497 NCT: https://clinicaltrials.gov/ct2/show/NCT00015977 PubMed:27683469 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5087 https://github.com/vaccineontology/VO/issues/143 354 5087 Clinical trial Gene name: KLK3 PSA Prostate Cancer Vaccine An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2236 NCT: https://clinicaltrials.gov/ct2/show/NCT00004211 PubMed:14711334 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5022 https://github.com/vaccineontology/VO/issues/144 354 5022 Clinical trial Gene name: KLK3 PSA RNA-Pulsed Dendritic Cell Vaccine A 30-residue prostate specific antigen (PSA) oligoepitope peptide (OP) vaccine with potential antineoplastic activity. PSA-OP peptide vaccine contains the PSA-1 and PSA-3 HLA-A2 epitopes and the PSA-9 HLA-class I-A3 epitope joined by peptide linker sequences. In an animal model, vaccination with this agent has been shown to elicit a cytotoxic T-lymphocyte immune response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29337 PubMed:9743387 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5234 https://github.com/vaccineontology/VO/issues/179 354 5234 Clinical trial Gene name: KLK3 PSA-OP Peptide Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the prostate-specific tumor associated antigens (TAAs) prostate specific antigen (PSA) and prostate acid phosphatase (PAP), and conjugated to the immunostimulant keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, prostate cancer antigen/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against prostate cancer cells expressing PSA and PAP, which may result in prostate cancer cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C92573 NCT: https://clinicaltrials.gov/ct2/show/NCT01171729 PubMed:12487060 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5353 56318 5353 Clinical trial Gene name: Acpp PSA-PAP/KLH-pulsed Autologous Dendritic Cell Vaccine A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C114289 NCT: https://clinicaltrials.gov/ct2/show/NCT02058680 PubMed:12487060 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5109 https://github.com/vaccineontology/VO/issues/180 1437 3558 5109 Clinical trial Gene name: IL-2|Gene name: GM-CSF PSA/IL-2/GM-CSF Vaccine A plasmid DNA vaccine encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery and electroporation of the PSA/PSMA DNA plasmid INO-5150, both PSA and PSMA are translated in cells which then activate the immune system. This induces cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing PSA and PSMA. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. PSA and PSMA are overexpressed on a variety of cancer cell types. The DNA encoding the TAAs in INO-5150 is based on both human and other primate antigen gene sequences. As the plasmid genes differ from the human gene sequences encoding these antigens, INO-5150 may overcome immune tolerance to human TAAs. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C123283 NCT: https://clinicaltrials.gov/ct2/show/NCT02514213 PubMed:32208168 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5252 https://github.com/vaccineontology/VO/issues/181 2346 5252 Clinical trial Gene name: FOLH1 PSA/PSMA DNA Plasmid INO-5150 vaccine A synthetic peptide based on sequence corresponding to positions 154-163 of the amino acids of prostate-specific antigen (PSA), VISNDVCAQV. Upon administration, PSA:154-163 peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2798 NCT: https://clinicaltrials.gov/ct2/show/NCT00004156 PubMed:19483644 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5106 https://github.com/vaccineontology/VO/issues/182 4582 5106 Clinical trial Gene name: MUC1 PSA:154-163 Peptide vaccine A cancer vaccine comprised of a synthetic peptide with an amino acid sequence corresponding to positions 154-163 of the amino acid sequence for prostate-specific antigen (PSA) with a leucine substitution at position 155. Upon administration, PSA:154-163(155L) peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29338 NCT: https://clinicaltrials.gov/ct2/show/NCT00109811 PubMed:19483644 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5155 https://github.com/vaccineontology/VO/issues/183 354 5155 Clinical trial Gene name: KLK3 PSA:154-163(155L) Peptide Vaccine A peptide-based cancer vaccine containing epitopes of T cell receptor gamma-chain alternate reading frame protein (TARP) and prostate-specific membrane antigen (PSMA) in combination with a Poly IC-LC immunoadjuvant, with potential antineoplastic activity. Upon administration, PSMA/TARP peptide vaccine may stimulate a host cytotoxic T-cell (CTL) response against TARP- and PSMA-expressing tumor cells, resulting in tumor cell cytotoxicity. The nuclear protein TARP and PSMA are commonly expressed in prostate cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78819 NCT: https://clinicaltrials.gov/ct2/show/NCT00694551 PubMed:34494382 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5052 https://github.com/vaccineontology/VO/issues/184 354 5052 Clinical trial Gene name: KLK3 PSMA/TARP Peptide Vaccine A cancer vaccine containing plasmid DNA encoding human prostatic acid phosphatase (PAP) (pTVG-HP) with potential immunostimulatory and antineoplastic activities. Upon administration, pTVG-HP plasmid DNA vaccine may stimulate the host immune system to generate a cytotoxic T lymphocyte (CTL) response against PAP-expressing prostate cancer cells. PAP or prostatic specific acid phosphatase (PSAP) is a tumor associated antigen (TAA) that may be overexpressed in prostate cancer. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C82407 NCT: https://clinicaltrials.gov/ct2/show/NCT02499835 PubMed:17102977 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5535 https://github.com/vaccineontology/VO/issues/185 55 5535 Clinical trial Gene name: ACP3 pTVG-HP Plasmid DNA Vaccine A cancer vaccine containing xenogenic DNA from rhesus macaque (Macaca mulatta) that encodes prostate specific antigen (PSA) with potential immunostimulating and antineoplastic activities. Upon repeated intradermal administration via electroporation, pVAXrcPSAv53l vaccine may induce a cytotoxic T-lymphocyte (CTL) response against PSA-expressing prostate cancer cells. Rhesus PSA is 89% homologous to human PSA. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82352 NCT: https://clinicaltrials.gov/ct2/show/NCT00859729 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5092 https://github.com/vaccineontology/VO/issues/187 354 5092 Clinical trial Gene name: KLK3 pVAXrcPSAv53l DNA Vaccine A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA). Administration of this agent may stimulate a cytotoxic T cell response against PSA-expressing tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2675 NCT: https://clinicaltrials.gov/ct2/show/NCT00005039 PubMed:17707059 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4988 https://github.com/vaccineontology/VO/issues/333 354 4988 Clinical trial Gene name: KLK3 Recombinant Fowlpox-Prostate Specific Antigen Vaccine A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38708 NCT: https://clinicaltrials.gov/ct2/show/NCT00108732 PubMed:16390546 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5434 https://github.com/vaccineontology/VO/issues/333 12519 3383 354 965 5434 Clinical trial Gene name: KLK3|Gene name: Cd80|Gene name: ICAM1|Gene name: CD58 Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine A cancer vaccine comprised of a recombinant fowlpox virus vector encoding TRICOM. TRICOM is comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3) that may enhance antigen presentation and activate cytotoxic T-cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2667 NCT: https://clinicaltrials.gov/ct2/show/NCT00450619 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5253 https://github.com/vaccineontology/VO/issues/132 12519 3383 965 5253 Clinical trial Gene name: Cd80|Gene name: ICAM1|Gene name: CD58 Recombinant Fowlpox-TRICOM Vaccine A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with recombinant vaccinia prostate-specific antigen vaccine stimulates the host immune system to mount a cytotoxic T-cell response against tumor cells expressing PSA. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2433 NCT: https://clinicaltrials.gov/ct2/show/NCT02649439 PubMed:12242725 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5154 https://github.com/vaccineontology/VO/issues/339 354 5154 Clinical trial Gene name: KLK3 Recombinant Vaccinia PSA Vaccine A recombinant vaccinia virus encoding prostate-specific antigen (PSA). Vaccination with recombinant vaccinia-PSA may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for PSA, which may decrease tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29945 NCT: https://clinicaltrials.gov/ct2/show/NCT00005039 PubMed:12242725 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5302 https://github.com/vaccineontology/VO/issues/350 354 5302 Clinical trial Gene name: KLK3 Recombinant Vaccinia-Prostate Specific Antigen Vaccine A recombinant vaccinia virus encoding prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) with potential use in cancer immunotherapy. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29563 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5307 https://github.com/vaccineontology/VO/issues/351 2346 354 5307 Clinical trial Gene name: KLK3|Gene name: Prostate-specific membrane antigen Recombinant Vaccinia-PSA/PSMA Vaccine A synthetic fowlpox viral vaccine containing the tumor-associated antigens prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; TRICOM). Vaccination with this viral vaccine may enhance antigen presentation and activate cytotoxic T-cells against PSA- or PSMA-expressing tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29559 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5005 https://github.com/vaccineontology/VO/issues/358 354 5005 Clinical trial Gene name: KLK3 rF-PSA/PSMA/TRICOM Vaccine A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38681 NCT: https://clinicaltrials.gov/ct2/show/NCT02772562 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5183 https://github.com/vaccineontology/VO/issues/359 12519 3383 354 965 5183 Clinical trial Gene name: ICAM1|Gene name: Cd80|Gene name: KLK3|Gene name: CD58 Rilimogene-galvacirepvec Vaccine A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1985 NCT: https://clinicaltrials.gov/ct2/show/NCT02159950 PubMed:20818862 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5216 https://github.com/vaccineontology/VO/issues/362 55 5216 Clinical trial Gene name: ACP3 Sipuleucel-T Vaccine A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62756 NCT: https://clinicaltrials.gov/ct2/show/NCT02855892 PubMed:27941629 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5101 https://github.com/vaccineontology/VO/issues/416 22059 5101 Clinical trial Gene name: Trp53 Telomerase Peptide Vaccine GV1001 A synthetic, peptide cancer vaccine directed against the human telomerase reverse transcriptase catalytic subunit (hTERT) with potential immunomodulating activity. Vaccination with the UV1 telomerase peptide may stimulate cytotoxic T-cells to recognize and kill telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Jie Zheng Jimmy Guo Oliver He Virginia He NCT: https://clinicaltrials.gov/ct2/show/NCT01784913 PubMed:28391357 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5478 7015 5478 Clinical trial Gene name: TERT UV1 Telomerase Peptide Vaccine An adenovirus type 5 (Ad5) encoding human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), with potential apoptosis-inducing and antineoplastic activities. Upon administration of recombinant Ad5 encoding TRAIL, the adenovirus selectively infects tumor cells and expresses TRAIL. The virally expressed TRAIL binds to and activates its receptors TRAIL receptor-1 (TRAIL-R1, death receptor 4, DR4) and TRAIL receptor-2 (TRAIL-R2, death receptor 5, DR5), which subsequently activate caspases and induce apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, members of the TNF receptor family, are overexpressed by a variety of cancer cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116879 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5397 8743 5397 Clinical trial Gene name: TNFSF10 Recombinant Adenovirus 5 Encoding Tumor Necrosis Factor-related Apoptosis-Inducing Ligand Vaccine A multipeptide cancer vaccine targeting renal cell carcinoma with potential immunopotentiating activity. Renal cell carcinoma peptides vaccine IMA901 consists of 10 different synthetic tumor-associated peptide (TUMAP) antigens (9 HLA-class I-binding and 1 HLA class II-binding); endogenously, these TUMAPs are expressed by the majority of renal cell carcinomas. Vaccination with this agent may significantly increase host cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing these peptide antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C70968 NCT: https://clinicaltrials.gov/ct2/show/NCT00523159 PubMed:23899354 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5013 https://github.com/vaccineontology/VO/issues/354 3105 3106 5013 Clinical trial Gene name: HLA-A|Gene name: HLA-B Renal Cell Carcinoma Peptides Vaccine IMA901 A cell-based preparation in which autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. Upon electroporation into autologous DCs, the RNA is translated and processed. BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. When AGS-003-BLD is reintroduced to the patient, the MHC-presented peptides interact with and activate CD8-positive T cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C129522 NCT: https://clinicaltrials.gov/ct2/show/NCT02170389 PubMed:25901286 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5373 958 5373 Clinical trial Gene name: CD40 Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003 Peripheral blood lymphocytes (PBL) harvested from the blood of a renal cancer patient and exposed in vitro to renal tumor-associated antigens (TAA). Introducing these renal tumor-reactive autologous peripheral blood lymphocytes back to the same patient target tumor cells expressing these TAAs and could induce a cytotoxic T-cell-mediated immune response against renal cell cancer. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48816 PubMed:33408117 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5196 5196 Clinical trial Renal Tumor-Reactive Autologous Peripheral Blood Lymphocyte Vaccine A peptide vaccine consisting of amino acids 65 through 76 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a glycine substitution at position 74. As a cancer vaccine, VHL-59: 65-76(V74G) may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38122 PubMed:20109232 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5097 7428 5097 Clinical trial Gene name: VHL VHL-42: 65-76(V74G) Peptide Vaccine A peptide vaccine consisting of amino acids 116 through 128 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a frameshift mutation. As a cancer vaccine, VHL-59: 116-128(FrSh116-128) peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38123 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5172 7428 5172 Clinical trial Gene name: VHL VHL-59: 116-128 Peptide Vaccine A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL14 peptide is a point mutation variant of the VHL protein; the mutation is in amino acid position 166. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2741 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5012 7428 5012 Clinical trial Gene name: VHL VHL14 Peptide Vaccine A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL16 peptide, also known as S111I, is a point mutation variant of the VHL tumor suppressor protein; the mutation is in amino acid position 111. Vaccination with this agent may stimulate a cytotoxic T-cell response in patients with VHL-associated cancers that express this variant of the VHL tumor suppressor protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2740 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5333 7428 5333 Clinical trial Gene name: VHL VHL16 Peptide Vaccine A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL2 (Y12M) peptide is a point mutation variant (from tyrosine to methionine at amino acid position 12) of the VHL protein. Vaccination with this peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2824 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5490 7428 5490 Clinical trial Gene name: VHL VHL2 (Y12M) Peptide Vaccine A cancer vaccine composed of peptides derived from a tumor-associated protein encoded by a mutated Von Hippel-Lindau (VHL) oncogene. VHL peptide vaccine may stimulate a cytotoxic T cell response against tumor cells expressing the VHL tumor-associated protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2492 NCT: https://clinicaltrials.gov/ct2/show/NCT00001703 PubMed:20109232 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5127 7428 5127 Clinical trial Gene name: VHL Von Hippel-Lindau Peptide Vaccine A synthetic peptide vaccine based on the sequences of a translocation mutation of 2 transcriptional factor genes, PAX3 and FKHR. PAX3/FKHR fusion proteins are frequently found in patients with rhabdomyosarcomas. Vaccination with PAX3/FKHR peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this PAX3/FKHR fusion protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49023 NCT: https://clinicaltrials.gov/ct2/show/NCT00001564 PubMed:15838707 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5484 https://github.com/vaccineontology/VO/issues/114 2308 5077 7422 5484 Clinical trial Gene name: PAX3|Gene name: FOXO1|Gene name: VEGFA PAX3/FKHR Peptide Vaccine A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a constitutively active form of the AKT Gene. The viral vector RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29908 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5044 https://github.com/vaccineontology/VO/issues/192 207 5044 Clinical trial Gene name: AKT1 RCAS-Akt Vaccine A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a human gene encoding the G12D mutant form of K-Ras. The viral vector, RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29910 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5500 3845 5500 Clinical trial Gene name: KRAS RCAS-Ras Vaccine A recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT). Telomerase expression has been directly linked to tumor development; its catalytic subunit is expressed in the majority of human cancer cells, but infrequently in normal cells. Vaccination with telomerase:540-548 peptide may stimulate cytotoxic T cells to recognize and kill telomerase-expressing cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2640 NCT: https://clinicaltrials.gov/ct2/show/NCT00069940 PubMed:11536162 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5098 7015 5098 Clinical trial Gene name: TERT Telomerase: 540-548 Peptide Vaccine To obtain SOCS1-silenced DCs, DCs derived from mouse bone marrow cells ex vivo were induced to differentiation in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4, and then transduced with Len-SOCS1-shRNA or control Len-GFP lentiviruses. The SOCS1-silenced DCs were loaded by TRP2 peptide to prepare the DC vaccine, which was induced to mature by LPS. The DCs were analyzed by flow cytometry (FCM) for surface expressions of MHCII and CD86 and by real-time PCR for the expressions of SOCS1, IL-10 as well as IL-12p40. B16 or IL-10-silenced B16 (IL-10(-/-);) cells were inoculated into C57BL/6 mice. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:23643168 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4071 https://github.com/vaccineontology/VO/issues/78 4071 Research 1(SOCS1)-silenced dendritic cell (DC) Vaccine A fragment of fibroblast growth factor-5 (FGF-5). Originally isolated from a renal cell carcinoma cell line that overexpressed FGF-5, FGF-5:117-126 peptide is recognized by tumor infiltrating cytotoxic T lymphocytes. Overexpressed by several cancer cell types, this peptide is being tested as a potential target for antineoplastic immunotherapies. (NCI04) Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5414 https://github.com/vaccineontology/VO/issues/79 5414 Clinical trial 117-126:FGF-5 Peptide Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5418 https://github.com/vaccineontology/VO/issues/80 5418 Clinical trial 12 Melanoma Peptide Vaccine 2 class major histocompatibility complex-restricted melanoma peptides. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21690475 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3978 https://github.com/vaccineontology/VO/issues/81 3978 Research 12MP Vaccine 4 treatment groups, vaccinated with 12 MHC class I-restricted melanoma peptides to stimulate CTL (12 MP, group A), plus a tetanus peptide (group B), or a mixture of 6 melanoma helper peptides (6 MHP, group C) to stimulate helper T lymphocytes (HTL), or with 6 melanoma helper peptide (6 MHP) alone (group D), in incomplete Freund's adjuvant plus granulocyte macrophage colony-stimulating factor. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:23653149 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4070 https://github.com/vaccineontology/VO/issues/82 4070 Clinical trial 12MP, 12MP/Tet, 12MP/6MHP, or 6MHP Vaccine A synthetic peptide consisting of amino acids 27 through 35 of the melanoma differentiation antigen MART-1. 27-35(27L) MART-1 has a leucine substitution at amino acid position 27 to improve binding to HLA-A*0201. Vaccination with this agent may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against melanoma cells expressing MART-1. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22495394 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5290 https://github.com/vaccineontology/VO/issues/83 2315 6490 7299 5290 Clinical trial Gene name: Tyrosinase|Gene name: gp100|Gene name: MLANA 27-35(27L):MART-1 Peptide Vaccine A topical gel containing a peptide derived from the human papillomavirus (HPV). Application of 851B gel may stimulate the host immune system to trigger a cytotoxic T-lymphocyte response to cells that express HPV. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4986 https://github.com/vaccineontology/VO/issues/84 4986 851B Gel Vaccine A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:17000686 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5244 https://github.com/vaccineontology/VO/issues/86 94025 5244 Clinical trial Gene name: MUC16 Abagovomab Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:11860704 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5543 https://github.com/vaccineontology/VO/issues/87 2875 7124 5543 Research Gene name: TNF|Gene name: GPT Ad CMV I kappaB alpha Vaccine A cancer vaccine consisting of a recombinant adenoviral vector encoding the tumor-associated antigen (TAA) human MUC-1 (hMUC-1) linked to the extracellular domain (ecd) of the co-stimulatory molecule CD40 ligand (CD40L) and an adenovirus signal sequence that encodes a secretory signal peptide (Ad-sig) with potential immunostimulating and antineoplastic activities. Due to the presence of the secretory signal peptide expressed by Ad-sig in the vaccine construct, transfected cells may secrete a fusion protein composed of hMUC-1 and the CD40L ecd. The CD40L moiety part of the fusion protein binds to CD40 receptors on dendritic cells (DCs). Subsequently, DCs may be activated and migrate, T-cells may expand, and a cytotoxic T lymphocyte (CTL) response against tumor cells that overexpress hMUC-1 may follow. MUC-1 is a hypoglycosylated TAA overexpressed by epithelial cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5179 https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.3098 https://github.com/vaccineontology/VO/issues/88 4582 959 5179 Clinical trial Gene name: MUC1|Gene name: CD40LG Ad-sig-hMUC-1/ecdCD40L Vaccine A replication-competent oncolytic adenovirus encoding the murine pro-inflammatory cytokine interleukin-12 (IL-12) gene and two suicide fusion genes, a yeast cytosine deaminase (yCD) and a mutant form of herpes simplex virus type 1 thymidine kinase (HSV-1 TKSR39), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of Ad5-yCD/mutTKSR39rep-hIL12, the adenovirus selectively infects and replicates in tumor cells, which results in direct tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL) responses against tumor cells, which may result in immune-mediated tumor cell death, inhibition of tumor cell proliferation and inhibition of tumor angiogenesis. In addition, Ad5-yCD/mutTKSR39rep-hIL12-infected cancer cells express yCD and TKSR39; upon administration of the prodrugs 5-fluorocytosine (5-FC) and valganciclovir (vGCV), the yCD and HSV-1 TKSR39 activate these prodrugs to form 5-fluorouracil (5-FU) and ganciclovir, respectively. 5-FU gets converted to 5-fluoro-uridine monophosphate (5-FUMP) and subsequently to 5-fluoro-deoxyuridine monophosphate (5-FdUMP); 5-FdUMP irreversible inhibits thymidylate synthase, inhibits deoxythymidine triphosphate (dTTP) formation and halts DNA synthesis. Once phosphorylated intracellularly, ganciclovir triphosphate competitively inhibits deoxyguanosine triphosphate (dGTP) incorporation into DNA and inhibits DNA synthesis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5308 https://www.cell.com/molecular-therapy-family/oncolytics/pdf/S2372-7705(20)30171-6.pdf, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281656/ https://github.com/vaccineontology/VO/issues/89 3592 3593 5308 Clinical trial Gene name: IL12B|Gene name: IL12A Ad5-yCD/mutTKSR39rep-hIL12 Vaccine A nonreplicating adenoviral vector (adenovector) encoding the melanoma differentiation-associated 7 gene (MDA7) with potential antineoplastic activity. After intratumoral injection and adenovector-mediated gene transfer of MDA7 into tumor cells, the expressed MDA7 transgene may inhibit tumor cell proliferation and induce tumor cell apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15300212 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5523 https://github.com/vaccineontology/VO/issues/92 5523 Clinical trial Adenovector Encoding MDA7 Vaccine A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities. The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain, leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88 is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4999 https://github.com/vaccineontology/VO/issues/93 2346 4999 Clinical trial Gene name: Prostate-specific membrane antigen Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201 A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA [CAP1-(6D)]. Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvent pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:25956394 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5137 https://github.com/vaccineontology/VO/issues/94 1048 5137 Clinical trial Gene name: CEACAM5 Adenoviral Vector Ad5-CEA(6D) Vaccine An adenovirus vector engineered to produce CD40 ligand. For use as a possible gene therapy agent. May induce apoptosis through the TNF pathway. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15153545 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5529 https://github.com/vaccineontology/VO/issues/95 5529 Research Adenovirus 5-CD40 Ligand Vaccine Fibroblast growth factor-2-retargeted adenoviral vectors may be used to increase the transduction of GBM-derived endothelial cells, enabling a new and efficient antiangiogenesis strategy for the treatment of malignant gliomas. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:16709032 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5489 https://github.com/vaccineontology/VO/issues/96 2247 5489 Research Gene name: FGF2 Adenovirus 5-Fibroblast Growth Factor 2 Vaccine A replication-defective, recombinant adenoviral serotype 5 (Ad5) encoding human guanylyl cyclase C (hGCC) and the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration, the Ad5-hGCC-PADRE vaccine expresses hGCC, which may induce both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated inhibition of tumor cell proliferation, and leads to tumor death. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT04111172 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5147 https://github.com/vaccineontology/VO/issues/97 2984 5147 Clinical trial Gene name: GUCY2C Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine A gene-viral vector complex comprised of an adenovirus vector and B7-1 gene targeting the CD80 antigen. Adenovirus B7-1 is used as a component in antineoplastic vaccines to elicit a cytotoxic T-cell response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5435 https://github.com/vaccineontology/VO/issues/98 941 5435 Research Gene name: CD80 Adenovirus B7-1 Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding HER-2/neu. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00307229 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5388 https://github.com/vaccineontology/VO/issues/99 24337 5388 Clinical trial Gene name: Erbb2 Adenovirus Encoding Rat HER-2/neu Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22737604 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5370 https://github.com/vaccineontology/VO/issues/100 2315 4105 7299 5370 Clinical trial Gene name: Tyrosinase|Gene name: MLANA|Gene name: MAGEA6 Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a replication-deficient adenovirus vector encoding HER-2 with potential antineoplastic activity. Upon administration, adenovirus HER2-transduced autologous dendritic cell vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by some breast, ovarian, and gastric cancers. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00197522 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5082 https://github.com/vaccineontology/VO/issues/101 2064 5082 Clinical trial Gene name: ERBB2 Adenovirus HER2-Transduced Autologous Dendritic Cell Vaccine A gene viral vector complex comprised of a replication-defective adenovirus and a herpes simplex virus thymidine kinase gene that activates ganciclovir, causing inhibition of DNA synthesis and apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:/8985364 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5122 https://github.com/vaccineontology/VO/issues/102 5122 Clinical trial Adenovirus RSV-TK Vaccine A replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (Ad.hIL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma and inducing cytotoxic T cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:33575474 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5285 https://github.com/vaccineontology/VO/issues/103 2346 5285 Clinical trial Gene name: Prostate-specific membrane antigen gene engineering Adenovirus-mediated Human Interleukin-12 Vaccine A cancer vaccine consisting of autologous dendritic cells (DCs) transduced with a recombinant adenovirus encoding p53 peptide, with potential immunomodulating activity. Intradermal vaccination with adenoviral-p53 transduced dendritic cell vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. p53, a tumor suppressor gene, is mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:20420527 PubMed:29515795 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5256 https://github.com/vaccineontology/VO/issues/104 7157 5256 Clinical trial Gene name: TP53 (P53) Adenovirus-p53 Transduced Dendritic Cell Vaccine A cancer vaccine composed of a genetically engineered, replication-deficient type 5 adenovirus carrying the human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with the adenovirus-PSA prostate cancer vaccine, the adenovirus infects cells and expresses PSA. In turn, PSA may activate the immune system and may induce a cytotoxic T-lymphocyte response against PSA-expressing tumor cells. PSA, a tumor associated antigen, is expressed by prostate epithelial cells and is overexpressed in prostate cancer. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5010 https://github.com/vaccineontology/VO/issues/105 2346 5010 Clinical trial Gene name: Prostate-specific membrane antigen gene engineering Adenovirus-PSA Prostate Cancer Vaccine A cell-based vaccine comprised of prostate cancer cells transduced with an adenoviral vector encoding human RTVP-1 (AdRTVP-1), with potential antineoplastic and immunostimulating activities. RTVP-1, also referred to as glioma pathogenesis-related protein 1 (GLIP1), is down-regulated in prostate tumors. Regulated by tumor suppressor p53, the expression of RTVP-1 functions as a tumor suppressor, and is abundant in normal human prostate epithelial cells as well as in differentiated macrophages. Administration of this vaccine leads to an induction of apoptosis through the expression of RTVP-1 and results in a reduction in cellular proliferation in prostate cancer cells. In addition, this cancer-cell based vaccine may induce a cytotoxic T lymphocyte (CTL) response against prostate specific tumor associated antigens, resulting in an immune-mediated prostate cancer cell death. Furthermore, RTVP-1 stimulates CTL and natural killer (NK) cell activities. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5203 https://github.com/vaccineontology/VO/issues/106 11010 5203 Clinical trial Gene name: GLIPR1 AdRTVP-1-Transduced Prostate Cancer Cell-Based Vaccine A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The Ii-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:32323103 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5436 https://github.com/vaccineontology/VO/issues/107 1437 2064 5436 Clinical trial Gene name: GM-CSF|Gene name: ERBB2 AE37 Peptide/GM-CSF Vaccine A cancer vaccine composed of naked plasmid DNA of the gene for the tumor-associated antigen alpha-fetoprotein (AFP), a macromolecule that acts as a specific immunologic target for hepatocellular carcinoma. This agent exerts an antitumor effect by inducing cytotoxic T-lymphocytes to attack AFP-expressing tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5275 https://github.com/vaccineontology/VO/issues/108 174 5275 Clinical trial Gene name: AFP AFP Gene Hepatocellular Carcinoma Vaccine A cancer vaccine made of a recombinant NY-ESO-1 protein with a TLR7 agonist Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:C5941317 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3991 https://github.com/vaccineontology/VO/issues/109 1485 3991 Clinical trial Gene name: NY-ESO-1 Ag NY-ESO-1 Vaccine A cancer vaccine containing the three frame shift peptides (FSP) AIM2(-1), HT001(-1) and TAF1B(-1), with potential immunomodulating activity. Upon administration, the AIM2(-1)/HT001(-1)/TAF1B(-1) FSP vaccine may induce an immune response against microsatellite instability (MSI) colorectal cancer-associated antigens. Frame shift mutations of AIM2 (absent in melanoma 2, an interferon-inducible protein), HT001 (asteroid homolog 1 or ASTE1, with an unknown function) and TAF1B (TATA box-binding protein-associated RNA polymerase I B, a transcription factor) are seen in MSI-positive colorectal cancers and may be associated with malignant transformation, tumor progression and the presence of tumor-infiltrating lymphocytes. These FSPs all have one-base deletions. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01461148 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5402 https://github.com/vaccineontology/VO/issues/110 28990 9014 9447 5402 Clinical trial Gene name: AIM2|Gene name: TAF1B|Gene name: ASTE1 AIM2(-1)/HT001(-1)/TAF1B(-1) Frameshift Peptide Vaccine A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with potential antitumor activity. Vaccination is associated with the expression of murine alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell allograft; murine alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell allograft. The hyperacute rejection involves the binding of pre-existing human anti-alpha-gal antibodies (which naturally occur against gut flora) to murine alpha-gal epitopes, resulting in the rapid activation of antibody-dependent cell-mediated cytotoxicity (ADCC) towards allograft cells. The host immune system then attacks endogenous pancreatic cancer cells, resulting in ADCC towards endogenous pancreatic cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:26787078 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5422 https://github.com/vaccineontology/VO/issues/145 1048 111518 5422 Clinical trial Gene name: CEACAM5|CEA Algenpantucel-L Vaccine A cancer vaccine consisting of allogeneic, immortalized dendritic precursor cells derived from a patient with acute myelogenous leukemia (AML), with potential immunostimulatory and antineoplastic activities. Upon ex vivo stimulation and expansion of the precursor cells into mature, fully functional dendritic cells (DCs) and subsequent administration, the allogeneic AML antigen-expressing DC vaccine may elicit a potent cytotoxic T-cell (CTL) and antibody response against AML antigen-expressing cells, resulting in tumor cell death. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5020 https://github.com/vaccineontology/VO/issues/146 5788 945 5020 Clinical trial Gene name: CD33|Gene name: PTPRC Allogeneic AML Antigen-expressing Dendritic Cell Vaccine An allogeneic whole cell vaccine, derived from irradiated allogenic tumor cells manipulated to express human B7.1 (CD80 antigen) and human leukocyte antigen (HLA) A1, with potential antitumor activity. Vaccination with allogeneic B7.1/HLA-A1 transfected tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15254047 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4998 https://github.com/vaccineontology/VO/issues/147 941 4998 Clinical trial Gene name: CD80 Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5257 https://github.com/vaccineontology/VO/issues/148 1048 4101 7490 5257 Clinical trial Gene name: CEACAM5|Gene name: WT1|Gene name: MAGEA2 Allogeneic Cellular Vaccine 1650-G A cancer vaccine consisting of allogeneic, immortalized dendritic cells (DCs) loaded with tumor specific antigens and activated, with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration of the allogeneic dendritic cell vaccine COMBIG-DC, these activated DCs attract natural killer (NK) cells, induce an anti-inflammatory response leading to the induction of NK-cell-mediated tumor cell death. Upon release of tumor associated antigens (TAAs) from the lysed tumor cells, these antigens are taken up by antigen presenting cells which activate the immune system to elicit a potent cytotoxic T-cell (CTL) response against the TAAs, resulting in the death of TAAs-expressing tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01525017 NCT: https://clinicaltrials.gov/ct2/show/NCT01974661 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5446 https://github.com/vaccineontology/VO/issues/149 3458 7124 5446 Clinical trial Gene name: IFNG|Gene name: TNF Allogeneic Dendritic Cell Vaccine COMBIG-DC A cell-based vaccine composed of allogeneic dendritic cells pulsed ex-vivo with an autologous myeloma idiotype with potential antineoplastic activity. Upon administration, allogeneic dendritic cell-myeloma idiotype vaccine may stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against myeloma cells, resulting in cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5102 https://github.com/vaccineontology/VO/issues/150 5102 Clinical trial Allogeneic Dendritic Cell-Myeloma Idiotype Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from an allogeneic glioblastoma (GBM) stem-like cell line, with potential immunostimulatory and antineoplastic activities. Upon administration allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine exposes the immune system to GBM stem cell antigens, which may result in cytotoxic T lymphocyte (CTL) and antibody responses against GBM cells. This leads to GBM cell lysis. GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5023 https://github.com/vaccineontology/VO/issues/151 7070 5023 Clinical trial Gene name: CD90 Allogeneic Glioblastoma Stem-like Cell Line Lysate-pulsed Autologous Dendritic Cell Vaccine An allogeneic tumor cell vaccine containing myeloma cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, allogeneic GM-CSF-based myeloma cellular vaccine secretes GM-CSF, which may potentiate a tumor-specific cytotoxic T-lymphocyte (CTL) response against myeloma cancer cell-associated antigens. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5327 https://github.com/vaccineontology/VO/issues/152 1437 4102 7490 9947 5327 Clinical trial Gene name: GM-SCF|Gene name: MAGEA3|Gene name: WT1|Gene name: MAGEC1 Allogeneic GM-CSF-Based Myeloma Cell Vaccine An allogenic vaccine consisting of irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene. Upon vaccination, the genetically modified cells secrete GM-CSF, thereby potentiating a tumor-specific T cell response against breast cancer cell-asociated antigens.A vaccine that is being studied as a way to help the body's immune system kill breast cancer cells. To make the vaccine, the GM-CSF gene is put into breast cancer cells in the laboratory. The cells are then treated with radiation to stop them from growing and injected into the same or a different patient. The GM-CSF protein made by the changed breast cancer cells may help the immune system kill breast cancer cells in the body. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5059 https://github.com/vaccineontology/VO/issues/153 2064 5059 Clinical trial Gene name: ERBB2 Allogeneic GM-CSF-Secreting Breast Cancer Vaccine An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01088789 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5075 https://github.com/vaccineontology/VO/issues/154 5075 Clinical trial Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5515 https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2010-01868&r=1 https://github.com/vaccineontology/VO/issues/155 5515 Clinical trial Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo A cancer vaccine, containing human-specific large multivalent immunogens (LMIs) isolated from the membrane fraction of cells from a breast cancer cell line, with potential immunostimulatory and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen breast cancer vaccine may stimulate a cytotoxic T lymphocyte (CTL) immune response against tumor cells that express the breast cancer cell-specific LMIs. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5269 https://github.com/vaccineontology/VO/issues/156 1493 5269 Clinical trial Gene name: CTLA4 Allogeneic Large Multivalent Immunogen Breast Cancer Vaccine A cancer vaccine, containing human-specific large multivalent immunogen (LMI) isolated from plasma membrane fractions of the melanoma cell lines MSM-M1 and MSM-M2, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen melanoma vaccine LP2307 may stimulate a CD8+ cytotoxic T lymphocyte (CTL) response against melanoma tumor cells that express melanoma-specific LMI. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00726739 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5423 https://github.com/vaccineontology/VO/issues/157 2315 6490 5423 Clinical trial Gene name: MLANA|Gene name: gp100 (PMEL) Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307 A cancer vaccine derived from two gentically modified human melanoma cell lines with potential antineoplastic activity. Allogeneic melanoma vaccine AGI-101H consists of a 1:1 mixture of cells from two genetically modified human melanoma cell lines, designated as Mich1H6 and Mich2H6, that have been gamma-irradiated to render the cells non-proliferative. Upon administration, this vaccine may stimulate a cytotoxic immune response against melanoma tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:32002306 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5376 https://github.com/vaccineontology/VO/issues/158 216 5376 Clinical trial Gene name: ALDH1A1 Allogeneic Melanoma Vaccine AGI-101H A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a mixture of lysates from five allogeneic mesothelioma tumor cell lines, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic mesothelioma tumor cell lysates. Upon re-administration of the allogeneic mesothelioma tumor lysate-pulsed autologous DC vaccine, the immune system is exposed to an undefined amount of mesothelioma-associated antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against mesothelioma tumor cells and leads to tumor cell lysis Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5440 https://github.com/vaccineontology/VO/issues/159 10232 5440 Clinical trial Gene name: MSLN Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous Dendritic Cell Vaccine A biologic product that consists of undifferentiated stem cells, obtained from adult bone marrow or other non-embryonic tissue sources, that are expanded in vitro and deposited in master cell banks for ""off-the-shelf"" use, with potential hematopoiesis-inducing and immunomodulating activities. Allogeneic multipotent adult progenitor cells (MAPCs) are non-immunogenic due to the lack of major histocompatibility (MHC) molecule expression, and so elicit no immune response upon administration. In vivo, bone marrow-derived adult stem cells are capable of maturing into a broad range of cell types and may help restore the immune system by producing multiple therapeutic molecules in response to inflammation and tissue damage. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5054 https://github.com/vaccineontology/VO/issues/160 5054 Clinical trial Allogeneic Multipotent Adult Progenitor Cells Vaccine A whole cell vaccine comprised of irradiated allogeneic renal cell carcinoma (RCC) with potential immunostimulating and antineoplastic activities. Allogeneic renal cell carcinoma vaccine MGN1601 contains two active ingredients: 1) genetically modified allogeneic RCC cells that are transiently transfected with four different MIDGE (Minimalistic Immunogenically Defined Gene Expression) vectors encoding IL-7, GM-CSF, CD80 and CD154 and 2) the synthetic DNA-based immunomodulator dSLIM-30L1, a TLR9 agonist.. Vaccination results in expression of IL-7, GM-CSF, CD80 and CD154, which all contribute to the activation or enhancement of immune responses. Furthermore, administration of this RCC vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5358 https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)36654-0 https://github.com/vaccineontology/VO/issues/161 941 959 5358 Clinical trial Gene name: CD80|Gene name: CD40LG Allogeneic Renal Cell Carcinoma Vaccine MGN1601 A vaccine composed of tumor cells isolated from the tumor of one patient, killed and processed, and administered to another patient to stimulate cytotoxic immune responses to a similar tumor cell type. The cells found in this type of whole-cell vaccine express many cell-surface tumor-associated antigens. This vaccine is frequently administered with an adjuvant immunostimulant. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5339 https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/allogeneic-tumor-cell-vaccine https://github.com/vaccineontology/VO/issues/162 5339 Clinical trial Allogeneic Tumor Cell Vaccine A vaccine composed of killed glioma cancer cells from another patient for use in immunotherapy Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:24829761 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5119 https://github.com/vaccineontology/VO/issues/163 5119 Clinical trial Allogenic Glioma Cancer Vaccine A vaccine consisting of a recombinant adenoviral vector encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:25041030 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5313 https://github.com/vaccineontology/VO/issues/164 149 5313 Clinical trial Gene name: AFP Alpha Fetoprotein Adenoviral Vector Vaccine An allogeneic renal cell cancer (RCC) vaccine composed of cell line-derived RCCs that are genetically engineered to express the murine alpha-1,3-galactosyltransferase (GalT), with potential immunostimulatory and antineoplastic activities. Not naturally occurring in humans, GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes on the cell membranes of the allogeneic RCCs present in the vaccine. This induces a hyperacute rejection reaction involving pre-existing human anti-alpha-gal antibodies, which bind to the foreign alpha-gal epitopes expressed by the allogeneic RCCs. This results in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous RCCs with unmodified carbohydrate epitopes. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5349 https://github.com/vaccineontology/VO/issues/165 11605 5349 Clinical trial Gene name: Gla Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with four alpha-fetoprotein (AFP) peptides, with potential immunostimulatory and antineoplastic activities. Upon administration, AFP peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against AFP-expressing cancer cells, resulting in tumor cell lysis. AFP is overexpressed in a variety of cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:16675576 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5315 https://github.com/vaccineontology/VO/issues/166 174 5315 Clinical trial Gene name: AFP Alpha-fetoprotein Peptide-Pulsed Autologous Dendritic Cell Vaccine A cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with the marine sponge glycolipid alpha-galactosylceramide (alpha-GalCer) with potential immunostimulatory and antimetastatic activities. Upon administration, alpha-galactosylceramide-pulsed autologous dendritic cells may result in the activation and proliferation of a subset of endogenous natural killer T (NKT) cells, B cells, and CD4+ and CD8+ T cells, and the production of interferon-gamma and interleukin-12; these cascade events may result in a T helper-1 cell-biased proinflammatory antitumor immune response. The NKT cell ligand alpha-GalCer was originally isolated from the marine sponge Agelas mauritianusis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:32188702 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5288 https://github.com/vaccineontology/VO/issues/167 5288 Clinical trial Alpha-Galactosylceramide-Pulsed Autologous Dendritic Cell Vaccine A mature polarized dendritic cell with potent immunostimulating activity. Treating dendritic cells (DCs) with interferon-alpha (IFN-a) and polyinosinic:polycytidylic acid (p-I:C) in addition to a cytokine cocktail (tumor necrosis factor alpha/Interleukin-1beta/IFN-gamma) produces mature but not exhausted alpha type-1 polarized DCs (alphaDC1) that are capable of: 1) high responsiveness to other lymphoid chemokines, and 2) producing high level of interleukin-12p70 (IL-12p70). Therefore, alphaDC1 has a much more significant capability of inducing helper T cell (CD4+ T-cell) responses in comparison with the ""gold standard"" DCs. When pulsed with specific tumor associated antigens (TAAs), alphaDC1 is able to induce a potent cytotoxic T lymphocyte (CTL) response against TAAs; as a result it can be used as a cancer vaccine. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5198 https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/alpha-type-1-polarized-dendritic-cells https://github.com/vaccineontology/VO/issues/168 2315 6490 7299 5198 Clinical trial Gene name: MLANA|Gene name: gp100 (PMEL)|Gene name: Tyrosinase Alpha-type-1 Polarized Dendritic Cell Vaccine A derivative of the Canarypox Virus, ALVAC can infect mammalian cells but it can't replicate. Thus, it produces a self-limiting infection which does not produce symptoms or harm the host. When carrying foreign genes it will cause transient expression of protein. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:16061912 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5334 https://github.com/vaccineontology/VO/issues/169 3458 5334 Clinical trial Gene name: IFNG -Obselete ALVAC Vaccine A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-B7-CEA expresses carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cells, and B7.1 (also known as CD80), the natural ligand for the T-cell antigen CD28, to augment the host immune response. This agent has been shown to stimulate a host immune response against tumor cells that express CEA. (NCI04) Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12596363 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5444 https://github.com/vaccineontology/VO/issues/210 1048 941 5444 Clinical trial Gene name: CD80|Gene name: CEACAM5 (CEA) ALVAC-B7-CEA Vaccine A replication-defective recombinant canarypox virus (ALVAC) that contains the entire human carcinoembryonic antigen (CEA) gene. Vaccination with ALVAC-CEA (VCP248) may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against CEA-positive tumor cells, thereby decreasing tumor growth. (NCI04) Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5003 https://github.com/vaccineontology/VO/issues/212 1048 5003 Clinical trial Gene name: CEACAM5 (CEA) ALVAC-CEA (VCP248) Vaccine A cancer vaccine that uses a viral vector system derived from the canarypox virus engineered to target the carcinoembryonic antigen (CEA). It causes infected cells to temporarily display CEA and activates the immune system to attack the tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:18676757 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5125 https://github.com/vaccineontology/VO/issues/213 941 5125 Clinical trial Gene name: CD80 ALVAC-CEA B7.1 Vaccine A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus, encoding for the tumor associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, ALVAC-CEA vaccine expresses CEA and may stimulate a host immune response against tumor cells expressing CEA. This may result in the inhibition of tumor growth and/or metastasis. CEA is overexpressed in a variety of tumor cell types. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5051 https://github.com/vaccineontology/VO/issues/214 1048 5051 Clinical trial Gene name: CEACAM5 (CEA) ALVAC-CEA Vaccine A cancer vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) encoding the cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC-ESO-1 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-1-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01982487 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5332 https://github.com/vaccineontology/VO/issues/215 1485 5332 Clinical trial Gene name: NY-ESO-1 ALVAC-ESO-1 Vaccine A vaccine comprise of a canarypox viral vector that carries the gene for human B7.1 (CD80 antigen) with potential use as an autologous therapeutic cancer vaccine. Tumor cells harvested from a patient are infected with ALVAC-hB7 1, thereby producing an autologous cell line that exhibits increased expression of HLA class I and class II, CD54 (ICAM), and CD80. Increased expression of these proteins by this autologous cell line may activate an antitumor T-cell response when the modified cells are administered to the patient. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00003556 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5181 https://github.com/vaccineontology/VO/issues/216 1493 5181 Clinical trial Gene name: CTLA4 ALVAC-hB7.1 Vaccine A cancer vaccine containing a replication-defective recombinant canarypox virus (ALVAC), encoding an epitope of MART-1 (melanoma antigen recognized by T-cells), with potential immunostimulatory and antineoplastic activities. Upon administration, the MART-1 epitope is expressed by the ALVAC vector in ALVAC-MART-1 vaccine; a host cytotoxic T lymphocyte (CTL) response against MART-1-expressing tumor cells may follow, resulting in tumor cell lysis and decreased tumor cell proliferation Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00612222 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5124 https://github.com/vaccineontology/VO/issues/217 2315 5124 Clinical trial Gene name: MLANA ALVAC-MART-1 Vaccine A therapeutic cancer vaccine, based on a replication-defective recombinant canarypox virus (ALVAC) encoding multiple melanoma antigens, with potential immunostimulatory and antineoplastic activities. Vaccination with ALVAC(2) melanoma multi-antigen therapeutic vaccine may stimulate the host immune system to mount an immune response against antigen-expressing melanoma cells, resulting in inhibition of tumor growth and/or metastasis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5394 https://github.com/vaccineontology/VO/issues/170 1485 6490 5394 Clinical trial Gene name: gp100 (PMEL)|Gene name: CTAG1B ALVAC(2) Melanoma Multi-antigen Vaccine A cancer vaccine consisting of a replication-defective recombinant canarypox virus [ALVAC(2)] encoding the cancer-testis antigen NY-ESO and the TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; also called TRICOM), with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC(2)/NY-ESO (M)/TRICOM vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells, including bladder, breast, hepatocellular, melanoma, and prostate tumor cells. TRICOM may enhance antigen presentation and activate cytotoxic T-cells. In addition, ALVAC(2) encodes the vaccinia virus (vv) E3L ad K3L genes, which may potentiate the translation of the NY-ESO and TRICOM genes. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01982487 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5268 https://github.com/vaccineontology/VO/issues/171 1485 3383 941 965 5268 Clinical trial Gene name: NY-ESO-1|Gene name: ICAM1|Gene name: CD80|Gene name: CD58 ALVAC(2)-NY-ESO-1 (M)/TRICOM Vaccine A cancer vaccine consisting of autologous dendritic cells loaded with separate preparations of acute myelogenous leukemia (AML) cell lysate and AML-specific messenger RNA (mRNA) with potential immunostimulatory and antineoplastic activities. Upon administration, AML mRNA plus lysate loaded autologous dendritic cell vaccine may elicit a potent cytotoxic T-cell (CTL) response against AML cells, resulting in tumor cell death. Autologous dendritic cells doubly-loaded with AML cell lysate and AML-specific mRNA may elicit superior primary, recall, and effector lytic immune responses compared to autologous dendritic cells loaded with tumor lysate or tumor mRNA alone. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5533 https://github.com/vaccineontology/VO/issues/219 5533 Clinical trial AML mRNA Positive Lysate Loaded Autologous Dendritic Cell Vaccine A plasmid DNA-based vaccine consisting of small biodegradable poly(lactide-co-glicolide) polymer microparticles encapsulating plasmid-DNA vector encoding a chimeric protein comprising epitopes derived from the E6 and E7 oncoproteins of the human papillomavirus (HPV) types 16 and 18, with potential antineoplastic activity. Upon intramuscular vaccination, amolimogene bepiplasmid may elicit the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 and -18 E6 and E7 and may result in a reduction in tumor cell growth. HPV types 16 and 18 oncoproteins E6 and E7 are most commonly involved in cervical cancer. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:19051140 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5243 https://github.com/vaccineontology/VO/issues/220 1489079 5243 Clinical trial Gene name: E7 Amolimogene Bepiplasmid Vaccine A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer; its expression is correlated with poor prognosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:32513836 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5331 https://github.com/vaccineontology/VO/issues/221 367 5331 Clinical trial Gene name: AR Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118 A modified vaccinia Ankara (MVA) encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epitopes. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15627214 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3994 https://github.com/vaccineontology/VO/issues/222 3994 Clinical trial Ankara (MVA) Vaccine Recombinant MVA-gp100M and ALVAC(2)-5T4 were constructed to complement existing ALVAC(2)-gp100M and MVA-5T4 vectors. Recombinant TAA expression in chicken embryo fibroblast cells was confirmed by Western blot analysis. 5T4 expression was approximately equal for both viruses, whereas ALVAC-derived gp100 was quickly degraded, at a time point when MVA-derived gp100 was still stable and expressed at high levels Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15627214 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4073 https://github.com/vaccineontology/VO/issues/223 4073 Clinical trial Ankara (MVA) and ALVAC(2) Vaccine An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5199 https://github.com/vaccineontology/VO/issues/224 5199 Clinical trial Anti-CD19/CD3 Tetravalent Antibody AFM11 Vaccine Autologous activated T cells that have been coated with bispecific antibodies (BiAb), with potential antineoplastic and immunomodulating activities. In vitro, T cells are activated through exposure to the anti-CD3 murine monoclonal antibody OKT3 and low-dose interleukin 2 (Il-2) for 6-14 days and then armed with anti-CD3 x anti-CD20 bispecific antibody (CD20Bi). Upon administration, anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (AATC) attach to CD3-expressing T cells and CD20-expressing tumor cells, selectively cross-linking T cells and tumor cells. This may result in the recruitment and activation of cytotoxic T lymphocyte (CTLs), CTL-mediated specific tumor cell lysis, and the secretion of antitumor cytokines and chemokines. CD20, a cell surface phosphoprotein, is found on normal B cells and most B-cell tumors. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5411 https://www.targetedonc.com/view/cd20-cd3-bispecific-antibodies-can-revolutionize-b-cell-lymphoma-therapy https://github.com/vaccineontology/VO/issues/225 931 5411 Clinical trial Gene name: MS4A1 Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells Cancer Vaccine Autologous human peripheral blood lymphocytes (PBLs), transduced with a retroviral vector encoding both the alpha and beta chains of a T cell receptor (TCR) specific for the carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. After transduction, expansion in culture, and reintroduction into the patient, anti-CEA TCR retroviral vector-transduced autologous lymphocytes bind to tumor cells expressing CEA, which may result in cytokine expression, activation and proliferation of T-cells, and a specific cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. The tumor-associated antigen (TAA) CEA is overexpressed by a variety of cancer cell types, including those of the gastrointestinal tract, lung, and breast. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5536 https://github.com/vaccineontology/VO/issues/226 1048 5536 Clinical trial Gene name: CEACAM5 (CEA) Anti-CEA TCR Retroviral Vector-Transduced Autologous Peripheral Blood Lymphocytes An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA-transfected autologous DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5375 https://github.com/vaccineontology/VO/issues/227 1493 5375 Clinical trial Gene name: CTLA4 Anti-CTLA4 MoAb RNA-transfected Autologous Dendritic Cell Vaccine An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA/GITRL RNA-transfected DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4) monoclonal antibody and tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes, while expression of GlTRL modulates T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5149 https://github.com/vaccineontology/VO/issues/228 1493 5149 Clinical trial Gene name: CTLA4 Anti-CTLA4 MoAb RNA/GITRL RNA-transfected Autologous Dendritic Cell Vaccine A peptide vaccine derived from the synthetic peptide pyroEHWSYGLRPG, corresponding to amino acids 22-31 of mouse gonadotropin releasing hormone (GnRH), with potential immunocastration activity. PEP223 is dimerized and contains a D-lysine (k) substitution at position 6 (pyroEHWSYkLRPG) to increase its immunogenicity. Anti-GnRH vaccine PEP223 may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GnRH, neutralizing its activity. In turn, testosterone production and tumor cell growth may be inhibited in testosterone-sensitive tumors. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00895466 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5405 https://github.com/vaccineontology/VO/issues/229 14714 5405 Clinical trial Gene name: Gnhr1 Anti-GnRH Vaccine PEP223 A monoclonal antibody that functionally mimics MUC-1 antigen, a tumor cell surface antigen. Administration of anti-idiotype MUC-1 monoclonal antibody may elicit an anti-idiotype antibody and corresponding T-cell response against MUC-1 expressing tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15550589 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5175 https://github.com/vaccineontology/VO/issues/230 4582 5175 Clinical trial Gene name: MUC1 Anti-idiotype MUC-1 Monoclonal Antibody Vaccine A synthetic antibody produced by a genetically homogenous population of hybrid cells (hybridoma) against determinant idiotypes (Id) which usually mimic human epitopes. Anti-Id vaccines may be effective in the treatment of B-cell lymphomas, resulting in tumor regression. Anti-idiotype vaccine therapy is less likely to induce autoimmunity if the target antigen is not normally expressed on normal tissues. Monoclonal antibodies have become powerful tools for tumor targeting, recognizing different protein markers on certain cancer cells and may be used alone or as delivery agents for drugs, toxins or radioactive material targeted to tumors. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5301 https://github.com/vaccineontology/VO/issues/231 5301 Clinical trial Anti-Idiotype Specified Monoclonal Antibody Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:9816036 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4015 https://github.com/vaccineontology/VO/issues/232 4015 Clinical trial anti-idiotypic mAb MK2-23+BCG A murine anti-idiotypic monoclonal antibody (anti-Id MoAb) that is directed against an idiotype mimicking a disialoganglioside GD3. GD3 represents a major surface marker on most human melanoma cells. Due to poor immunogenicity of GD3, anti-Id MoAb BEC2 (Ab2) was raised against a mouse anti-GD3 MoAb, R24 (Ab1). This anti-Id MoAb was shown to be functionally mimicking GD3 in stimulating an immune response to produce Ab3 that may be used in combination with other adjuvants for treatment of melanomas. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5433 https://github.com/vaccineontology/VO/issues/233 5433 Clinical trial anti-idiotypic monoclonal antibody BEC2 vaccine An immunotherapeutic agent targeting the tumor-associated antigen (TAA), cancer/testis antigen NY-ESO-1, with potential antineoplastic activity. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5485 https://github.com/vaccineontology/VO/issues/234 1485 5485 Clinical trial Gene name: NY-ESO-1 anti-NY-ESO-1 Immunotherapeutic GSK-2241658A Vaccine Human autologous CD62L-positive T-lymphocytes transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the anti-NY-ESO1 TCR-transduced autologous CD62L+-derived T-Lymphocytes bind to NY-ESO-1-overexpressing tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. CD62L, also called L-selectin, is a lymphoid homing receptor and differentiation marker and is expressed on a subset of CD8-positive T-lymphocytes; it is involved in the migration of T-lymphocytes to lymph nodes and may improve the efficacy for ex vivo-expanded T-cells following adoptive cell therapy. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5081 https://github.com/vaccineontology/VO/issues/235 1485 30484 5081 Clinical trial Gene name: NY-ESO-1|Gene name: CTAG2 anti-NY-ESO1 TCR-transduced Autologous CD62L+-derived T-Lymphocytes Vaccine Human autologous peripheral blood lymphocytes (PBLs) transduced with an anti-p53 T cell receptor gene with potential antineoplastic activity. PBLs are harvested from a patient and pulsed with a retroviral vector that encodes the T-cell receptor gene specific for a mutated form of p53. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these modified PBLs express the anti-p53 T cell receptor which binds to mutant p53-overexpressing tumor cells; PBL-mediated tumor growth inhibition may follow. Many tumor cell types overexpress mutant p53 proteins, which are associated with the loss of apoptosis regulation and abnormal cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00393029 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5447 https://github.com/vaccineontology/VO/issues/236 7157 5447 Clinical trial Gene name: TP53 (P53) anti-p53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes Vaccine An immunotherapeutic agent targeting the tumor-associated antigen (TAA), preferentially expressed antigen of melanoma (PRAME), with potential antineoplastic activity. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01853878 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5361 https://github.com/vaccineontology/VO/issues/237 23532 5361 Clinical trial Gene name: PRAME anti-PRAME Immunotherapeutic GSK2302032A Vaccine An individualized, therapeutic cancer vaccine (IVAC) composed of liposomes containing RNA encoding two or three tumor associated antigens (TAAs) that are specifically expressed in the patient's individual cancer selected from a warehouse (""off the shelf"") and p53 RNA, with potential immunostimulatory and antineoplastic activities. Upon administration, the antigen-targeted personalized breast cancer vaccines are translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL) and memory T-cell immune responses against the TAAs. The RNAs in the vaccine are specifically selected for an individual patient after RNA profiling of the patient's tumor. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5138 https://github.com/vaccineontology/VO/issues/238 6490 5138 Clinical trial Gene name: gp100 (PMEL) antigen-targeted Personalized Breast Cancer Vaccine A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01133704 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5420 https://github.com/vaccineontology/VO/issues/239 2346 354 55 5420 Clinical trial Gene name: ACPP|Gene name: Prostate|Gene name: KLK3 APC8015F vaccine A cell based cancer vaccine composed of mature polarized dendritic cells (DCs) and pulsed with apoptotic autologous tumor cells that has potential immunostimulating and antineoplatic activities. Dendritic cells (DCs) were treated with interleukin-1beta, tumor necrosis factor alpha, interferon-alpha (IFN-a), IFN-gamma and polyinosinic:polycytidylic acid (p-I:C) to produce mature alpha type-1 polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). The alphaDC1 are subsequently pulsed with apoptotic autologous tumor cells. Upon administration, these DCs are able to induce a potent cytotoxic T lymphocyte (CTL) response against tumor associated antigens (TAAs), resulting in tumor cell lysis and inhibition of tumor cell growth. Apoptotic tumor cells contain an array of TAAs Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21509164 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5222 https://github.com/vaccineontology/VO/issues/240 5222 Clinical trial Apoptotic Autologous Tumor Cells-pulsed Alpha-type-1 Polarized Dendritic Cells Vaccine A vaccine comprised of autologous epithelial ovarian cells infected with ALVAC-hB7.1 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5319 https://www.clincosm.com/trial/recurrent-ovarian-epithelial-cancer-houston-alvac-hb71-recombinant https://github.com/vaccineontology/VO/issues/242 155971 5319 Clinical trial Gene name: env AUT-OV-ALVAC-hB7.1 Vaccine An autologous tumor cell vaccine containing chronic lymphocytic leukemia (CLL) B cells transduced with an adenoviral vector carrying chimeric CD154 (ad-CD154) with potential antineoplastic activity. Administration of autologous ad-CD154 transduced CLL B cells may result in increases in the numbers of leukemia-specific CD4+ T cells and high serum-levels of IL-12 and IFN-gamma. Due to ligation of CD154 to CD40 on CLL cells, this agent may induce CLL cells to express the proapoptotic molecule BID and death receptors CD95 (Fas) and DR5, rendering CLL B cells first resistant and then sensitive to Fas-mediated apoptosis. In addition, autologous ad-CD154 transduced CLL B cells may induce MHC class I-dependent cytotoxic T lymphocyte (CTL) responses against autologous leukemia cells. CD154 is a type II membrane glycoprotein and ligand for CD40; both molecules are important in cognate co-stimulatory cell-cell interactions. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00779883 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5053 https://github.com/vaccineontology/VO/issues/243 959 5053 Clinical trial Gene name: CD40LG Autologous Ad-CD154-Transduced CLL B Cells Vaccine Human autologous peripheral blood lymphocytes (PBLs) transduced with a glycoprotein 100 (gp100) epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector encoding the TCR specific for amino acid residues 154-162 of gp100 (KTWGQYWQV). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient and bind to melanoma cells expressing the gp100 protein, which may result in specific cytotoxic T-lymphocyte (CTL) killing of gp100-expressing melanoma cells. gp100 is a melanocyte lineage-specific antigen overexpressed in melanomas. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00509496 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5507 https://github.com/vaccineontology/VO/issues/244 6490 5507 Clinical trial Gene name: gp100 (PMEL) Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes Vaccine Human autologous peripheral blood lymphocytes (PBLs) transduced with a melanoma antigen MART-1 epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector that encodes the TCR specific for an epitope of MART-1 (F5 TCR). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient, and bind to melanoma cells expressing the MART-1 antigen, which may result in specific cytotoxic T-lymphocyte (CTL) killing of MART-1-expressing melanoma cells. MART-1 (melanoma antigen recognized by T cells 1), also known as Melan-A, is a melanocyte lineage-specific transmembrane protein. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00509288 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5293 https://github.com/vaccineontology/VO/issues/245 2315 5293 Clinical trial Gene name: MLANA Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes Vaccine A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with CD133-positive autologous brain tumor stem cells (BTSCs) -derived mRNA with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous CD133-positive BTSC mRNA-pulsed autologous dendritic cell vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against the CD133-positive BTSCs from which the autologous tumor mRNA is derived. CD133, a tumor-associated antigen (TAA) and neural stem cell marker, has been found on a specific subset of glioblastoma multiforme (GBM) stem cells; its presence has been correlated with resistance to conventional chemotherapy and radiotherapy. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5463 https://mhlw-grants.niph.go.jp/system/files/2013/134041/201328051A/201328051A0017.pdf https://github.com/vaccineontology/VO/issues/246 8842 5463 Clinical trial Gene name: PROM1 Autologous CD133-Positive BTSC mRNA-Pulsed Autologous Dendritic Cell Vaccine A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced with an adenoviral vector encoding the gene for the human CD40 ligand (CD40L; TRAP; CD154), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous CD40L-expressing B-CLL vaccine expresses the co-stimulatory molecule CD40L, which binds to its cognate receptor, CD40, on antigen presenting cells (APC). This induces apoptosis, stimulates maturation and proliferation of APCs, and facilitates a cytotoxic T-lymphocyte (CTL) response against tumor cells. CD40L is a type II membrane protein that binds to CD40, which is a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor superfamily. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5174 https://github.com/vaccineontology/VO/issues/247 959 5174 Clinical trial Gene name: CD40LG Autologous CD40L-expressing B-CLL Vaccine A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with tumor cell lysates from a colorectal cancer patient containing tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous colorectal tumor antigen-pulsed DC vaccine exposes the immune system to colorectal tumor cell antigens, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the colorectal cancer cells. This leads to cancer cell lysis. The tumor cell lysate contains a range of antigens that are essential for the neoplastic growth and survival of the cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5150 https://github.com/vaccineontology/VO/issues/248 174 5150 Clinical trial Gene name: AFP Autologous Colorectal Tumor Antigen-pulsed Dendritic Cell Vaccine An autologous tumor cell vaccine containing CD34+ hematopoietic progenitor cell (HPC)-derived Langerhans-type dendritic cells (LCs) electroporated with mRNA encoding the full-length cancer-testis antigens, CT7 and melanoma-associated antigen 3 (MAGE-A3), and the self-differentiation tumor antigen, Wilms tumor 1 (WT1) with potential immunomodulating and antineoplastic activity. The autologous CT7/MAGE-A3/WT1 mRNA-electroporated Langerhans-type dendritic cells are prepared by drawing a blood sample containing the CD34+ HPCs from a cancer patient. The CD34+ HPCs are treated with a combination of cytokines which specifically support LC development, and the LC population is enriched and expanded ex vivo. The cultured LCs are allowed to mature for one day and then electroporated separately with CT7, MAGE-A3 or WT1 mRNA before final maturation. Upon intradermal administration into the patient, the mature LCs may activate cell-mediated immunity and induce both cytotoxic CD8+ T cells and CD4+ helper T cells against cancer cells expressing CT7, MAGE-A3 and WT1 tumor antigens. This may result in the immune-mediated inhibition of tumor cell proliferation, leading to tumor cell death. CT7 and MAGE-A3 are tumor-specific proteins overexpressed in a number of cancers but not in healthy tissues other than testis and placenta. WT1 is a transcription factor important in development and cancer pathogenesis, which is overexpressed in a variety of cancers, including multiple myeloma, leukemia, ovarian cancer, malignant mesothelioma, neural tumors and renal carcinoma. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01995708 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5128 https://github.com/vaccineontology/VO/issues/249 7490 5128 Clinical trial Gene name: WT1 Autologous CT7/MAGE-A3/WT1 mRNA-Electroporated Langerhans-Type Dendritic Cells Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22774527 PubMed:31771601 PubMed:34862245 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3967 https://github.com/vaccineontology/VO/issues/250 3967 Clinical trial autologous dendritic cell vaccine (DCV) A cell-based cancer vaccine composed of autologous, immature dendritic cells (DCs), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, immature DCs are isolated and re-administered intra-tumorally. The immature DCs internalize and process the tumor-associated antigens (TAAs), migrate to the lymphatic system, and then expose the immune system to the TAAs. This induces a specific cytotoxic T-lymphocyte (CTL) response against the cancer cells leading to tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT02649829 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5085 https://github.com/vaccineontology/VO/issues/251 958 5085 Clinical trial VO:0007576 Gene name: CD40 Autologous Dendritic Cell Vaccine ACT2001 A cancer vaccine comprised of autologous dendritic cells (DCs) that have been transduced ex vivo with an adenoviral vector containing the CCL21 gene with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, autologous dendritic cell-adenovirus CCL21 vaccine expresses the chemokine CCL21, which may induce an antitumoral cytotoxic immune response in the tumor microenvironment. CCL21 [chemokine (C-C motif) ligand 21] has been shown to attract antigen presenting cells (APCs), like leukocytes and DCs, and natural killer (NK) cells and their T-cell effectors to induce a cytotoxic immune response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT03546361 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5030 https://github.com/vaccineontology/VO/issues/252 6366 5030 Clinical trial Gene name: CCL21 Autologous Dendritic Cell-Adenovirus CCL21 Vaccine An autologous vaccine composed of dendritic cells (DC) that have been transduced with a p53 tumor suppressor gene-modified virus. When the autologous dendritic cell-adenovirus p53 vaccine is administered, the host cytotoxic T lymphocytes (CTL) are directed against p53-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:20420527 PubMed:29515795 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5088 https://github.com/vaccineontology/VO/issues/253 7157 5088 Clinical trial Gene name: TP53 (P53) Autologous Dendritic Cell-Adenovirus P53 Vaccine A cell-based vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from heat-treated allogeneic melanoma tumor cells. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T-cell and antibody responses to melanoma cells bearing shared melanoma antigens such as MelanA/MART-1, gp100, MAGE3, resulting in tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5495 https://github.com/vaccineontology/VO/issues/254 2315 4102 6490 5495 Clinical trial Gene name: MLANA|Gene name: gp100 (PMEL)|Gene name: MAGEA3 Autologous Dendritic Cell-Allogeneic Melanoma Tumor Cell Lysate Vaccine cancer vaccine consisting of autologous dendritic cells transfected with autologous tumor mRNA and the human CD40 ligand (CD40L) gene with immunostimulatory and antitumor activities. Vaccination with autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine may elicit a cytotoxic T cell response against tumor cells from which the autologous tumor mRNA was derived. When expressed by dendritic cells, tumor antigens and the co-stimulatory molecule CD40L, which binds to CD40 receptors on antigen presenting cells (APC), facilitate both humoral and cellular immune responses against tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:20884622 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5066 https://github.com/vaccineontology/VO/issues/255 6490 5066 Clinical trial Gene name: gp100 (PMEL) Autologous Dendritic Cell-Autologous Tumor mRNA-Human CD40L Vaccine A therapeutic interleukin-12 (IL-12)-expressing dendritic cell (DC)-based vaccine composed of autologous monocyte-derived DCs loaded with autologous tumor cell lysate and exposed to the microbial cell wall component lipopolysaccharide (LPS), with potential immunomodulating and antineoplastic activities. The monocyte-derived immature DCs are loaded with autologous tumor cell lysates and are subsequently exposed to LPS and interferon-gamma (IFN-gamma). Upon administration of autologous DC-based immunotherapeutic AV0113, the mature DCs migrate into the lymph nodes, express the immune stimulatory cytokine interleukin-12 (IL-12) and activate the immune system by promoting the activation of natural killer (NK) cells and induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Exposure to LPS and IFN-gamma allows the maturation of DCs and optimizes the presentation of tumor-associated antigens (TAAs) by DCs to T-lymphocytes. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5284 https://ascopubs.org/doi/10.1200/jco.2014.32.15_suppl.2052 https://github.com/vaccineontology/VO/issues/256 5284 Clinical trial Autologous Dendritic Cell-based Immunotherapeutic AV0113 Vaccine A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous tumor cells with potential immunostimulatory and antineoplastic activities. Autologous dendritic cell-tumor fusion vaccine is generated in vitro by mixing DCs and irradiated tumor cells harvested from individual patients and treating them with polyethylene glycol (PEG) to produce DC-tumor cell fusion hybrid cells. Upon administration, autologous dendritic cell-tumor fusion vaccine may elicit antitumor humoral and cellular immune responses. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:23685836 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5056 https://github.com/vaccineontology/VO/issues/257 4582 6382 952 5056 Clinical trial VO:0007577 Gene name: MUC1|Gene name: CD38|Gene name: SDC1 Autologous Dendritic Cell-Tumor Fusion Vaccine A vaccine consisting of autologous cancer cells modified with the hapten, Dinitrophenyl. The treatment program consists of multiple intradermal injections of irradiated DNP-modified autologous tumor cells mixed with bacillus Calmette-Guerin. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:/9400626 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5537 https://github.com/vaccineontology/VO/issues/258 5537 Clinical trial Autologous Dinitrophenyl Vaccine A cancer vaccine consisting of autologous ovarian cancer cell peptide antigens conjugated to the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of autologous dinitrophenyl-modified ovarian cancer vaccine may induce a cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5459 https://github.com/vaccineontology/VO/issues/259 5459 Clinical trial Autologous Dinitrophenyl-Modified Ovarian Cancer Vaccine A cell-based vaccine composed of autologous tumor cells with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5118 https://github.com/vaccineontology/VO/issues/260 5118 Clinical trial Autologous EBV-Transformed B Lymphoblastoid-Tumor Fusion Cell Vaccine A cell-based vaccine composed of autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5225 https://github.com/vaccineontology/VO/issues/261 1880 5225 Clinical trial Gene name: GPR183 Autologous Epstein-Barr Virus-Transformed B-Lymphoblastoid Cell Vaccine Multipotent self-renewing adherent non-hematopoietic stromal cells harvested from a patient's bone marrow and grown in vitro. When injected back into the patient, autologous expanded mesenchymal stem cells OTI-010 may differentiate into various mesenchyme-derived cell types and, in some instances, may augment bone marrow engraftment after whole-body irradiation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5491 https://github.com/vaccineontology/VO/issues/262 5491 Clinical trial Autologous Expanded Mesenchymal Stem Cells OTI-010 Vaccine An autologous tumor cell vaccine containing irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Autologous breast cancer cells are transduced ex vivo with an adenovirus vector encoding the GM-CSF gene and irradiated and then reintroduced into the patient. Upon repeated subcutaneous administration of the vaccine, autologous GM-CSF-secreting breast cancer cells secrete GM-CSF, which may stimulate a tumor-specific cytotoxic T-lymphocyte (CTL) response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5250 https://github.com/vaccineontology/VO/issues/263 2064 5250 Clinical trial Gene name: ERBB2 Autologous GM-CSF-Secreting Breast Cancer Vaccine A lethally irradiated, autologous colorectal cancer vaccine consisting of patient-specific colorectal cancer cells genetically modified to secrete the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon vaccination, the autologous GM-CSF-secreting lethally irradiated colorectal cancer cell vaccine releases GM-CSF. In turn, GM-CSF may increase the body's immune response against tumor cells by promoting the maturation and activation of dendritic cells (DCs), and enhancing tumor-specific antigen presentation to both B- and T-cells, which leads to better recognition of tumors by the immune system. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5188 https://github.com/vaccineontology/VO/issues/264 10232 5188 Clinical trial Gene name: MSLN Autologous GM-CSF-secreting Lethally Irradiated Colorectal Cancer Cell Vaccine An autologous cancer vaccine composed of lethally irradiated leukemia cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injection, the autologous GM-CSF-secreting lethally irradiated leukemia cell vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the immune system to attack tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-lymphocytes. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5240 https://github.com/vaccineontology/VO/issues/265 1437 7490 5240 Clinical trial Gene name: GM-CSF|Gene name: WT1 Autologous GM-CSF-Secreting Lethally Irradiated Leukemia Cell Vaccine A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5266 https://github.com/vaccineontology/VO/issues/266 3308 5266 Clinical trial Gene name: HSPA4 Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858 A vaccine consisting of lethally irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous tumor DNA derived from a head and neck squamous cell carcinoma (HNSCC), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous HNSCC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses HNSCC tumor-associated antigens (TAAs), which may activate the immune system to induce a cytotoxic T-lymphocyte (CTL) response against HNSCC cells. The MRC-5 cell line, established in 1966, is a human diploid lung fibroblast cell line derived from the human lung tissue of a 14-week-old male fetus. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT02211027 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5043 https://github.com/vaccineontology/VO/issues/267 6375 5043 Clinical trial Gene name: XLC1 Autologous HNSCC DNA-transfected Semi-allogeneic Fibroblasts MRC-5 Vaccine A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced ex vivo with an adenoviral vector encoding the gene for the human cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous IL-2-expressing B-CLL vaccine expresses IL-2, stimulates natural killer (NK) cells, and may enhance the cytotoxic T-lymphocyte (CTL) immune response against the patient's B-CLL cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00458679 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5228 https://github.com/vaccineontology/VO/issues/268 12519 3383 942 5228 Clinical trial Gene name: Cd80|Gene name: CD86|Gene name: ICAM1 Autologous IL-2-expressing B-CLL Vaccine A cancer vaccine composed of tumor-specific idiotype determinants derived from an individual's tumor cells which are conjugated to keyhole limpet hemocyanin, an immunostimulant carrier protein. When injected into the individual from whom the tumor cells were isolated, this vaccine may stimulate an antitumoral cytotoxic T-lymphocytic immune response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00104819 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5057 https://github.com/vaccineontology/VO/issues/269 3123 5057 Clinical trial VO:0007579 Gene name: HLA-DRB1 Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous lymphoma cells with potential immunostimulatory and antineoplastic activities. Upon intranodal administration, autologous lymphoma cell lysate-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against lymphoma cells, which may result in lymphoma cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5248 https://github.com/vaccineontology/VO/issues/270 5248 Clinical trial Autologous Lymphoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine consisting of hybrid cells created by electrofusing allogeneic dendritic cells (DCs) and autologous lymphoma cells with potential immunostimulating and antitumor activities. Upon administration, autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against specific autologous lymphoma-associated antigens, resulting in lymphoma cell apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5503 https://github.com/vaccineontology/VO/issues/272 1638 2315 6490 7299 5503 Clinical trial Gene name: gp100 (PMEL)|Gene name: MLANA|Gene name: DCT|Gene name: Tyrosinase Autologous Lymphoma Cell/Allogeneic Dendritic Cell Electrofusion Hybrid Vaccine A cell-based cancer vaccine consisting of hybrid cells created by electrofusing autologous dendritic cells (DCs) and autologous lymphoma cells with potential immunostimulating and antitumor activities. Upon administration, autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against specific autologous lymphoma-associated antigens, resulting in lymphoma cell apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5431 https://github.com/vaccineontology/VO/issues/273 5431 Clinical trial Autologous Lymphoma Cell/Autologous Dendritic Cell Electrofusion Hybrid Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous melanoma cells containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against melanoma cells, which may result in melanoma cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5148 https://github.com/vaccineontology/VO/issues/274 1485 2315 5148 Clinical trial Gene name: NY-ESO-1|Gene name: MLANA-Dupuli Autologous Melanoma Lysate-Pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and conjugated to the immunostimulant Keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against melanoma cells, which may result in melanoma cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5213 https://github.com/vaccineontology/VO/issues/275 3123 5213 Clinical trial Gene name: HLA-DRB1 Autologous Melanoma Lysate/KLH-Pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with both a lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and a synthetic peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/NY-ESO-1-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody-mediated immune responses against melanoma cells, which may result in melanoma cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5158 https://github.com/vaccineontology/VO/issues/276 1485 5158 Clinical trial Gene name: NY-ESO-1 Autologous Melanoma Lysate/NY-ESO-1-pulsed Autologous Dendritic Cell Vaccine A vaccine consisting of irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous non-small cell lung cancer (NSCLC)-derived DNA with potential immunostimulatory and antineoplastic activities. Upon administration, autologous NSCLC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses NSCLC tumor-associated antigens (TAAs) in addition to MHC class I-determinants and the co-stimulatory molecule B7.1, which may induce a cytotoxic T-lymphocyte (CTL) response against NSCLC cells. The MRC-5 cell line is a human diploid lung fibroblast cell line extablished in 1966. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5377 https://github.com/vaccineontology/VO/issues/277 5377 Clinical trial Autologous NSCLC DNA-Transfected Semi-Allogeneic Fibroblasts MRC-5 Vaccine A personalized cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with immunogenic peptides derived from autologous non-small cell lung cancer (NSCLC) cells, with potential immunostimulating and antineoplastic activities. During leukapheresis, mature DCs are loaded with autologous NSCLC-derived peptides. Upon re-administration of the NSCLC peptide-specific DC vaccine, the immune system is exposed to NSCLC-associated antigens. This results in the induction of a specific cytotoxic T-lymphocyte (CTL) response against NSCLC cells and tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5311 https://github.com/vaccineontology/VO/issues/278 5311 Clinical trial Autologous NSCLC Peptide-specific Dendritic Cell Vaccine A cancer vaccine consisting of autologous, mature monocyte-derived dendritic cells (DCs) transfected with oncofetal antigen immature laminin receptor protein (OFA-iLRP) RNA, with potential antineoplastic activity. Upon administration, DCs in the OFA-iLRP RNA-transfected autologous dendritic cell vaccine express, process, and present OFA-iLRP to the host immune system, which may mount a potent cytotoxic T-cell (CTL) response against OFA-iLRP-expressing tumor cells. As a highly conserved protein, OFA-iLRP is preferentially expressed in fetal tissues and in many types of cancer, including hematopoietic malignancies, but is not detectable in normal differentiated adult cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00715832 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5368 https://github.com/vaccineontology/VO/issues/279 16785 5368 Clinical trial Gene name: Rspa Autologous OFA-iLRP RNA-Transfected Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous, irradiated dendritic cells (DCs) pulsed with ovarian tumor cell lysate containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous ovarian tumor cell lysate-pulsed dendritic cell vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian tumor cells expressing the patients ovarian tumor cell-specific TAAs, which may result in ovarian tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5427 https://github.com/vaccineontology/VO/issues/280 5427 5427 Clinical trial Gene name: ERBB2 Autologous Ovarian Tumor Cell Lysate-Pulsed Dendritic Cell Vaccine A specific population of autologous, pluripotent bone marrow derived cells that express high levels of the cytosolic enzyme aldehyde dehydrogenase (ALDH) with potential protective and neuro-cognition improving activity. Expression of high levels of ALDH is an indicator of the biological activity in heterogenous early stage stem cells. Upon intravenous administration, these ALDH bright cells may protect normal cells and may repair damaged cells. These cells may also protect brain cells from damage and may improve neurocognition. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5220 https://discovery.lifemapsc.com/regenerative-medicine/cell-therapy-applications/brain-ald451-bone-marrow-derived-cells-for-malignant-glioma https://github.com/vaccineontology/VO/issues/281 216 217 5220 Clinical trial Gene name: ALDH1A1|Gene name: ALDH2 Autologous Pluripotent ALDHbr Stem Cells ALD-451 Vaccine A genetically-modified autologous dendritic cell-based vaccine expressing a drug-inducible costimulatory CD40 receptor (iCD40) with potential immunomodulating and antineoplastic activities. Autologous dendritic cells (DCs) are genetically modified to express the iCD40 receptor and are pulsed with the tumor antigen prostate-specific membrane antigen (PSMA). Upon intradermal administration, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizer agent AP1903 is administered; AP1903 binds to and activates iCD40 receptors presented on DC surfaces, thus activating the DCs and stimulating a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. This delayed activation strategy optimizes DC accumulation in local draining lymph nodes prior to DC activation. iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to a drug-binding domain. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5282 https://github.com/vaccineontology/VO/issues/282 2346 928 5282 Clinical trial Gene name: CD40|Gene name: Prostate Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101 A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with renal cell carcinoma (RCC) tumor cell lysate containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous renal cell carcinoma tumor lysate-dendritic cell vaccine may stimulate anti-tumoral cytotoxic T-lymphocyte (CTL) and antibody responses against RCC tumor cells expressing RCC TAAs, resulting in RCC tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5018 https://github.com/vaccineontology/VO/issues/283 2315863 7015 5018 Clinical trial Gene name: Survivin|Gene name: TERT Autologous Renal Cell Carcinoma Tumor Lysate-Pulsed Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from sarcoma cells with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous sarcoma lysate-pulsed dendritic cell vaccine exposes the immune system to an undefined amount of sarcoma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the sarcoma TAA-expressing cells, resulting in sarcoma cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5189 https://github.com/vaccineontology/VO/issues/284 5189 Clinical trial Autologous Sarcoma Lysate-pulsed Dendritic Cell Vaccine A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with autologous T cell receptor gamma-chain alternate reading frame protein (TARP) peptide with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous TARP peptide-pulsed dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against TARP-expressing cancer cells, resulting in tumor cell lysis. The highly immunogenic nuclear protein TARP is commonly expressed in breast and prostate cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT02362451 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5024 https://github.com/vaccineontology/VO/issues/285 6862 5024 Clinical trial Gene name: TBXT Autologous TARP Peptide-Pulsed Dendritic Cell Vaccine An autologous chronic lymphocytic leukemia cancer vaccine consisting of patient-specific membrane proteins directly extracted from patient autologous tumor cells and incorporated into liposomes along with Interleukin 2 (IL-2) to produce membrane-patched proteoliposomes, with potential immunostimulating and antineoplastic activities. After subcutaneous injection of the autologous tumor cell proteoliposomes chronic lymphocytic leukemia vaccine, liposomes deliver the encapsulated tumor antigens into the cytosol of antigen presenting cells (APCs). Subsequently, the APCs process the antigens and present antigen-derived peptides to the immune system. This may enhance recognition of tumors by the immune system, and activate both cytotoxic CD8+ T cells and CD4+ helper T cells against tumor cells. IL-2 is incorporated into the vaccine to leverage its ability to expand activated T cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5108 https://github.com/vaccineontology/VO/issues/287 3558 5108 Clinical trial Gene name: IL2 Autologous Tumor Cell Proteoliposome Chronic Lymphocytic Leukemia Vaccine A therapeutic agent produced by isolating tumor cells from an individual and processing these tumor cells into a vaccine formulation in vitro; the vaccine is then administered to the individual from whom the tumor cells were isolated. Typically combined with an adjuvant immunostimulant, an autologous cell vaccine may elicit a cytotoxic T-lymphocytic immune response to cell surface-expressed tumor-associated antigens (TAAs), resulting in tumor cell death. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22854664 PubMed:32558897 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5396 https://github.com/vaccineontology/VO/issues/288 942 5396 Clinical trial Gene name: CD86 Autologous Tumor Cell Vaccine A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with specific tumor-associated peptide antigens (TAPA), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous TAPA-pulsed DC vaccine exposes the immune system to the specific TAPAs, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the TAPA-expressing cancer cells. This leads to cancer cell lysis. This vaccine is specific towards peptides derived from the following proteins: sperm autoantigenic protein 17 (SP17), ropporin, A-kinase anchor protein 4 (AKAP4), pituitary tumor-transforming 1 (PTTG1) and SPANX family member B (SPANX-B). Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:18528294 PubMed:23482679 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5035 https://github.com/vaccineontology/VO/issues/289 53340 54763 728695 8852 9232 5035 Clinical trial Gene name: SPA17|Gene name: ROPN1|Gene name: AKAP4|Gene name: PTTG1|Gene name: SPANXB1 Autologous Tumor-associated Peptide Antigen-pulsed Dendritic Cell Vaccine An autologous therapeutic vaccine for the treatment of acute myelogenous leukemia. This vaccine is prepared from blood samples of patients following their first relapse. Tumor cells extracted from blood sample are modified with hapten, a process that makes the cells appear foreign to the patient's body and results in stimulating immune response against the cancer. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5404 https://github.com/vaccineontology/VO/issues/290 2315 4102 5404 Clinical trial Gene name: MAGEA3|Gene name: MLANA Autologous-Cell Leukemia Vaccine An autologous-cell vaccine for melanoma. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5110 https://github.com/vaccineontology/VO/issues/291 5110 Clinical trial Autologous-Cell Melanoma Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21036724 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5230 https://github.com/vaccineontology/VO/issues/296 5230 Clinical trial BCG, Cell Wall Skeleton Vaccine A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. (NCI04)A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:7479929 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5399 https://github.com/vaccineontology/VO/issues/297 598 7306 5399 Clinical trial VO:0007589 Gene name: BCL2L1|Gene name: TYRP1 Bcl-Xs Adenovirus Vaccine A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:26211534 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5374 https://github.com/vaccineontology/VO/issues/298 7042 5374 Clinical trial Gene name: TGFB2 Belagenpumatucel-L Vaccine A synthetic vaccine combining the peptide antigens of two proteins, ras oncoprotein and tumor suppressor p53 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15983396 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4992 https://github.com/vaccineontology/VO/issues/299 7157 4992 Clinical trial Gene name: TP53 (P53) Berzofsky Ras/P53 Peptide Vaccine A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5439 https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-05711&r=1 https://github.com/vaccineontology/VO/issues/310 925 5439 Clinical trial Gene name: CD8A Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine A cell-based cancer vaccine comprised of brain tumor initiating cells (BTICs), with potential immunostimulating and antineoplastic activity. BITCs are from the glioblastoma multiforme (GBM) cell line GBM-6 and contain glioma stem-like cell-associated antigens. Upon administration, the BITC vaccine may stimulate a specific anti-tumoral cytotoxic T-lymphocyte (CTL) response against brain tumor cancer cells and brain tumor stem like cells, resulting in tumor cell lysis. BITC have unique antigenicity and have the ability to self-renew; vaccination against BITC antigens may kill these cells and may prevent tumor recurrences. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5210 https://github.com/vaccineontology/VO/issues/311 3383 941 965 5210 Clinical trial Gene name: CD58|Gene name: ICAM1|Gene name: CD80 Brain Tumor Initiating Cell Vaccine A cancer vaccine consisting of recombinant modified vaccinia Ankara (rMVA) encoding the prostate specific antigen (PSA), the prostate-specific membrane antigen (PSMA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Vaccination with PSA/PSMA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells over-expressing PSA or PSMA. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29561 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5309 https://github.com/vaccineontology/VO/issues/312 5309 Clinical trial rMVA-PSA/PSMA/TRICOM vaccine A vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) that encodes the gene for human interleukin-12 (hIL-12). Produced mainly by B-cells, IL-12 is an endogenous cytokine that activates natural killer (NK) cells, promotes cytotoxic T lymphocyte (CTL) responses, induces the release of interferon-gamma (IFN-gamma), and may exhibit antitumor and anti-angiogenic effects. Vaccination with canarypox-hIL-12 melanoma vaccine may stimulate the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth and/or metastasis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5544 https://github.com/vaccineontology/VO/issues/313 2521 5544 Clinical trial Gene name: FUS Canarypox-hIL-12 Melanoma Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:/7629885 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5329 https://github.com/vaccineontology/VO/issues/372 5329 Clinical trial CAP-2 (CEA Peptide 9-mer) Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5380 https://link.springer.com/article/10.1007/s11888-014-0250-5 https://github.com/vaccineontology/VO/issues/373 5380 Clinical trial CAP-3 (CEA Peptide 9-mer) Vaccine 9-residue human leukocyte antigen (HLA)-restricted fragment of carcinoembryonic antigen (CEA). Vaccination with carcinoembryonic antigen peptide 1-6D, which has the amino acid sequence YLSGANLNL, may elicit a cytotoxic T lymphocyte (CTL) immune response against tumors expressing CEA. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00203892 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5356 https://github.com/vaccineontology/VO/issues/374 1048 5356 Clinical trial Gene name: CEACAM5 (CEA) Carcinoembryonic Antigen Peptide 1-6D Vaccine A cancer vaccine, consisting of alphavirus vector-derived virus-like replicon particles expressing the 9-amino-acid carcinoembryonic antigen peptide (CAP) 1-6D, with potential antineoplastic activity. Vaccination with this agent may elicit a cytotoxic T lymphocyte (CTL) immune response against CEA-expressing tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22630596 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5129 https://github.com/vaccineontology/VO/issues/375 1048 5129 Clinical trial Gene name: CEACAM5 (CEA) Carcinoembryonic Antigen Peptide 1-6D Virus-Like Replicon Particles Vaccine A cancer vaccine comprised of an epitope from the Carcinoembryonic Antigen obtained from cancer cells that can stimulate an immune response against tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22630596 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5209 https://github.com/vaccineontology/VO/issues/376 1048 5209 Clinical trial Gene name: CEACAM5 (CEA) Carcinoembryonic Antigen Peptide-1 Vaccine A vaccine comprised of autologous dendritic cells pulsed with mRNA-encoded Carcinoembryonic Antigen (CEA) targeting tumor cells expressing CEA. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21187495 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5041 https://github.com/vaccineontology/VO/issues/377 1048 5041 Clinical trial Gene name: CEACAM5 (CEA) Carcinoembryonic Antigen RNA-pulsed DC Cancer Vaccine A plasmid DNA vaccine containing the mammalian expression vector pUMVC3 (pNGVL3) encoding epitopes of CD105 (Endoglin), Y-box binding protein 1 (Yb-1), SRY-box 2 (SOX2), cadherin 3 (CDH3), and murine double minute 2 (MDM2) proteins, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of pUMVC3-CD105/Yb-1/SOX2/CDH3/MDM2-epitopes plasmid DNA vaccine, the plasmid transfects cells and the peptides are expressed. This generates a specific memory Th1 (T-helper) cell immune response, stimulates secretion of cytokines by the T cells and leads to a cytotoxic T-lymphocyte (CTL) response against CD105/Yb-1/SOX2/CDH3/MDM2-expressing tumor cells. CD105/Yb-1/SOX2/CDH3/MDM2 proteins are highly immunogenic tumor associated antigens that are overexpressed in breast cancer. Additionally, these antigens are associated with breast cancer stem cells and with epithelial to mesenchymal transformation (EMT). Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5193 https://github.com/vaccineontology/VO/issues/379 1001 2022 4193 4904 6657 5193 Clinical trial Gene name: ENG|Gene name: YBX1|Gene name: SOX2|Gene name: CDH3|Gene name: MDM2 CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted peptides derived from the CD133 antigen, with potential antineoplastic activity. Upon intradermal administration, the CD133 antigen peptide-pulsed autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells, resulting in tumor cell lysis. CD133, a cancer stem cell marker, is expressed on hematopoietic stem and progenitor cells and overexpressed on many types of cancer cells; it is associated with resistance to chemotherapy and increased cancer survival. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T-cells. Epitope design that is restricted to those epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT02049489 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5107 https://github.com/vaccineontology/VO/issues/380 8842 5107 Clinical trial Gene name: PROM1 CD133 Antigen Peptide-pulsed Autologous Dendritic Cell Vaccine A vaccine comprised of CD80-transfected allogenic breast cancer cells to induce T-cell response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5476 https://github.com/vaccineontology/VO/issues/381 2064 941 5476 Clinical trial VO:0007592 Gene name: CD80|Gene name: ERBB2 CD80 Breast Cancer Vaccine Autologous human dendritic cells pulsed with RNA encoding the carcinoembryonic antigen (CEA) are being studied for possible use in the treatment of cancer expressing CEA. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21187495 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5045 https://github.com/vaccineontology/VO/issues/382 1048 5045 Clinical trial Gene name: CEACAM5 (CEA) CEA RNA-pulsed Autologous Human Cultured Dendritic Cells Vaccine A plasmid vaccine encoding wild type human carcinoembryonic antigen (CEA) fused to a tetanus toxoid T helper epitope, with potential antineoplastic activity. Upon vaccination and subsequent intradermal electroporation, CEA/tetanus toxoid T helper epitope fusion protein-expressing DNA plasmid vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA, a tumor associated antigen, is overexpressed in a variety of cancer cell types. The tetanus toxoid helper peptide epitope, obtained from the bacterial Clostridium tetani toxoid, binds to class II MHC molecules and increases the helper T-cell response thereby inducing an increased and long-term immune response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5367 https://github.com/vaccineontology/VO/issues/383 1048 5367 Research Gene name: CEACAM5 (CEA) CEA/Tetanus Toxoid T Helper Epitope Fusion Protein-Expressing DNA Plasmid Vaccine A complex, replication-selective, E1B and partial E3 gene deleted, adenovirus type 11p (Ad11p)/Ad3 chimeric oncolytic virus with potential antineoplastic activity. Upon intralesional injection of enadenotucirev, the adenovirus selectively and rapidly replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation in host cells, which promotes viral replication. Deletion of E1B prevents replication in normal, healthy cells that express wild-type p53. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of the E3 gene, which encodes the adenovirus death protein, enhances the safety profile of the administered adenovirus. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5316 https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(05)00564-2 https://github.com/vaccineontology/VO/issues/384 5316 Clinical trial Chimeric Ad11p/Ad3 Oncolytic Virus Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the human cytomegalovirus (CMV) phosphoprotein pp65, with potential immunostimulatory and antineoplastic activities. Upon administration, the CMV pp65 peptide-pulsed autologous DC vaccine exposes the immune system to the CMV pp65 peptide, which may result in a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells leading to cell lysis. The CMV pp65 protein, also called the 65 kDa lower matrix phosphoprotein, is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types, such as glioblastoma Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4985 https://academic.oup.com/neuro-oncology/article/22/Supplement_3/iii306/6018727 https://github.com/vaccineontology/VO/issues/385 3077579 4985 Clinical trial Gene name: UL83 CMV pp65 Peptide-pulsed Autologous Dendritic Cell Vaccine A poloxamer-formulated, bivalent DNA vaccine containing two plasmids encoding both the human cytomegaloviral (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with potential immunostimulatory properties. Upon intramuscular injection of CMVpp65/gB plasmid vaccine ASP0113, the expressed proteins may activate the immune system to mount both cellular and humoral immune responses against CMV-positive cells. This results in cell lysis of CMV-infected cells and prevents both viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients exposed to infected donor cells or tissues in transplant recipients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants. The poloxamer-based delivery system enhances DNA delivery. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5306 https://github.com/vaccineontology/VO/issues/386 3077579 5306 Clinical trial Gene name: UL83 CMVpp65/gB Plasmid Vaccine ASP0113 A vaccine composed of synthetic peptides derived from beta-human chorionic gonadotropin (hCG) conjugated to diphtheria toxoid. Vaccination with this peptide may elicit the host immune response against hCG-producing cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:/9815634 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5372 https://github.com/vaccineontology/VO/issues/389 11716682 5372 Clinical trial Gene name: tox1 CTP-37-DT Vaccine A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with cyclin B1 peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, cyclin B1 peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and anti-cyclin B1 antibody responses against cyclin B1-expressing cancer cells, resulting in tumor cell lysis. Cyclin B1, a key regulator of the cell cycle and cell division, is overexpressed in a variety of cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01398124 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5139 https://github.com/vaccineontology/VO/issues/390 931 5139 Clinical trial Gene name: MS4A1 Cyclin B1 Peptide-pulsed Autologous Dendritic Cell Vaccine A preparation of autologous lymphocytes with potential immunopotentiating and antineoplastic activities. Cytokine-induced killer (CIK) cells are CD3- and CD56-positive, non-major histocompatibility complex (MHC)-restricted, natural killer (NK)-like T lymphocytes, generated ex-vivo by incubation of peripheral blood lymphocytes (PBLs) with anti-CD3 monoclonal antibody, interleukin (IL)-2, IL-1, and interferon gamma (IFN-gamma) and then expanded. When reintroduced back to patients after autologous stem cell transplantation, CIK cells may recognize and kill tumor cells associated with minimal residual disease (MRD). CIK cells may have enhanced cytotoxic activity compared to lymphokine-activated killer (LAK) cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:23210562 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5070 https://github.com/vaccineontology/VO/issues/391 174 5070 Clinical trial Gene name: AFP Cytokine-Induced Killer Cells Vaccine A vaccine composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15256471 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5163 https://github.com/vaccineontology/VO/issues/392 5163 Clinical trial Dendritic Cell Tumor Cell Lysate Vaccine A cancer vaccine consisting of lymphocytes harvested from a patient with lung cancer and induced to become antigen-presenting cells (APCs) known as dendritic cells. The dendritic cells are transduced with the gene encoding an antigen specific to the patient's cancer and then returned to the patient. In the host, the altered cells stimulate the immune system to mount a primary T cell response against lung tumor cells expressing the target antigen. Dendritic cell-autologous lung tumor vaccines have been investigated for use in cancer immunotherapy. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5161 https://github.com/vaccineontology/VO/issues/393 5161 Clinical trial Dendritic Cell-Autologous Lung Tumor Vaccine A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of carcinoembryonic antigen (CEA), a tumor-associated antigen expressed by a wide range of cancers. When the altered dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing CEA. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21187495 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5417 https://github.com/vaccineontology/VO/issues/394 1048 5417 Clinical trial Gene name: CEACAM5 (CEA) Dendritic Cell-CEA Peptide Vaccine An autologous dendritic cells vaccine with antineoplastic property. Dendritic cells harvested from cancer patients are pulsed with human gp100 melanoma antigen and MART-1 (melanoma antigen recognized by T-cells) antigen; both antigens are up-regulated in melanomas. Vaccination with this vaccine may elicit the host immune response against MART-1 or gp100 expressing cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5067 https://github.com/vaccineontology/VO/issues/395 2315 6490 5067 Clinical trial Gene name: gp100 (PMEL)|Gene name: MLANA Dendritic Cell-gp100-MART-1 Antigen Vaccine A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of MART-1 (melanoma antigen recognized by T-cells), an antigen expressed by melanoma cells. When the altered dendritic cells are returned to the patient, they stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing MART-1. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5524 https://github.com/vaccineontology/VO/issues/396 2315 5524 Clinical trial Gene name: MLANA Dendritic Cell-MART-1 Peptide Vaccine A vaccine comprised of autologous dendritic cells pulsed with a recombinant prostate specific membrane antigen. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5000 https://github.com/vaccineontology/VO/issues/397 2346 5000 Clinical trial Gene name: Prostate-specific membrane antigen gene engineering: Dendritic Cell-Recombinant Prostate-Specific Membrane Antigen Vaccine An engineered lentiviral vector targeting dendritic cells (DCs) and containing nucleic acids encoding for the human tumor-associated cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the DC-targeting lentiviral vector ID-LV305 targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, stimulates DC maturation and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells, which may result in tumor cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5493 https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2018-00926&r=1 https://github.com/vaccineontology/VO/issues/398 1485 5493 Clinical trial Gene name: NY-ESO-1 Dendritic Cell-targeting Lentiviral Vector ID-LV305 Vaccine A cancer vaccine consisting of autologous renal cell carcinoma (RCC) tumor cells modified with the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of DNP-modified autologous renal cell carcinoma tumor cell vaccine may induce a cytotoxic T-lymphocyte (CTL) response against renal cell carcinoma tumor cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5338 https://github.com/vaccineontology/VO/issues/400 5338 Clinical trial Dinitrophenyl-Modified Autologous Renal Cell Carcinoma Tumor cell Vaccine A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of DNA plasmid encoding interleukin-12 INO-9012, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5016 https://jitc.bmj.com/content/9/7/e003019 https://github.com/vaccineontology/VO/issues/401 2902 5016 Clinical trial Gene name: GRIN1 DNA Plasmid Encoding Interleukin-12 INO-9012 Vaccine A DNA-based combination immunotherapeutic, INO-3112, composed of VGX-3100, a preparation of DNA plasmids encoding the E6 and E7 genes of human papillomavirus (HPV) subtypes 16 and 18, combined with INO-9012, a DNA plasmid encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12) with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery by electroporation of VGX-3100, the HPV E6 and E7 proteins are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the E6 and E7 antigens, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are associated with the development of certain types of cancer. Upon intramuscular delivery by electroporation of INO-9012, IL-12 is expressed and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of VGX-3100 alone. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT03439085 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5136 https://github.com/vaccineontology/VO/issues/402 1489078 1489079 5136 Clinical trial Gene name: E7|Gene name: E6 DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 A therapeutic DNA vaccine composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), the second is a dimerization entity and the third part encodes a protein that specifically binds to antigen presenting cells (APCs), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration, the DNA vaccine VB10.16 expresses HPV16 E6/7 and a protein that targets receptors on APCs. Upon binding to APCs and subsequent internalization, the APCs mature and the HPV16 E6/7 antigenic protein is presented by the APCs. This attracts and stimulates B-lymphocytes, CD4-positive T-lymphocytes and elicits a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV16-associated E6 and E7 oncoproteins, which result in tumor cell lysis. HPV16 E6/7, a viral antigen, plays a key role in the development of certain types of cancer. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:36129459 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5207 https://github.com/vaccineontology/VO/issues/403 1489078 1489079 5207 Clinical trial Gene name: E7|Gene name: E6 DNA Vaccine VB10.16 A cancer vaccine consisting of a DNA plasmid encoding epitopes of the human preferential antigen of melanoma (PRAME) and the prostate specific membrane antigen (PSMA) with potential immunostimulating activity. Upon direct administration of this vaccine into lymph nodes, peptides expressed by DNA plasmid vector pPRA-PSM may activate the immune system, resulting in a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing cells. PRAME and PSMA are tumor associated antigens upregulated in a number of cancer cell types. As part of the MKC1106-PP regimen exploiting the 'prime-boost strategy', this plasmid is responsible for priming the immune response and is used in conjunction with a peptide vaccine consisting of PRAME and PSMA that boosts the immune system against PRAME- and PSMA-expressing tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00423254 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5407 https://github.com/vaccineontology/VO/issues/404 2346 5407 Research Gene name: Prostate-specific membrane antigen DNA Vector pPRA-PSM Vaccine A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5378 https://github.com/vaccineontology/VO/issues/126 4582 1048 5378 Clinical trial Gene name: CEACAM5|Gene name: MUC1 Falimarev vaccine A therapeutic cancer vaccine containing a truncated, synthetic peptide mimic of the human angiogenic activator vascular endothelial growth factor (VEGF), consisting of 79 amino acids (amino acids 26-104 of VEGF), and emulsified in the immunoadjuvant RFASE, with potential immunostimulatory and antitumor activities. Upon intramuscular vaccination, the hVEGF26-104 moiety of hVEGF26-104/RFASE acts as an antigen and induces an immune response against VEGF, which results in anti-VEGF antibody binding to and neutralization of endogenous VEGF. This prevents the binding of endogenous VEGF to the VEGF receptor (VEGFR) and blocks VEGFR-mediated endothelial cell signaling, resulting in an inhibition of both angiogenesis and tumor cell proliferation. VEGF plays a key role in angiogenesis, tumor cell proliferation and invasion. RFASE, which belongs to the group of sulpholipopolysaccharides (SLPs), is a synthetic polysaccharide covalently coupled to lipid groups and sulphate groups, and is able to induce a strong humoral immune response upon antigen administration. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5090 https://github.com/vaccineontology/VO/issues/456 7422 5090 Clinical trial Gene name: VEGFA hVEGF26-104/RFASE Peptide Vaccine A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus subtype 6 (HPV-6), with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV-6-targeting immunotherapeutic vaccine INO-3106 expresses the HPV-6 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing those proteins, resulting in tumor cell lysis. HPV-6 infections are associated with aerodigestive malignancies. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5464 https://github.com/vaccineontology/VO/issues/438 2829163 5464 Clinical trial Gene name: HPV6 E6 HPV-6-targeting Immunotherapeutic Vaccine INO-3106 A liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Upon vaccination, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against MUC-1-expressing tumor cells, resulting in growth inhibition. MUC-1 antigen is a high-molecular-weight transmembrane glycoprotein that is overexpressed on the cell surfaces of many epithelial tumor cells as well as on the cell surfaces of some B-cell lymphoma cells and multiple myeloma cells. (NCIT_C2195). Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5103 https://github.com/vaccineontology/VO/issues/65 4582 5103 Clinical trial Gene name: MUC1 Emepepimut-S Vaccine An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration of the gp96-Ig-secreting allogeneic bladder cancer cell vaccine HS-410, the live, irradiated tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs). This enhances antigen cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to the induction of a potent CTL response against the TAAs on the endogenous bladder cancer cells. This vaccine also induces a memory T cell response that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum (ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows for gp96, normally an ER-resident chaperone peptide, to be released from cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5033 https://github.com/vaccineontology/VO/issues/209 7184 5033 Clinical trial Gene name: HSP90B1 gp96-secreting Allogeneic Bladder Cancer Cell Vaccine HS-410 A cancer vaccine consisting of a recombinant fowlpox virus vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5300 https://github.com/vaccineontology/VO/issues/131 1485 5300 Clinical trial Gene name: NY-ESO-1 Fowlpox-NY-ESO-1 Vaccine A cancer vaccine comprised of autologous dendritic cells pulsed with synthetic glioma-associated antigen (GAA) peptides with potential antineoplastic activity. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against GAA peptide-expressing glioma cells, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5096 https://github.com/vaccineontology/VO/issues/137 2548 5096 Clinical trial Gene name: GAA Glioma-Associated Antigen Peptide-Pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine comprised of dendritic cells (DCs) pulsed with various, synthetic glioma-associated antigen (GAA) peptides, with potential antineoplastic activity. Upon subcutaneous administration, the glioma-associated peptide-loaded DC vaccine SL-701 exposes the immune system to various GAA peptides. This may stimulate both anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against the GAA-expressing glioma cells, which may result in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5073 https://github.com/vaccineontology/VO/issues/138 1956 5073 Clinical trial Gene name: EGFR Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5202 https://github.com/vaccineontology/VO/issues/426 55553 5202 Clinical trial Gene name: SOX6 HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5298 https://github.com/vaccineontology/VO/issues/458 3417 5298 Clinical trial Gene name: IDH1 IDH1R132H Mutation-targeting IDH1 Peptide Vaccine A peptide vaccine consisting of a peptide derived from isocitrate dehydrogenase 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Intradermal vaccination with the IDH1R132H-specific peptide vaccine PEPIDH1M may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. The IDH1 point mutation of amino acid residue 132 is highly expressed in gliomas and is associated with increased production of the oncometabolite R-2-hydroxyglutarate Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5461 https://github.com/vaccineontology/VO/issues/459 3417 5461 Clinical trial Gene name: IDH1 IDH1R132H-Specific Peptide Vaccine PEPIDH1M A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from malignant glioma cells with potential immunostimulatory and antineoplastic activities. Upon administration, malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine exposes the immune system to undefined malignant glioma tumor-associated antigens (TAAs), which may result in anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against glioma cells and glioma cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5215 https://github.com/vaccineontology/VO/issues/494 4100 6490 5215 Gene name: MAGEA1|Gene name: gp100 Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine An antineoplastic vaccine directed against a peptide found in the epidermal growth factor receptor class III variant (EGFRvIII), a constitutively activated mutant of the wild-type tyrosine kinase. This protein variant is present in a substantial proportion of malignant gliomas and other human cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5531 https://github.com/vaccineontology/VO/issues/64 1100818972 5531 Clinical trial Gene name: EGFR EGFRvIII Peptide Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5151 https://github.com/vaccineontology/VO/issues/127 5151 Clinical trial Fas-Chimera Transgene-expressing Endothelial Tumor Cell-targeting Adenovector VB-111 Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with purified peptides derived from the tumor-associated antigen (TAA) CD133, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, monocytes are differentiated into DCs and are mixed with the CD133 peptides. Upon intradermal re-administration of the ICT-121 DC vaccine, the DCs present the CD133 peptides to the immune system, which stimulates the immune system to induce a specific cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells and leads to tumor cell lysis. CD133 is overexpressed on various types of cancer cells; its overexpression is correlated with increased resistance to chemotherapy. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5277 https://github.com/vaccineontology/VO/issues/457 8842 5277 Clinical trial Gene name: PROM1 ICT-121 Dendritic Cell Vaccine A multivalent vaccine againt breast cancer that comprised of the epitope antigens of Globo H hexasaccharide 1 (Globo H), GM2 ganglioside, Lewis-Y, MUC1-32(aa), TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin, with potential antineoplastic activity. The antigens included in this vaccine are associated various cancer cells. Vaccination with this multivalent vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5229 https://github.com/vaccineontology/VO/issues/174 4582 2760 5229 Clinical trial Gene name: GM2A|Gene name: MUC1 Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH Conjugate Vaccine A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted HER-2-derived peptides, with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated with GM-CSF, interleukin-4, interferon-gamma and bacterial lipopolysaccharide (LPS), a toll-like receptor type 4 agonist, to produce highly polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). Upon administration, HER2-pulsed autologous DC vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5237 https://github.com/vaccineontology/VO/issues/306 2064 5237 Clinical trial Gene name: ERBB2 HER2-pulsed Autologous Type-1 Polarized Dendritic Cell Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4997 https://github.com/vaccineontology/VO/issues/447 1442 7494 4997 Clinical trial Gene name: XBP1|Gene name: CSH1 hTERT/Survivin/CMV Multipeptide Vaccine A cancer vaccine containing a plasmid encoding the mammaglobin-A gene with potential immunostimulating and antineoplastic activities. Upon administration, mammaglobin-A DNA vaccine may induce both humoral and cytotoxic T lymphocyte (CTL) immune responses against tumor cells that express mammaglobin-A, which may result in decreased tumor growth. The 10 kiloDalton (kD) glycoprotein mammglobin-A is expressed in over 80% of human breast cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5166 https://github.com/vaccineontology/VO/issues/495 4582 634 5166 Gene name: CEACAM1|Gene name: MUC1 Mammaglobin-A DNA Vaccine A cancer vaccine consisting of a proprietary, recombinant modified vaccinia Ankara (MVA) viral vector encoding an epitope of human epidermal growth factor receptor 2 (HER2) with potential antineoplastic activity. Upon administration, modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine may stimulate the host immune system to mount humoral and cytotoxic T lymphocyte responses against HER2-expressing tumor cells, resulting in tumor cell lysis. HER2, also known as ErbB-2, is a tyrosine kinase growth factor receptor and a member of the epidermal growth factor receptor family; it plays a significant role in the pathogenesis of some breast cancers Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5036 https://github.com/vaccineontology/VO/issues/530 2064 2315 5036 Gene name: MLANA-Dupli|Gene name: ERBB2 Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), Bacille Calmette-Guerin (BCG), measles, Serratia marcescens and pneumococcal, with potential immunostimulating activity. Subcutaneous administration of the DPT/BCG/measles/Serratia/pneumococcus vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor. (NCIT_C62801). Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4987 https://github.com/vaccineontology/VO/issues/51 4987 Clinical trial E1M(184V) Peptide Vaccine A cancer vaccine containing autologous dendritic cells (DCs) that are pulsed with mRNA encoding human telomerase reverse transcriptase (hTERT) and survivin peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT mRNA/survivin peptide-double-loaded autologous dendritic cell vaccine may elicit an immune response against cancer cells expressing hTERT and survivin by activating cytotoxic T-cells (CTLs), natural killer cells (NKs), and B-lymphocytes. The tumor associated antigens (TAAs) hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types and play key roles in tumor cell growth and survival. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5121 https://github.com/vaccineontology/VO/issues/440 7015 5121 Clinical trial Gene name: TERT hTERT mRNA/Survivin Peptide-double-loaded Autologous Dendritic Cell Vaccine A therapeutic cancer vaccine consisting of four epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, including hTERT (540-548) acetate, hTERT (611-626) acetate, hTERT (672-686) acetate and hTERT (766-780) acetate, emulsified individually in the adjuvant montanide ISA-51 VG and administered with the immune response modifier (IRM) imiquimod, with potential immunostimulating and antineoplastic activities. Each hTERT peptide emulsion is administered individually by intradermal injection. Subsequently, imiquimod is applied topically to the injection site(s). Vaccination with GX 301 may elicit a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells. Telomerase is expressed in the majority of human cancer cells, infrequently expressed in normal cells, and is directly linked to tumorigenesis. Imiquimod stimulates cytokine production through the activation of toll-like receptor 7 (TLR-7), and also exhibits antiproliferative effects. Montanide ISA-51, also known as incomplete Freund's adjuvant (IFA), is a stabilized water-in-oil emulsion containing mineral oil with mannide oleate, which contains vegetable-grade (VG) oleic acid derived from olive oil. ISA-51 non-specifically stimulates cell-mediated immune responses to antigens. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5516 https://github.com/vaccineontology/VO/issues/441 7015 5516 Clinical trial Gene name: TERT hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5065 https://github.com/vaccineontology/VO/issues/445 7015 5065 Clinical trial Gene name: TERT hTERT Vaccine V934/V935 A poxvirus made non-infectious by ultraviolet light or other inactivation methods in order to reduce its pathogenicity. In cancer gene therapy, inactivated vaccinia virus may be used as a vector to express a protein that kills tumor cells or elicits specific anti-tumor immunity. In a cancer vaccine application, tumor cells taken from the host may be adsorbed with inactivated vaccinia virus and returned to the host, where the modified tumor cells may stimulate an anti-tumor immune response. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5130 https://github.com/vaccineontology/VO/issues/465 5130 Clinical trial Inactivated Vaccinia Virus Vaccine A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5099 https://github.com/vaccineontology/VO/issues/466 1048 4582 5099 Clinical trial Gene name: CEACAM5|Gene name: MUC1 Inalimarev Vaccine A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated double-deleted Listeria monocytogenes bacteria JNJ-64041809 is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5258 https://github.com/vaccineontology/VO/issues/472 5258 Clinical trial Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809 Vaccine A conjugate consisting of keyhole-limpet hemocyanin (KLH) and fluorescein isothiocyanate (FITC) with potential immunostimulating activity. Vaccination with KLH-FITC may elicit an immune response against fluorescein and the production of anti-fluorescein IgG antibodies. KLH, a natural protein isolated from the marine mollusk keyhole limpet, is an immunostimulant carrier protein. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5146 https://github.com/vaccineontology/VO/issues/473 5146 Clinical trial KLH-FITC Vaccine A cell-based vaccine targets tumors expressing the HER2/neu marker. HER-2/neu is a growth factor receptor, and its overexpression has been associated with a number of cancers including breast, ovarian, colon and lung cancers. APC8024 comprise of autologous antigen-presenting peripheral blood mononuclear cells (APCs) that have been exposed to HER2/neu protein and can be administered to the patient. These cells may stimulate an antitumor T-cell response to cancer cells expressing HER2/neu. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5538 https://github.com/vaccineontology/VO/issues/475 2064 5538 Clinical trial Gene name: ERBB2 Lapuleucel-T Vaccine A cell-based cancer vaccine consisting of autologous dendritic cells (DCs) pulsed with mesothelioma tumor lysate with potential immunostimulating and antineoplastic activities. Upon administration, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount a specific cytotoxic T lymphocyte (CTL) response against mesothelioma tumor cells, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5187 https://github.com/vaccineontology/VO/issues/525 1234 5187 Gene name: CCR5 Mesothelioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5235 https://github.com/vaccineontology/VO/issues/526 5235 Methanol Extraction Residue of BCG Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5347 https://github.com/vaccineontology/VO/issues/529 5347 Gene name: P10 Mimotope-P10s-PADRE Peptide Vaccine A vaccine consisting of a monoclonal antibody (MoAb) directed against an idiotype that mimics a human milk fat globule (HMFG) membrane epitope. Vaccination with monoclonal antibody 11D10 anti-idiotype vaccine induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5286 https://github.com/vaccineontology/VO/issues/533 4240 5286 Gene name: MFGE8 Monoclonal Antibody 11D10 Anti-Idiotype Vaccine A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA). This agent is used as a cancer vaccine against tumors that express CEA. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5452 https://github.com/vaccineontology/VO/issues/534 1048 5452 Gene name: CEACAM5 Monoclonal Antibody 3H1 Anti-Idiotype Vaccine An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5308 https://github.com/vaccineontology/VO/issues/536 2583 5308 Gene name: B4GALNT1 Monoclonal Antibody A1G4 Anti-Idiotype Vaccine An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5469 https://github.com/vaccineontology/VO/issues/537 6489 5469 Gene name: ST8SIA1 Monoclonal Antibody GD2 Anti-Idiotype Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5239 https://github.com/vaccineontology/VO/issues/538 5239 Montanide ISA-51/Survivin Peptide Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5362 https://github.com/vaccineontology/VO/issues/544 4255 5362 Gene name: MGMT MSCV-MGMT(P140K) Vaccine A cancer vaccine comprised of a synthetic peptide derived from the mucin 1 (MUC1) antigen with potential antineoplastic activity. Upon administration, MUC1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in decreased tumor growth. Overexpressed on many tumor cells, MUC1 antigen, a mammary-type apomucin, is a high-molecular-weight transmembrane glycoprotein. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5517 https://github.com/vaccineontology/VO/issues/545 4582 5517 Gene name: MUC1 MUC-1 Peptide Vaccine A peptide vaccine containing human mucin 2 (MUC2) protein conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. MUC2, a secretory or gel forming glycoprotein expressed predominantly in goblet cells of the gastrointestinal and respiratory tracts, is overexpressed as an aberrant or deglycosylated form in various tumors such as gastric carcinomas and some hormone-refractory prostate cancers. MUC2 protein is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with MUC2-KLH may result in the production of antibodies as well as elicit a cytotoxic T- lymphocyte (CTL) response against tumor cells expressing MUC2 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5169 https://github.com/vaccineontology/VO/issues/547 4583 5169 Gene name: MUC2 MUC-2-KLH Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5123 https://github.com/vaccineontology/VO/issues/548 4582 5123 Gene name: MUC1 MUC1 Antigen/SB AS-2 Vaccine A peptide vaccine, containing human tumor-associated epithelial mucin (MUC1) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with MUC1-KLH conjugate vaccine may stimulate humoral and cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing the MUC1 antigen. In this vaccine, MUC1 antigen is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in an aberrant or deglycosylated form in various cancers such as those of the breast, prostate, and ovary. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5251 https://github.com/vaccineontology/VO/issues/549 4582 5251 Gene name: MUC1 MUC1-KLH Conjugate Vaccine A peptide vaccine containing the human tumor-associated antigen epithelial mucin (MUC1 antigen) conjugated with keyhole limpet hemocyanin (KLH) and combined with the nonspecific immunoadjuvant QS21, with potential antineoplastic activity. MUC1 antigen is linked with KLH, an immunostimulant and a hapten carrier, in order to enhance immune recognition; the co-administration of saponin-derived QS21 potentially amplifies the total immune response to the MUC1 antigen. Administration of MUC1-KLH vaccine/QS21 may result in both the production of antitumor antibodies and the stimulation of a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the MUC1 antigen. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed as an aberrant or deglycosylated form in various cancers such as breast, prostate and ovarian cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5160 https://github.com/vaccineontology/VO/issues/550 4582 5160 Gene name: MUC1 MUC1-KLH Vaccine/QS21 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5068 https://github.com/vaccineontology/VO/issues/551 4582 5068 Gene name: MUC1 MUC1-targeted Peptide GO-203-2C Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5522 https://github.com/vaccineontology/VO/issues/552 2348 5522 Gene name: FOLR1 Multi-epitope Folate Receptor Alpha Peptide Vaccine A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5064 https://github.com/vaccineontology/VO/issues/556 10643 54742 5064 Gene name: LY6K |Gene name: IGF2BP3 Multipeptide Vaccine S-588210 A cancer vaccine consisting of autologous dendritic cells which have been pulsed with a mutant p53 peptide. Vaccination with mutant p53 peptide pulsed dendritic cells may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. Many tumor cells overexpress mutant p53 proteins, resulting in the loss of apoptosis regulation and abnormal cell proliferation. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5364 https://github.com/vaccineontology/VO/issues/559 5364 Mutant p53 Peptide Pulsed Dendritic Cell Vaccine A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5091 https://github.com/vaccineontology/VO/issues/564 4582 5091 Gene name: MUC1 MVA-MUC1-IL2 Vaccine A combination peptide vaccine of 2 chimeric peptides of the promiscuous T cell epitope derived from measles virus fusion protein (MVF; amino acid residues 288-302) co-synthesized with B-cell epitopes derived from the HER-2/neu a.a. 597-626 and HER-2/neu a.a. 266-296, with potential antineoplastic activity. Vaccination with MVF-HER-2(597-626)/MVF-HER-2(266-296) peptide vaccine may be capable of inducing an active specific immune response, mounting a cytotoxic T-lymphocyte (CTL) response and an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress the HER-2 protein. The oncogenic protein HER-2, a member of the human epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in a variety of cancers and is correlated with increased tumor growth, progression and a poor prognosis. HER-2(597-626) corresponds to the binding site of trastuzumab on the extracellular domain IV of HER-2; HER-2 (266-296) corresponds to the binding site of pertuzumab on the dimerization loop of domain II of HER-2 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5400 https://github.com/vaccineontology/VO/issues/566 2064 5400 Gene name: ERBB2 MVF-HER-2(597-626)/MVF-HER-2 (266-296) Peptide Vaccine A vaccine formulation consisting of several types of human papillomavirus (HPV)-derived noninfectious virus-like particles (VLPs) with potential immunoprophylactic activity. Upon administration, HPV L1 VLP vaccine V504 may generate humoral immunity against various HPV L. major capsid proteins, thereby preventing cervical infection upon exposure to the associated HPV types. VLPs are composed of self-assembling L. major capsid proteins or functional L. major capsid protein derivatives. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5449 https://github.com/vaccineontology/VO/issues/450 5449 Clinical trial Human Papilloma Virus L1 Virus-Like Particle V504 Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5408 https://github.com/vaccineontology/VO/issues/478 1489079 2829163 5408 Clinical trial Gene name: HPV6 E6|Gene name: E7 Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101 A cancer vaccine consisting of a humanized monoclonal antibody that mimics a tumor-associated antigen 791Tgp72 (also known as CD55). Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing CD55, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5195 https://github.com/vaccineontology/VO/issues/532 1604 5195 Gene name: CD55 Monoclonal Antibody 105AD7 Anti-idiotype Vaccine A multipeptide vaccine consisting of peptides derived from lymphocyte antigen 6 complex locus K (LY6K) and type I and II vascular endothelial growth factor receptors (VEGFRs) with potential antineoplastic activity. Upon administration, LY6K/VEGFR1/VEGFR2 multipeptide vaccine may elicit an antitumor cytotoxic T-lymphocyte (CTL) immune response against LY6K-expressing tumor cells and/or VEGFR-expressing vascular endothelial cells involved in tumor angiogenesis. LY6K is a tumor-associated antigen (TAA) that occurs singly in glycosylphosphatidyl-inositol (GPI)-linked cell-surface glycoproteins or as three-fold repeated domain in the urokinase-type plasminogen activator receptor; VEGFRs are cell surface receptors that stimulate endothelial cell proliferation, invasion, angiogenesis, and vasculogenesis upon ligand binding and receptor activation. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5164 https://github.com/vaccineontology/VO/issues/486 54742 7422 5164 Clinical trial Gene name: LY6K|Gene name: VEGFA LY6K/VEGFR1/VEGFR2 Multipeptide Vaccine A carbohydrate-based vaccine comprised of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), with potential immunostimulating and antineoplastic activities. Upon administration of Globo H-DT vaccine OBI-833, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. The hexasaccharide Globo H is a tumor-associated antigen (TAA) commonly found on a variety of tumor cells. DT-CRM197, also called diphtheria toxin cross-reacting material 197, is used to increase the immunogenicity of the Globo H carbohydrate antigen. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5055 https://github.com/vaccineontology/VO/issues/172 11716682 5055 Clinical trial Gene name: tox1 Globo H-DT Vaccine OBI-833 A synthetic peptide derived from the protein ESW/FLI1 type 2 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently found in patients with Ewing's sarcoma or primitive neuroectodermal tumors (PNET). Vaccination with EF-2 peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this EWS/FL1 type 2 fusion protein. (NCIT_C49064). Jie Zheng Justin Song Oliver He Penny Pan PubMed:/2753158 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5432 https://github.com/vaccineontology/VO/issues/63 297374825 5432 Clinical trial Gene name: CD22 EF-2 Peptide Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5421 https://github.com/vaccineontology/VO/issues/554 4100 6490 5421 Gene name: MAGEA1|Gene name: gp100 Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107 Human mesenchymal stem cells (MSCs) transduced with a retroviral vector encoding a modified form of the cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, IL-12-expressing MSC vaccine GX-051 secretes IL-12. IL-12 activates the immune system by both promoting the secretion of interferon-gamma, which activates natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death in tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5168 https://github.com/vaccineontology/VO/issues/461 5168 Clinical trial IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051 A dendritic cell (DC)-based vaccine composed of program death ligands 1 and 2 (PDL1/L2)-silenced DCs and loaded with the recipient's minor histocompatibility antigens (MiHA), with potential use for graft-versus-tumor (GVT) induction following allogeneic stem cell transplantation (allo-SCT). Donor DCs are electroporated ex vivo with MiHA mRNA and small interfering RNAs (siRNAs) designed to silence the expression of PD L1/L2. After allo-SCT and upon intravenous administration of the MiHA-loaded PD-L1/L2-silenced DC vaccine, the DCs induce the expansion and activation of MiHA-specific CD8-positive T-cells. These tumor antigen-reactive T-cells exert their GVT effect by killing miHA-positive tumor cells. PD-L1/L2, co-inhibitory ligands expressed on DCs, play key roles in preventing MiHA-specific CD8-positive T-cell expansion; silencing enhances MiHA-specific CD8-positive T-cell expansion and activity and improves the GVT effect. The MiHA are human leukocyte antigen (HLA)-bound peptides and are exclusively expressed by the recipient's hematopoietic tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5015 https://github.com/vaccineontology/VO/issues/528 5133 5015 Gene name: PDCD1 MiHA-loaded PD-L1/L2-silenced Dendritic Cell Vaccine A multi-antigen DNA vaccine consisting of plasmids encoding the hepatitis C virus (HCV) nonstructural proteins 3 (NS3), 4A (NS4A), 4B (NS4B) and 5A (NS5A), with potential immunomodulating and cancer preventive activities. Administered via intramuscular injection followed by electroporation, cells transfected with the HCV DNA vaccine INO-8000 express the encoded HCV proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against HCV-infected liver cells expressing the NS3, NS4A, NS4B or NS5A proteins. This results in the eradication of HCV-infected cells. HCV, a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, is associated with the development of hepatocellular carcinoma (HCC) Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5002 https://github.com/vaccineontology/VO/issues/304 3845 5002 Clinical trial Gene name: KRAS HCV DNA Vaccine INO-8000 A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the suicide gene FCU1 with potential antineoplastic activity. FCU1 is a bifunctional yeast cytosine deaminase (CD) / uracil phosphoribosyltransferase (UPRT) fusion gene. Upon intratumoral administration, MVA-FCU1TG4023 enters tumor cells where FCU1 is expressed. Subsequently, the noncytotoxic prodrug 5-fluorocytosine (5-FC) is administered systemically and is deaminated by CD in FCU1- transduced tumor cells into 5-fluorouracil (5-FU), which is then directly metabolized to 5-fluoro-uridine monophosphate (5-FUMP) by UPRT; 5-FUMP may then be further transformed to 5-fluoro-deoxyuridine monophosphate (5-FdUMP), an irreversible inhibitor of thymidylate synthase and, so, DNA synthesis through deprivation of deoxythymidine triphosphate (dTTP). 5-FU and its active metabolites may then selectively kill tumor cells, avoiding toxicity in nonmalignant cells. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5312 https://github.com/vaccineontology/VO/issues/563 5312 MVA-FCU1 TG4023 vaccine A peptide derived from the oncogenic human papillomavirus (HPV) early gene product E6. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions and has a high affinity for the most common human lymphocyte antigen (HLA), HLA-A2. Immunogenic peptides from the HPV 16 E6 may be used to trigger a T-cell-mediated immune response to HPV. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5474 https://github.com/vaccineontology/VO/issues/429 1489078 5474 Clinical trial Gene name: E6 HPV 16 E6 (18-26) peptide vaccine A synthetic peptide vaccine consisting of amino acids 86 through 93 (TLGIVCPI) of the viral oncoprotein human papillomavirus (HPV) 16 E7. Vaccination with HPV-16 E7:86-93 peptide, which binds to HLA-A* 0201 molecule, may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 E7. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5184 https://github.com/vaccineontology/VO/issues/431 1489079 5184 Clinical trial Gene name: E7 HPV 16 E7:86-93 peptide vaccine A vaccine consisting of human papillomavirus-derived noninfectious virus-like particles (VLPs), containing the L. major capsid protein. Vaccination with HPV 16 L1-VLP results in increases in T cell-proliferative response to HPV 16 L1-VLP, as well as significant increases in cytokine (interferon-gamma, interleukin-5 and -10) responses to L1 VLP. This agent may reduce the incidence of persistent HPV-16 infection, which may be responsible for half of all cases of cervical cancer including high-grade cervical intraepithelial neoplasia. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5520 https://github.com/vaccineontology/VO/issues/432 25479185 5520 Clinical trial Gene name: L1 HPV 16 L1-VLP vaccine A synthetic peptide vaccine consisting of amino acids 13 through 21 of the viral oncoprotein human papillomavirus (HPV) 18 E6. The HPV 18E6 peptide cross-reacts immunologically with both HPV type 16 and HPV type 18, the most common HPV types involved in cervical cancer. Vaccination with HPV-18 E6:13-21 peptide may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV 16 and 18. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5159 https://github.com/vaccineontology/VO/issues/433 5159 Clinical trial HPV 18 E6:13-21 peptide vaccine Noninfectious, synthetic, virus-like particles (VLP) containing the major viral capsid protein, L1, of the human papillomavirus type 18 with potential immunoprotective activity. Vaccination with HPV 18 L1-VLP may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) response against cells positive for HPV 18, thereby preventing cervical infection upon exposure to HPV type 18. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5247 https://github.com/vaccineontology/VO/issues/434 5247 Clinical trial HPV 18 L1-VLP vaccine A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV DNA plasmids therapeutic vaccine VGX-3100 expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5226 https://github.com/vaccineontology/VO/issues/435 1489078 1489079 5226 Clinical trial Gene name: E6|Gene name: E7 HPV DNA plasmids therapeutic vaccine VGX-3100 A vaccine directed against Human Papillomavirus Type 11 that causes majority of the genital warts and anogenital cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5227 https://github.com/vaccineontology/VO/issues/437 5227 Clinical trial HPV-11 Vaccine A synthetic agent derived from human papillomavirus (HPV) E7 nuclear protein which is used to produce vaccines against HPV infection and HPV-related neoplasms. HPV E7 oncogenic protein binds the retinoblastoma tumor suppressor protein, pRB, as well as a number of other cellular proteins, and serves as a transcriptional activator. This protein is important in the induction and maintenance of cellular transformation and is co-expressed in the majority of HPV-containing carcinomas. PADRE(R) is a proprietary family of molecules that enhances the immune systems response against an administered immunogen such as the HPV E7 nuclear protein. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5162 https://github.com/vaccineontology/VO/issues/451 1489079 5162 Clinical trial Gene name: E7 human Papillomavirus 16 E7 Peptide/Padre 965.10 Vaccine A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5233 https://github.com/vaccineontology/VO/issues/452 5233 Clinical trial Human Papillomavirus 16/18 L1 virus-like particle/AS04 vaccine A vaccinia viral based vaccine, encoding epitopes of E6 and E7 proteins from human papillomavirus (HPV) types 16 and 18, with immunostimulatory and antineoplastic activities. HPV types 16 and 18 account for approximately 70% of cervical cancers. Vaccination with this HPV-TA (tumor antigen) vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for E6 and E7 from either type 16 or 18 HPV, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5279 https://github.com/vaccineontology/VO/issues/453 1489078 1489079 5279 Clinical trial Gene name: E6|Gene name: E7 Human Papillomavirus Tumor Antigen Vaccine A vaccine consisting of noninfectious, recombinant virus-like particles (VLP) containing the major viral capsid protein L1 of nine strains of human papillomavirus (HPV), with potential immunoprotective activity. Vaccination with HPV V503 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against cells positive for any of these nine strains of HPV, thereby preventing cervical infection upon exposure to certain HPV subtypes. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5167 https://github.com/vaccineontology/VO/issues/454 5167 Clinical trial Gene name: major capsid protein L1 Human Papillomavirus Vaccine V503 A peptide based vaccine consisting of amino acids 12 through 20 of the E7 gene of the Human Papilloma Virus type 16. HPV-16 E7 12-20 peptide vaccine may elicit a specific CD8 T-cell response to the E7 oncogene protein, thereby inhibiting the abrogation of p53 and pRb function and thus prevent tumorigenesis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5079 https://github.com/vaccineontology/VO/issues/430 1489079 5079 Clinical trial Gene name: E7 HPV 16 E7:12-20 Peptide Vaccine A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5083 https://github.com/vaccineontology/VO/issues/436 1489078 1489079 5083 Clinical trial Gene name: E6|Gene name: E7 HPV E6/E7 DNA Vaccine GX-188E A vaccine consisting of a plasmid DNA encoding the human prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express this antigen, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5262 https://github.com/vaccineontology/VO/issues/455 2346 5262 Clinical trial Gene name: Prostate-specific membrane antigen Human Prostate-Specific Membrane Antigen Plasmid DNA Vaccine A vaccine consisting of a plasmid DNA encoding the murine prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express PSMA, resulting in tumor cell lysis Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5105 https://github.com/vaccineontology/VO/issues/540 5105 Mouse Prostate-Specific Membrane Antigen Plasmid DNA Vaccine Early-to late-stage myeloid progenitor cells derived from adult human stem cells with potential hematopoietic activity. Upon infusion, human myeloid progenitor cells CLT-008 proliferate into mature myeloid cells, including granulocytes, macrophages, platelets, and erythrocytes. These myeloid progenitor cells die within forty-five days after a burst of hematopoiesis. This agent cannot create lymphoid cells, including T cells associated with graft-versus-host disease Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5511 https://github.com/vaccineontology/VO/issues/449 5511 Clinical trial Human Myeloid Progenitor Cells CLT-008 vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with corpses of apoptotic leukemic cells, with potential immunostimulatory and antineoplastic activities. Upon vaccination, autologous dendritic cells pulsed with leukemic apoptotic corpse may activate the immune system to mount an anti-tumoral cytotoxic T-lymphocyte (CTL) response against leukemic cells expressing leukemia-associated antigens, which may result in leukemic cell lysis and inhibition of tumor cell growth. Apoptotic tumor cell corpses contain an array of tumor associated antigens Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5004 https://github.com/vaccineontology/VO/issues/476 5004 Clinical trial Leukemic Apoptotic Corpse-Pulsed Autologous Dendritic Cells Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5200 https://github.com/vaccineontology/VO/issues/555 3077513 3077579 5200 Gene name: UL83|Gene name: UL123 Multi-peptide CMV-Modified Vaccinia Ankara Vaccine This is an autologous lung cancer vaccine consisting of patient-specific lung cancer cells genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), an immunostimulatory cytokine (NCIT_C1979). GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5453 https://github.com/vaccineontology/VO/issues/302 1437 5453 Clinical trial Gene name: GM-CSF GVAX Lung Cancer Vaccine A peptide vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. gp100:280-288(288V) peptide has a valine substitution at amino acid position 288 to improve immunogenicity. Vaccination with gp100:280-288(288V) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5112 https://github.com/vaccineontology/VO/issues/419 3791 5112 Clinical trial Gene name: KDR HLA-A*2402-Restricted VEGFR1 Peptide Vaccine A cancer vaccine containing two HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from: vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5294 https://github.com/vaccineontology/VO/issues/420 3791 5294 Clinical trial Gene name: KDR HLA-A2402-Restricted VEGFR1/2 Multipeptide Vaccine A cancer vaccine consisting of allogeneic neuroblastoma tumor cells have been genetically modified to secrete the human cytokine interleukin-2 (IL-2) and the human chemokine lymphotactin (Lptn) with potential immunostimulating and antineoplastic activities. Upon administration, IL-2 and Lptn are secreted by the IL-2/Lptn gene-modified allogeneic neuroblastoma tumor cell vaccine, potentially enhancing the cytotoxic T lymphocyte (CTL) response elicited by vaccine neuroblastoma tumor-associated antigens (TAAs) against host neuroblastoma tumor cells. Produced by activated progenitor T cells, Lptn belongs to the C chemokine subfamily and is a potent chemotactic factor for lymphocytes; IL-2 stimulates natural killer (NK) cells and may enhance a vaccine-elicited CTL immune response against tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5173 https://github.com/vaccineontology/VO/issues/462 6375 5173 Clinical trial Gene name: XCL1 IL-2/Lptn Gene-Modified Allogeneic Neuroblastoma Tumor Cell Vaccine An immunotherapeutic containing a proprietary adjuvant system combined with a melanoma-associated antigen peptide MAGE-A3 epitope with potential immunomodulating and antineoplastic activities. Intramuscular administration with GSK1572932A may stimulate the immune system to exert both humoral and cellular immune responses against MAGE-A3-expressing tumor cells. MAGE-A3, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types, including non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, and bladder cancer. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5343 https://github.com/vaccineontology/VO/issues/463 4102 5343 Clinical trial Gene name: MAGEA3 Immunotherapeutic GSK1572932A GVAX cancer vaccines are autologous cell vaccines comprised of tumor cells which have been irradiated and genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), a hormone which plays a key role in stimulating the body's immune response to vaccines. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5211 https://github.com/vaccineontology/VO/issues/301 1493 354 5211 Clinical trial Gene name: CTLA4|Gene name: KLK3 GVAX Cancer Vaccine A replication-defective adenoviral serotype 5 vector encoding a recombinant form of the human cytokine interferon-gamma (IFN-g), with potential antineoplastic and immunoregulatory activities. Upon intratumoral administration, the sustained expression of IFN-g by IFN-g-expressing adenovirus vaccine ASN-002 promotes a T-helper type 1 (Th1) immune response and inhibits the Th2-mediated cytokine production observed in many cutaneous lymphomas. IFN-g also mediates interleukin-12 (IL-12) production by antigen-presenting cells (APCs); activates macrophages, cytotoxic T-cells, and natural killer (NK) cells; upregulates major histocompatibility complex (MHC) molecules; and stimulates antibody-dependent cellular cytotoxicity (ADCC). Altogether, these IFN-g-mediated effects may result in both an inhibition of tumor cell proliferation and tumor cell death. Compared to IFN-g injections, the prolonged local production of IFN-g at the tumor site allows for higher efficacy and a reduction of systemic toxicity Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5540 https://github.com/vaccineontology/VO/issues/470 2546420 5540 Clinical trial Gene name: WHcAg Interferon-gamma-expressing Adenovirus Vaccine ASN-002 A vaccine based on anti-idiotype (Id) monoclonal antibodies combined with interleukin-2 (IL-2). Anti-Id vaccines have been shown to be effective in treatment of B-cell lymphoma in animal models and in clinical trials, resulting in tumor regression; the addition of interleukin-2 (IL-2) may augment the therapeutic effect of anti-Id vaccines. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5352 https://github.com/vaccineontology/VO/issues/471 5176180 5352 Clinical trial Gene name: gp72 Interleukin-2 Anti-Idiotype Vaccine A chimeric lymphoma vaccine generated by combining the recipient's Ig idiotype (Id) protein with keyhole limpet hemocyanin (KLH), an immune stimulant, with potential antineoplastic activity. Vaccination with KLH-Lymphoma Ig Vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5519 https://github.com/vaccineontology/VO/issues/474 5519 Clinical trial KLH-Lymphoma Ig Vaccine A preparation of autologous peripheral blood mononuclear cells (PBMCs) radiolabeled with indium In 111 with radioisotopic activity. Autologous PBMCs are isolated, expanded ex vivo, radiolabeled with indium In 111, and then infused back into the patient. Gamma scintigraphy may then be used to image gamma ray-emitting indium In 111 PBMCs localized in lymphoma tissue. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5212 https://github.com/vaccineontology/VO/issues/467 1048 5212 Clinical trial Gene name: CEACAM5 Indium In 111-Labeled Autologous Peripheral Blood Mononuclear Cells Vaccine A preparation of autologous peripheral polymorphonuclear (PMNLs) radiolabeled with indium In 111 with radioisotopic activity. Autologous PMNLs are isolated, expanded ex vivo, radiolabeled with indium In 111, and then infused back into the patient. Gamma scintigraphy may then be used to image gamma ray-emitting indium In 111 PMNLs localized in lymphoma tissue. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5273 https://github.com/vaccineontology/VO/issues/468 5273 Clinical trial Indium In 111-Labeled Autologous Polymorphonuclear Leukocytes Vaccine Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated protein ESO-1 in vitro, and then transferred back to the same patient to target tumor cells expressing ESO-1. ESO-1 is a human self-antigen expressed by melanomas. The ESO-1 gene encodes several MHC class I- and MHC class II-restricted epitopes that may activate cytotoxic T-cell-mediated tumor destruction Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5178 https://pubmed.ncbi.nlm.nih.gov/?term=ESO-1+Reactive+Autologous+Peripheral+Blood+Lymphocyte https://github.com/vaccineontology/VO/issues/67 1485 5178 Clinical trial Gene name: NY-ESO-1 ESO-1 Reactive Autologous Peripheral Blood Lymphocyte vaccine A recombinant fowlpox virus-based vaccine vector designed to express various tumor-associated peptide antigens. Strong CD8 cytotoxic T cell responses may be induced after prolonged immunization with fowlpox virus vaccines and have been associated with tumor regression. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5042 https://github.com/vaccineontology/VO/issues/130 4582 1048 5042 Clinical trial Gene name: CEACAM5|Gene name: MUC1 Fowlpox Virus Vector Vaccine A cancer vaccine containing of a synthetic form of the renal cell carcinoma (RCC)-associated antigen G250 with potential antineoplastic activity. Vaccination with G250 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the G250 antigen, resulting in decreased tumor growth. Found in the majority of renal cell carcinomas, G250 is a cell surface tumor-associated antigen (TAA) that contains an HLA-A2.1-restricted epitope that is recognized by CTLs. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5249 https://github.com/vaccineontology/VO/issues/135 2315 5249 Clinical trial Gene name: MLANA Gag:267-274 Peptide Vaccine An autologous dendritic cell (DC) cancer vaccine with GITRL RNA-transfected that has potential immunostimulatory activity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5410 https://github.com/vaccineontology/VO/issues/136 1493 5410 Clinical trial Gene name: CTLA4 GITRL RNA-transfected Autologous Dendritic Cell Vaccine Used C57BL/6 mice and irradiated B16 tumor cells expressing granulocyte and macrophage colony-stimulating factor (GM-CSF), interleukin-12 (IL-12) or both. Tumor was transplanted by the injection of wild-type B16 cells. Tumor growth and survival were measured to evaluate the efficacy of vaccination. Specific humoral response and immunoglobulin G (IgG) switch were evaluated measuring total IgG and IgG1 and IgG2a subtypes against tumor membrane proteins of B16 cells Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4061 https://github.com/vaccineontology/VO/issues/176 4061 Clinical trial GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccine A recombinant, oncolytic serotype 5/3 capsid-modified adenovirus encoding the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus enhances antigen presentation, promotes natural killer (NK) cell-mediated killing and causes a cytotoxic T cell (CTL) response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. CGTG-102 is designed to replicate only in cells with defects in the p16/Rb/E2F pathway, attributed to a mutation common in many solid tumors. Replacement of the Ad5 capsid protein knob with a knob domain from serotype 3 causes higher transduction in cancer cells as compared to normal cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5111 https://github.com/vaccineontology/VO/issues/177 5111 Clinical trial GM-CSF-encoding Oncolytic Adenovirus CGTG-102 vaccine A vaccine that injected peptides of gp100, MART-1, MAGE-3 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3993 https://github.com/vaccineontology/VO/issues/196 6490 3993 Clinical trial Gene name: gp100 gp100 + Mart-1 + Mart-3 vaccine A vaccine consisting of a replication-defective recombinant adenovirus that encodes the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with gp100 adenovirus vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5133 https://github.com/vaccineontology/VO/issues/197 6490 5133 Clinical trial Gene name: gp100 gp100 Adenovirus Vaccine A vaccine consisting of microscopic gold particles coated with plasmid DNA encoding the glycoprotein 100 (gp100) melanoma antigen and granulocyte-macrophage colony-stimulating factor (GM-CSF). Vaccination with gp100 and GM-CSF DNA/gold vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against gp100 positive cells, resulting in decreased tumor growth. GM-CSF is thought to increase the induction and activation of antigen-presenting cells (APC), allowing for a reduction in the dose of gp100 administered. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5084 https://github.com/vaccineontology/VO/issues/198 6490 5084 Clinical trial Gene name: gp100 gp100 and GM-CSF DNA/Gold Vaccine A recombinant peptide derived from the human melanoma antigen glycoprotein 100 (gp100) with potential use in cancer immunotherapy. gp100 protein(184V) has a valine substitution at position 184. Vaccination with this peptide may evoke a cytotoxic T lymphocyte (CTL) response against tumor cells expression the gp100 antigen. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5482 https://github.com/vaccineontology/VO/issues/199 6490 5482 Clinical trial Gene name: gp100 gp100 Protein (184V) vaccine A cancer vaccine consisting of a recombinant vaccinia virus encoding the gp100 melanoma-melanocyte antigen. gp100 human antigen is a wild-type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5153 https://github.com/vaccineontology/VO/issues/200 6490 5153 Clinical trial Gene name: gp100 gp100 Vaccinia Vaccine A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the melanoma antigen glycoprotein 100 (gp 100) with potential antineoplastic activity. The expression of gp100 may generate a cellular immune response to melanoma cells; this effect is enhanced by the co-administration of interleukin 2 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5135 https://github.com/vaccineontology/VO/issues/201 6490 5135 Clinical trial Gene name: gp100 gp100-Fowlpox Vaccine Peripheral blood lymphocytes (PBL) harvested from host blood and stimulated in vitro with tumor-specific gp 100 antigen. 'Pulsing' PBL with gp100, a tumor associated antigen (TAA) commonly expressed by melanoma cells, may increase melanoma-reactive cytotoxic lymphocytes (CTL) in the PBL cell population. Autologous gp100-pulsed PBL have been administered to melanoma patients in order to augment cytotoxic immune responses to melanoma. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5007 https://github.com/vaccineontology/VO/issues/202 6490 5007 Clinical trial Gene name: gp100 gp100-Pulsed Peripheral Blood Mononuclear Cell vaccine Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to the same patient to target tumor sites expressing gp100. gp100 human antigen is a wild-type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4990 https://github.com/vaccineontology/VO/issues/203 6490 4990 Clinical trial Gene name: gp100 gp100-Reactive Autologous Peripheral Blood Lymphocyte vaccine To understand why cancer vaccine-induced T cells often do not eradicate tumors, we studied immune responses in mice vaccinated with gp100 melanoma peptide in incomplete Freund's adjuvant (peptide/IFA), which is commonly used in clinical cancer vaccine trials (Hailemichael et al., 2013). Immunization Route: Intramuscular injection (i.m.) Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4078 https://github.com/vaccineontology/VO/issues/204 6490 4078 Clinical trial Gene name: gp100 gp100/IFA vaccine A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5095 https://github.com/vaccineontology/VO/issues/205 6490 5095 Clinical trial Gene name: gp100 gp100: ES209-217(210M) Peptide vaccine A peptide consisting of amino acid residues 154 through 162 of the melanoma-melanocyte antigen gp100. Vaccination with gp100:154-162 peptide may enhance tumor-specific T-cell immunity. gp100 antigen is a self-antigen expressed by melanocytes, pigmented retinal cells, and most melanoma lesions and is recognized via class I and II HLA-restricted mechanisms. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5145 https://github.com/vaccineontology/VO/issues/206 6490 5145 Clinical trial Gene name: gp100 gp100:154-162 Peptide Vaccine A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5050 https://github.com/vaccineontology/VO/issues/207 6490 5050 Clinical trial Gene name: gp100 gp100:209-217 Peptide vaccine A vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with gp100:280-288 peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5526 https://github.com/vaccineontology/VO/issues/208 6490 5526 Clinical trial Gene name: gp100 gp100:280-288 Peptide Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3989 https://github.com/vaccineontology/VO/issues/307 6490 3989 Clinical trial Gene name: gp100 Hexapeptide melanoma vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A1-binding melanoma-associated antigen peptides MAGE-1 and MAGE-3 with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against MAGE1- and MAGE-3-expressing cancer cells, resulting in tumor cell lysis. HLA-A1 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A1 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5185 https://github.com/vaccineontology/VO/issues/423 4100 4102 5185 Clinical trial Gene name: MAGEA3|Gene name: MAGEA1 HLA-A1-Binding MAGE-1/MAGE-3 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted melanoma-associated antigen peptides tyrosinase (TYR), MART-1(melanoma antigen recognized by T-cells) and melanoma antigen glycoprotein 100 (gp100), with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against Tyr-, MART-1 and gp100-expressing cancer cells, resulting in tumor cell lysis. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5034 https://github.com/vaccineontology/VO/issues/425 2315 6490 5034 Clinical trial Gene name: gp100 |Gene name: MLANA HLA-A2-Binding TYR/MART-1/gp100 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5270 https://github.com/vaccineontology/VO/issues/448 7015 5270 Clinical trial Gene name: TERT hTERT/Survivin/Melanoma Tumor Cell-Derived mRNA-Transfected Dendritic Cell Vaccine A peptide vaccine consisting of a combination of seven synthetic long peptides (SLPs), which are each about 30 amino acids in size, and derived from cancer-testis antigens (CTA) and melanocytic differentiation proteins (MDP), with potential immunostimulating and antitumor activities. Upon administration, long peptide vaccine 7 may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against tumor cells expressing these peptides. CTA and MDP are overexpressed in a variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5143 https://github.com/vaccineontology/VO/issues/484 3845 7157 5143 Clinical trial Gene name: TP53|Gene name: KRAS Long Peptide Vaccine 7 A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3) with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-3.A1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-3, resulting in tumor cell lysis. MAGE-3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5021 https://github.com/vaccineontology/VO/issues/489 4102 5021 Gene name: MAGEA3 MAGE-3.A1 Peptide Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4003 https://github.com/vaccineontology/VO/issues/497 6490 4003 Gene name: gp100 MART-1 Vaccine A vaccine consisting of recombinant adenovirus vector encoding MART-1 (melanoma antigen recognized by T-cells 1), an immunogenic protein of unknown function that is expressed by certain types of melanoma. Vaccination with MART-1 adenovirus vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against MART-1 positive melanoma cells, resulting in an antitumor effect. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5398 https://github.com/vaccineontology/VO/issues/498 2315 5398 Gene name: MLANA-Dupli MART-1 Adenovirus Vaccine A synthetic cancer vaccine derived from a melanoma-associated antigen, MART-1. Antigenic peptides derived from MART-1 are recognized by CD8+ T lymphocytes and have been used to immunize patients with advanced melanomas; prolonged immunization may result in a reduction in tumor size. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5254 https://github.com/vaccineontology/VO/issues/502 2315 5254 Gene name: MLANA-Dupli MART-1 Fowlpox Vaccine A cancer vaccine consisting of an attenuated recombinant vaccinia virus expressing the melanoma-associated antigen MART-1. Vaccination with this agent may stimulate cytotoxic host immune responses to melanoma cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5204 https://github.com/vaccineontology/VO/issues/503 2315 5204 Gene name: MLANA-Dupli MART-1 Vaccinia Vaccine Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201 positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5028 https://github.com/vaccineontology/VO/issues/504 4100 6490 5028 Gene name: gp100|Gene name: MAGEA3 MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5141 https://github.com/vaccineontology/VO/issues/505 2315 6490 5141 Gene name: MLANA|Gene name: gp100 MART-1:26-35(27L) Peptide Vaccine A natural or synthetic peptide cancer vaccine consisting of amino acid residues 27 through 35 of the melanoma-associated antigen MART-1 with potential antineoplastic activity. Vaccination with MART-1:27-35 peptide may induce cytotoxic host immune responses against melanoma cells that express this peptide Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5450 https://github.com/vaccineontology/VO/issues/506 2315 5450 Gene name: MLANA MART-1:27-35 Peptide Vaccine A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) encapsulated in noninfectious virus-like particles (VLP) with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A VLP vaccine may activate the immune system to exert a specific cytotoxic T lymphocyte (CTL) response against cancer cells expressing the Melan A antigen, resulting in tumor cell lysis. Melan A is an antigen that is upregulated in most melanomas. VLP stimulates the immune system and promotes the CTL response. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5142 https://github.com/vaccineontology/VO/issues/507 2315 5142 Gene name: MLANA Melan-A VLP Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5318 https://github.com/vaccineontology/VO/issues/508 2315 4102 5318 Gene name: MLANA|Gene name: MAGEA3 Melan-A/MAGE-3.DP4 Peptide Vaccine Jie Zheng Justin Song Oliver He Penny Pan https://github.com/vaccineontology/VO/issues/517 7299 Gene name: Tyrosinase Melanoma DNA vaccine TA2M(TM) encoding tyrosinase peptides A synthetic allogeneic cancer vaccine. Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with an adjuvant (such as DETOX or RIBI). This agent may be combined with immunomodulatory cytokines such as interferon alpha. Melanoma theraccine may induce a rise in the level of cytotoxic T-lymphocyte precursors. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4989 https://github.com/vaccineontology/VO/issues/522 282617 4989 Gene name: IFNL3 Melanoma Theraccine A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, melapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5014 https://github.com/vaccineontology/VO/issues/523 5014 Melapuldencel-T Vaccine A multipeptide cancer vaccine comprised of 12 melanoma peptides restricted by Class I MHC (12MP), plus a tetanus helper peptide Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5261 https://github.com/vaccineontology/VO/issues/524 22178 6490 5261 Gene name: gp100|Gene name: TRP-1 MELITAC 12.1 Peptide Vaccine A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities. Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5039 https://github.com/vaccineontology/VO/issues/535 2064 5039 Gene name: ERBB2 Monoclonal Antibody 4B5 Anti-Idiotype Vaccine A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100. Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5386 https://github.com/vaccineontology/VO/issues/539 20431 5386 Gene name: Pmel17 Mouse gp100 Plasmid DNA Vaccine Jie Zheng Justin Song Oliver He Penny Pan https://github.com/vaccineontology/VO/issues/543 768 Gene name: CA9 mRNA-Electroporated Dendritic Cells Vaccine A plasmid DNA vaccine encoding the mouse tumor associated antigen tyrosinase-related protein-2 (TYRP2) with potential immunostimulating and antineoplastic activities. Upon administration, murine TYRP2 plasmid DNA vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing TYRP2; this vaccine may also induce an immune response against tyrosinase-related protein-1 (TYRP1). TYRP2 and TYRP1, melanosomal membrane glycoproteins upregulated in melanoma cells, are involved in melanin synthesis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5310 https://github.com/vaccineontology/VO/issues/558 1638 5310 Gene name: DCT Murine TYRP2 Plasmid DNA Vaccine A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and LAMP. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5276 https://github.com/vaccineontology/VO/issues/446 7015 5276 Clinical trial Gene name: TERT hTERT-LAMP mRNA-loaded Autologous Dendritic Cell Vaccine GRNVAC1 A recombinant 19-residue peptide vaccine consisting of amino acids 161 through 180 of the cancer/testis (CT) antigen. ESO-1 (161-180) peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. (NCI04) (NCIT_C28775). Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5264 https://github.com/vaccineontology/VO/issues/66 1485 5264 Clinical trial Gene name: NY-ESO-1 ESO-1 (161-180) Peptide Vaccine A 9-residued peptide vaccine consisting of amino acids 157 through 165 of the cancer/testis (CT) antigen ESO-1. Modified at position 165 (cysteine to valine) to improve immunogenicity, ESO-1:157-165(165v) peptide administered as a vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5473 https://pubmed.ncbi.nlm.nih.gov/?term=ESO-1%3A157-165%28165V%29+Peptide https://github.com/vaccineontology/VO/issues/68 1485 5473 Clinical trial Gene name: NY-ESO-1 ESO-1:157-165(165V) Peptide vaccine A recombinant virus-based vaccine that contains various peptide antigens. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. Strong CD8 T cell responses may be induced after prolonged immunization and have been associated with tumor regression. Jie Zheng Justin Song Oliver He Penny Pan PubMed:15757474 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5031 https://github.com/vaccineontology/VO/issues/129 354 634 5031 Clinical trial Gene name: CEACAM1|Gene name: KLK3 Fowlpox Virus Vaccine A peptide vaccine against the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), with potential immunomodulating and antineoplastic activities. Vaccination with indoleamine 2,3-dioxygenase peptide vaccine may activate the immune system to induce an immune response against IDO-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and may eradicate IDO-expressing tumor cells. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression; Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5144 https://github.com/vaccineontology/VO/issues/469 3620 5144 Clinical trial Gene name: IDO1 Indoleamine 2,3-dioxygenase Peptide Vaccine A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity. Jie Zheng Justin Song Oliver He Penny Pan PubMed:22855837 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5317 https://github.com/vaccineontology/VO/issues/128 2348 5317 Clinical trial Gene name: FOLR1 Folate-FITC vaccine A cancer vaccine consisting of a recombinant vaccinia virus encoding the tumor-associated gene MAGE-1 that is contaminated with bovine viral diarrhea virus (BVDV). The MAGE-1 gene is a member of the melanoma antigen-encoding gene family which is expressed in various malignant tumors such as hepatocellular carcinoma and germ cell tumors in addition to melanoma. Vaccination with vaccinia virus expressing human MAGE-1 may generate antitumoral T-cell responses. BVDV is an RNA pestivirus that may contaminate vaccines due to its presence in the fetal calf serum used as a growth supplement in the tissue culture of mammalian cells used in vaccine production. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5157 https://github.com/vaccineontology/VO/issues/488 4100 5157 Gene name: MAGEA1 MAGE-1 Vaccinia Contaminated with BVDV A peptide cancer vaccine comprised of a peptide derived from the human melanoma antigen A3 (MAGE-A3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5395 https://github.com/vaccineontology/VO/issues/491 4102 5395 Gene name: MAGEA3 MAGE-A3 Peptide Vaccine An oncolytic adenoviral vaccine composed of a replication-defective, E1- and E3-deleted adenovirus serotype 5 (Ad5) with a transgene encoding the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon administration, MAGE-A3-expressing adenovirus type 5 vaccine selectively replicates in cancer cells and expresses MAGE-A3. This induces an immune response against tumor cells expressing the MAGE-A3 antigen, which leads to tumor cell death. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5336 https://github.com/vaccineontology/VO/issues/492 4102 5336 Gene name: MAGEA3 MAGE-A3-expressing Adenovirus Type 5 Vaccine A peptide vaccine consisting of multiple epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with potential immunostimulating and antineoplastic activities. hTERT I540/R572Y/D988Y multipeptide vaccine contains strongly antigenic peptide epitopes I540 (9-mer), R572Y (9-mer) and D988Y (10-mer). Vaccination with this agent may elicit a cytotoxic T cell (CTL) response against telomerase-expressing tumor cells. Directly linked to tumorigenesis, telomerase is expressed in the majority of human cancer cells but is infrequently expressed in normal cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5191 https://github.com/vaccineontology/VO/issues/439 7015 5191 Clinical trial Gene name: TERT hTERT I540/R572Y/D988Y Multipeptide Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with tumor-derived clonal immunoglobulin (Ig) with potential immunostimulatory and antineoplastic activities. Upon administration, idiotype-pulsed autologous dendritic cell vaccine APC8020, containing idiotype (Id) protein structures that can be recognized by antibodies and by CD41 T lymphocytes and CD81 T lymphocytes, may stimulate antitumoral cytotoxic T lymphocyte (CTL) and antibody responses against Id-expressing tumor cells. The Id represents the unique antigenic determinants in the variable regions of the clonal Ig. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5344 https://github.com/vaccineontology/VO/issues/460 5344 Clinical trial Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020 A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5460 https://github.com/vaccineontology/VO/issues/565 354 55 5460 Gene name: KLK3|Gene name: ACP3 MVA-PSA/PAP Prostate Cancer Vaccine A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation. (NCIT_C91076). Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5314 https://github.com/vaccineontology/VO/issues/560 3783709 5698 5314 Clinical trial Gene name: EBNA-1|Gene name: PSMB9 MVA-EBNA1/LMP2 Vaccine A peptide vaccine containing amino acids residues from 340 through 349 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:340-349 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5466 https://github.com/vaccineontology/VO/issues/482 5689 5466 Clinical trial Gene name: PSMB9 LMP-2:340-349 Peptide Vaccine A peptide vaccine containing amino acids residues from 419 through 427 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:49-427 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5479 https://github.com/vaccineontology/VO/issues/483 5689 5479 Clinical trial Gene name: PSMB9 LMP-2:419-427 Peptide Vaccine A cancer vaccine comprised of synthetic peptides derived from human melanoma antigen A1 (MAGE-A1), human melanoma antigen A3 (MAGE-A3) and cancer-testis antigen NY-ESO-1 with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A1/MAGE-A3/NY-ESO-1 peptides vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A1, MAGE-A3 and NY-ESO-1, resulting in tumor cell lysis. The MAGE-A1, MAGE-A3, and NY-ESO-1 tumor-associated antigens (TAAS) are overexpressed by a variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5263 https://github.com/vaccineontology/VO/issues/490 4100 4102 5263 Gene name: MAGEA3|Gene name: MAGEA1 MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine A trivalent cancer vaccine containing the ganglioside lactones GM2, GD2 and GD3 conjugated with the immunostimulant keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with GM2 lactone/GD2 lactone/GD3 lactone-KLH conjugate trivalent vaccine may elicit antibodies against tumor cells expressing any of these epitopes, resulting in an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing these gangliosides. GM2, GD2 and GD3 are tumor associated antigens (TAAs) that are overexpressed in a variety of tumor cell membranes. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5532 https://github.com/vaccineontology/VO/issues/178 117189 2760 5532 Clinical trial Gene name: GM2A|Gene name: GRDX GM2/GD2/GD3 Lactone-KLH Conjugate Trivalent Vaccine A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from ring finger protein 43 (RNF43); translocase of outer mitochondrial membrane 34 (TOMM34); and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing RNF43, TOMM34, and VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5429 https://github.com/vaccineontology/VO/issues/421 10953 3791 5429 Clinical trial Gene name: KDR|Gene name: TOMM34 HLA-A*2404-Restricted RNF43-TOMM34-VEGFR1-VEGFR2 Multipeptide Vaccine A peptide vaccine comprised of synthetic HLA-A1, -A2 and -B35 restricted survivin epitopes combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. Upon administration, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine may stimulate a cytotoxic T cell response against tumor cells that overexpress survivin, resulting in tumor cell lysis. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5120 https://github.com/vaccineontology/VO/issues/422 5120 Clinical trial Gene name: Survivin HLA-A1, A2, B35-Restricted Survivin Peptides/Montanide ISA-51 Vaccine A dendritic cell (DC) vaccine containing ex vivo expanded autologous DCs obtained from a patient with leukemia with potential immunostimulating activity. Upon reintroduction into the host, the host dendritic cell vaccine-001 MSSM/BIIR may stimulate the immune system to mount a leukemia-specific cytotoxic T lymphocyte (CTL) response. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5246 https://github.com/vaccineontology/VO/issues/428 1489078 5246 Clinical trial Gene name: E6 Host Dendritic Cell Vaccine-001 MSSM/BIIR A multi-peptide cancer vaccine with potential immunostimulating and antineoplastic activities. IMT-1012 immunotherapeutic vaccine contains twelve different synthetic peptides or tumor associated antigens (TAAs), including cyclin I (CCNI), cyclin-dependent kinase CDC2, EDDRI and TACE/ADAM17, each of which is involved in a different pathway associated with tumor growth, survival, and metastasis. Each antigen in the vaccine elicits a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing that antigen. This multi-antigen/multi-pathway targeting strategy provides broad immunotherapeutic coverage with respect to tumor complexity and heterogeneity and may result in enhanced vaccine efficacy. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5048 https://github.com/vaccineontology/VO/issues/464 10983 983 5048 Clinical trial Gene name: CDK1|Gene name: CCNI IMT-1012 Immunotherapeutic Vaccine A cancer vaccine containing four HLA-A0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigens (TAAs) tyrosinase-related protein 2 (TRP2), glycoprotein 100 (gp100), Ephrin receptor A2 (EphA2) and human epidermal growth factor receptor 2 (HER2). Upon administration, HLA-A0201-restricted TRp2-gp100-EphA2-HER2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against TRP2-gp100-EphA2-HER2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5355 https://github.com/vaccineontology/VO/issues/309 2064 6490 5355 Clinical trial Gene name: PMEL|Gene name: ERBB2 HLA-A0201-Restricted TRP2-gp100-EphA2-HER2 multipeptide Vaccine A cancer vaccine containing three HLA-A0201-restricted peptide epitopes with potential immunostimulatory, antiangiogenic, and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigen (TAA) URLC (up-regulated in lung cancer 10) and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells and the tumor microvasculature expressing VEGFR 1 and 2 peptides; this may result in tumor cell lysis, the inhibition of tumor angiogenesis, and decreased tumor growth. HLA-A0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5017 https://github.com/vaccineontology/VO/issues/417 3791 54742 5017 Clinical trial Gene name: KDR|Gene name: LY6K HLA-A*0201-Restricted URLC10-VEGFR1-VEGFR2 Multipeptide Vaccine A live-attenuated, double-deleted strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a mutant form of the tumor associated antigens, epidermal growth factor receptor (EGFRvIII) and the cancer/testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated Listeria monocytogenes encoding EGFRvIII-NY-ESO-1 vaccine targets dendritic cells and expresses EGFRvIII and NY-ESO-1. This promotes both a potent innate immune response and an adaptive immune response involving the recruitment and activation of T lymphocytes against EGFRvIII and NY-ESO-1-expressing tumor cells, which results in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4991 https://github.com/vaccineontology/VO/issues/480 1485 1956 4991 Clinical trial Gene name: EGFR|Gene name: CTAG1B Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623 A multivalent vaccine comprised of the epitope antigens of Globo H hexasaccharide 1 (Globo H), GM2 ganglioside, Lewis-Y, MUC1-32-mer, TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin, with potential antineoplastic activity. The antigens included in this vaccine are associated various cancer cells. Vaccination with this multivalent vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5104 https://github.com/vaccineontology/VO/issues/173 4582 2760 5104 Clinical trial Gene name: GM2A|Gene name: MUC1 Globo H-GM2-Lewis-y-MUC1-32-mer-TF(c)-Tn(c)-KLH Conjugate Vaccine Peripheral blood lymphocytes (PBL) transfected to express MOv have been designed for possible use in autologous adoptive cellular immunotherapy of ovarian adenocarcinomas that overexpress folate-binding protein. MOv-PBLs express MOv-gamma (MOv), a chimeric receptor gene product derived from a recombinant gene encoding the variable region of murine monoclonal antibody MOv18 against folate-binding protein (FBP), often overexpressed in human ovarian cancer cells, and the human gene encoding the IgG and IgE Fc receptor gamma subunit. Autologous vaccination with these PBLs stimulates a host cytotoxic T lymphocyte response against ovarian cancer cells that overexpress FBP. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5335 https://github.com/vaccineontology/VO/issues/541 4343 5335 Gene name: MOV10 MOv-PBL Vaccine An attenuated oncolytic vaccinia virus encoding the light-emitting fusion protein Renilla luciferase-Aequorea green fluorescent protein (RUC-GFP) with potential bioluminescent and antineoplastic activities. Upon administration, light-emitting oncolytic vaccinia virus GL-ONC1 specifically enters tumor cells due to the permeable nature of the tumor vasculature. Once inside the cell, the virus replicates, resulting in tumor cell lysis and the release of mature viral particles into the tumor microenvironment. Released viral particles may then infect and destroy neighboring tumor cells. In addition, the release of tumor-associated antigens (TAAs) by lysed tumor cells into the bloodstream may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against the tumor. The expression of RUC-GFP by this agent allows for both detection and monitoring of virally infected tumor cells in vivo and vitro with luciferase-mediated bioluminescence imaging and fluorescence imaging techniques. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5385 https://github.com/vaccineontology/VO/issues/477 5385 Clinical trial Gene name: Tumor Associated Antigen Light-Emitting Oncolytic Vaccinia Virus GL-ONC1 Vaccine A cancer vaccine containing an HLA-A*0201-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide (sequence: TLFWLLLTL) with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*0201-restricted VEGFR1-derived peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR1, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5413 https://github.com/vaccineontology/VO/issues/418 3791 5413 Clinical trial Gene name: KDR HLA-A*0201-Restricted VEGFR1 Peptide Vaccine A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA) and TRICOM, a combination of three immunostimulants (i.e., B7.1, ICAM-1, and LFA-3). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5038 https://github.com/vaccineontology/VO/issues/132 354 5038 Clinical trial Gene name: KLK3 Fowlpox-PSA-TRICOM Vaccine A prostate cancer vaccine containing mRNAs encoding prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA) and six-transmembrane epithelial antigen of the prostate (STEAP), with potential antitumor activity. Upon administration, mRNA-derived prostate cancer vaccine CV9103 may stimulate the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PSCA- and STEAP-expressing prostate tumor cells. The mRNA used in this vaccine is modified and formulated to have enhanced translational potency and adjuvant activities. PSA, PSMA, PSCA and STEAP may be upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5369 https://github.com/vaccineontology/VO/issues/542 26872 5369 Gene name: STEAP1 mRNA-Derived Prostate Cancer Vaccine CV9103 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5126 https://github.com/vaccineontology/VO/issues/546 4583 5126 Gene name: MUC2 MUC-2-Globo H-KLH Conjugate Vaccine A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties; the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF. Jie Zheng Justin Song Oliver He Penny Pan https://github.com/vaccineontology/VO/issues/194 7124 Clinical trial Gene name: TNF Golnerminogene Pradenovec Vaccine A peptide vaccine comprised of synthetic HLA-A2- and HLA-A3-binding peptides, derived from amino acid sequences of fibroblast growth factor-5 (FGF-5), combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. HLA-A2, A3-restricted FGF-5 peptides contain motifs recognized by the MHC class I molecules HLA-A2 and HLA-A3 and may stimulate a cytotoxic T-cell response against tumor cells that overexpress FGF-5. Montanide ISA-51, a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5465 https://github.com/vaccineontology/VO/issues/424 2250 5465 Clinical trial Gene name: FGF5 HLA-A2, A3-Restricted FGF-5 Peptides/Montanide ISA-51 Vaccine A naturally occurring 9-residue peptide of fibroblast growth factor 5 (FGF-5). Recognized by tumor infiltrating cytotoxic T lymphocytes originally isolated from a renal cell carcinoma that overexpressed FGF-5, FGF-5:172-176/217-220 peptide activates various cytotoxic CD8 lymphocytes in an HLA-restricted manner. Overexpressed in several cancer cell lines, FGF-5 is a tumor-associated antigen that may be useful in cancer immunotherapy. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5498 https://github.com/vaccineontology/VO/issues/134 4108 5498 Clinical trial Gene name: MAGEA9 G250 Peptide Vaccine A synthetic peptide derived from the protein ESW/FLI1 type 1 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently found in patients with Ewing's sarcoma or primitive neuroectodermal tumors (PNET). Vaccination with EF-1 peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this EWS/FL1 type 1 fusion protein. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5509 https://github.com/vaccineontology/VO/issues/52 253970502 100306940 5509 Clinical trial Gene name: FL1|Gene name: EWSR1 EF-1 Peptide Vaccine A cancer vaccine comprised of a 43 amino acid epitope from glycoprotein MUC1 (mucin 1) and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A encapsulated in cholesterol/dipalmitoylphosphatidylcholine (DPPC)/dimyristoylphosphatidylglycerol (DMPG) liposomes, with potential immunostimulatory and antineoplastic activities. The MUC1 epitope is composed of two 20 amino glycosylated VNTR (various number tandem repeats) from human MUC1A and including 6 glycosylated sites modified by Tn (alfa-N-acetyl-D-galactosamine). Immunization of liposomal MUC1/PET-lipid A vaccine results in an antibody as well as a cytotoxic T-lymphocyte (CTL) response against hypoglycosylated MUC1 expressing tumor cells. The tumor associated antigen MUC1, a type I transmembrane protein, is overexpressed and aberrantly glycosylated in a variety of tumor cells. As a vaccine adjuvant, PET lipid A, also known as penta erythritol lipid A, stimulates both cellular and humoral responses to the vaccine antigen. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5488 https://github.com/vaccineontology/VO/issues/479 4582 5488 Clinical trial Gene name: MUC1 Liposomal MUC1/PET-lipid A Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5345 https://github.com/vaccineontology/VO/issues/493 4102 5345 Gene name: MAGEA3 MAGE-A3/HPV 16 Peptide Vaccine A peptide derived from the tumor suppressor protein Von Hippel-Lindau (VHL). This peptide, sequence: MEAGRPRPCCAR, was constructed based on a frameshift mutation of one of the VHL gene products; the more abundant protein VHLp18(MEA) (where MEA stands for three amino acids, Met-Glu-Ala). Vaccination with FrSh61(MEA)VHL33 peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5236 https://github.com/vaccineontology/VO/issues/133 7428 5236 Clinical trial Gene name: VHL FrSh61 (MEA) VHL33 Peptide Vaccine A cancer vaccine based on virus-like replicon particles (VRP) packaged with an alphaviral vector encoding the extracellular domain (ECD) and transmembrane (TM) regions of the human epidermal growth factor receptor 2 (EGFR2, NEU or HER2), with potential antineoplastic activity. After immunization with HER2 ECD+TM virus-like replicon particles vaccine AVX901, the VRPs infect cells and express HER2 ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. The alphaviral replicon of this vaccine is an attenuated strain of the Venezuelan equine encephalitis virus (VEEV) in which 3 of the 7 viral genes were substituted with a truncated HER2 gene to create a self-amplifying replicon RNA. HER2, a tyrosine kinase involved in several cell growth signaling pathways, is dysregulated or overexpressed in a wide variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5442 https://github.com/vaccineontology/VO/issues/305 2064 5442 Clinical trial Gene name: ERBB2 HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901 Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5303 5303 Clinical trial Ad5-yCD/mutTKSR39rep-hIL12 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5324 5324 Clinical trial Ad5F35-LMP1/LMP2-Transduced Autologous Dendritic Cell vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5534 5534 Clinical trial Alpha Fetoprotein Plasmid DNA Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4995 4995 Clinical trial ALVAC-CEA (6D)-B7.1 Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4051 4051 Clinical trial autologous dendritic cells (DCs) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3981 3981 Research autologous monocyte-derived mature DCs pulsed with p53, survivin and telomerase-derived peptide vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4029 4029 Research Bacille Calmette Guerin for melanoma of lower extremity vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4028 4028 19 Licensed 40213271 Bacillus Calmette-Guerin vaccine vaccine Bacillus Calmette-Guerin (BCG) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4036 4036 Research Bacillus Calmette-Guerin (BCG), C. parvum vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4035 4035 Research Bacillus Calmette-Guerin (BCG), dinitrochlorobenzene (DNCB) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4034 4034 Research bacillus Calmette-Guerin (MER) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4021 4021 Research BCG and chemotherapy for malignant melanoma vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4022 4022 Clinical trial BCG and Corynebacterium parvum for malignant melanoma vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4033 4033 Clinical trial BCG treatment after surgical tumor removal vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4017 4017 Research Biolistic DNA vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3984 3984 Research Canvaxin Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4072 4072 Research class I HLA-A0201-restricted gp100209-2M peptide vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5456 5456 Clinical trial Contusugene ladenovec vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3990 3990 Research CpG 7909/PF3512676 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4170 4170 Licensed CVB4/p24(73(3)) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5494 5494 Clinical trial Dendritic Cell-Idiotype-Keyhole Limpet Hemocyanin Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5346 5346 Clinical trial DEPDC1/MPHOSH1 Peptide Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5116 5116 Clinical trial DLK1/EPHA2/HBB/NRP1/RGS5/TEM1 Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4060 4060 Clinical trial DNA Vaccine encoding p42.3 Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3998 3998 Research DNP-modified autologous vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4076 4076 Research electroloading of mature dendritic cells with melanoma whole tumor cell lysate vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4067 4067 Research ESAT-6-gpi DNA vaccine combined with B16F10-ESAT-6-gpi/IL-21 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4081 4081 Research Flagrp170 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4018 4018 Licensed FVAX vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4047 4047 Research GM-CSF transfected cells vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4008 4008 Research gp100 Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3974 3974 Clinical trial gp100:209-217(210M) peptide vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5438 5438 Clinical trial gp100:280-288(288V) Peptide Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5062 5062 Clinical trial GVAX Pancreatic Cancer Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4010 4010 Research hapten dinitrophenyl vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3992 3992 Research HCA587 protein vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4053 4053 Clinical trial hMART-IT vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3986 3986 Research HSP65-HER2 fusion peptide vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4058 4058 Research Hsp70 chaperone-based gel composition vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3982 3982 Research HSPPC-96 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3980 3980 Research human leukocyte antigen class I-modified peptide vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4077 4077 Research HUVECs-OK432 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3976 3976 Clinical trial IDD-3 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4009 4009 Research IFN/tremem vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4062 4062 Clinical trial IL-12p70 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3977 3977 Research IMM-101 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4069 4069 Clinical trial Incomplete Freund's adjuvant (IFA) alone, or a melanoma vaccine in IFA Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4037 4037 Research intralesional bacile Calmette-Guerin (BCG) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4038 4038 Research intralesional bacile Calmette-Guerin (BCG), DTIC, vincristine vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3975 3975 Research Ipilimumab vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4045 4045 Research ipilimumab, vemurafenib vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4012 4012 Research irradiated autologous cell vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4050 4050 Clinical trial irradiated melanoma cells plus BCG vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5472 5472 Clinical trial KSA-KLH Conjugate Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4000 4000 Licensed L612 HuMAb vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3968 3968 Research Large Multivalent Immunogen (LMI) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4048 4048 Research long-peptide vaccine and mAb Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4066 4066 Research mAb PC61 and DC/tumor fusion vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4005 4005 Research MAGE-A12:170-178 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4059 4059 Clinical trial MAGE-A3 + AS15 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4039 4039 Clinical trial MAGE-A3-genetically modified lymphocyte vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4065 4065 Research MCMV-TRP2 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4046 4046 Research mCRT-vGPCR-coated whole-cell vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3996 3996 Research Melacine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3985 3985 Research Melan-A/Mart-1 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3979 3979 Research Melanoma-specific Melan-A/Mart-1 peptide + virus-like nanoparticles Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5412 5412 Clinical trial Modified Vaccinia Virus Ankara Vaccine Expressing p53 Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4068 4068 Licensed mouse/human gp10025-33 peptide plus CpG adjuvant; mouse/human gp100; mouse/human gp10025-33 peptide-pulsed DCs vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5224 5224 Clinical trial Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4063 4063 Clinical trial Multipeptide melanoma vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4030 4030 Research Oral Bacille Calmette-Guerin for malignant melanoma vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3983 3983 Research OVA-TEXO vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4032 4032 Clinical trial procarbazine, dactinomycin, velba vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4031 4031 Research Pulmonary BCG immunotherapy for malignant melanoma vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6075 6075 Research RIPO(H3.3) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4011 4011 Research alpha-GalCer-loaded tumor-cell vaccine A cancer that is caused by human papillomavirus (HPV) infection. HPV infection can lead to six types of cancer including anal, cervical, oropharyngeal, penile, vaginal, and vulvar cancer. placeholder, will send new term requst to DOID Jie Zheng, Xingxian Li, Anna Maria Masci https://github.com/vaccineontology/VO/issues/677 disposition HPV associated cancer An infection that has as part organisms of the human papillomavirus (HPV). Jie Zheng https://github.com/vaccineontology/VO/issues/677 material entity HPV infection Either a tumor-specific or a tumor-associated antigen. Anna Maria Masci Barry Smith Jie Zheng Oliver He https://github.com/vaccineontology/VO/issues/677 material entity tumor antigen Cancer vaccine that prevents cancer formation and development. Anna Maria Masci Barry Smith Jie Zheng Oliver He https://github.com/vaccineontology/VO/issues/677 preventive cancer vaccine Cancer vaccine that aims to eliminate or control tumor cells. Anna Maria Masci Barry Smith Jie Zheng Oliver He https://github.com/vaccineontology/VO/issues/677 therapeutic cancer vaccine A cancer vaccine that uses whole cells to deliver cancer antigen(s). Oliver He PubMed:22595050 https://github.com/vaccineontology/VO/issues/683 whole cell cancer vaccine A whole cell cancer vaccine that uses whole tumor cells to deliver cancer antigen(s). Jie Zheng Oliver He PubMed:37355722 https://github.com/vaccineontology/VO/issues/683 whole tumor cell cancer vaccine A cancer vaccine that is composed of a plasmid vaccine vector (a circular double stranded DNA molecule) containing the whole of parts of genes encoding one or more vaccine antigen proteins. Jie Zheng DNA cancer vaccine Antigen that is only expressed by tumor cells. Anna Maria Masci Barry Smith Jie Zheng Oliver He material entity tumor-specific antigen Antigen that is overexpressed by tumor cells. Anna Maria Masci Barry Smith Jie Zheng Oliver He material entity tumor-associated antigen A vaccine that is designed to immunize against a single antigen or single strain of a pathogen. Jie Zheng Xingxian Li role vaccine monovalent role human papillomavirus vaccine with license for human use. Jie Zheng vaccine licensed human papillomavirus vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:C7828795 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1051 https://github.com/vaccineontology/VO/issues/343 2064 1051 Research Gene name: ERBB2 Cancer Her-2/neu Protein Subunit Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:17266027 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1052 https://github.com/vaccineontology/VO/issues/315 6528 1052 Research Gene name: SLC5A5 Cancer DNA Vaccine MIDGE/hNIS encoding hNIS protein Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:19526360 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1053 https://github.com/vaccineontology/VO/issues/318 2315863 1053 Research Gene name: Survivin Cancer DNA Vaccine pSURV encoding Survivin Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21448901 PubMed:31980914 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1047 https://github.com/vaccineontology/VO/issues/368 1485 1047 Research Gene name: CTAG1B Cancer Subunit NY-ESO-1 Protein Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1048 https://github.com/vaccineontology/VO/issues/314 13805 1048 Research Gene name: Eng Cancer DNA Vaccine encoding Endoglin Boosted with Recombinant Endoglin Protein Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:10678354 PubMed:8363286 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1049 https://github.com/vaccineontology/VO/issues/345 14972 1049 Research Gene name: H2-K1 Cancer recombinant vector vaccine encoding H-2Kb An xenogenic DNA vaccine encoding human TEM8 carried by attenuated Salmonella typhimurium to help reduce tumor growth and suppress angiogenesis in the tumors. Allen Xiang Oliver He PubMed:19609240 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1046 1046 Research cancer DNA vaccine encoding TEM8 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:10881691 PubMed:19188665 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1064 https://github.com/vaccineontology/VO/issues/319 4072 1064 Research Gene name: EPCAM Cancer EPCAM protein vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:19034678 PubMed:32164575 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1066 https://github.com/vaccineontology/VO/issues/371 7422 1066 Clinical trial Gene name: VEGFA Cancer VEGFA protein vaccine Allen Xiang Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1058 1058 cancer Retroviral vector vaccine encoding Cd40lg Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:/7533183 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1059 https://github.com/vaccineontology/VO/issues/317 12524 1059 Research Gene name: Cd86 Cancer DNA Vaccine pLXSHDmB7-2 encoding Cd86 Allen Xiang Oliver He prostate cancer DNA vaccine encoding prostatic acid phosphatase (PAP) Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:C5187854 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=891 https://github.com/vaccineontology/VO/issues/367 7015 891 Clinical trial Gene name: TERT Cancer Subunit GV1001 Protein Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:wler=tru VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=894 https://github.com/vaccineontology/VO/issues/366 1084 894 Research Gene name: CEACAM3 Cancer Subunit DC (Tat-CEA) vaccine example to be eventually removed example to be eventually removed failed exploratory term The term was used in an attempt to structure part of the ontology but in retrospect failed to do a good job Person:Alan Ruttenberg failed exploratory term metadata complete Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete. metadata complete organizational term Term created to ease viewing/sort terms for development purpose, and will not be included in a release organizational term ready for release Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release." ready for release metadata incomplete Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors. metadata incomplete uncurated Nothing done yet beyond assigning a unique class ID and proposing a preferred term. uncurated pending final vetting All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the term editor. pending final vetting placeholder removed placeholder removed terms merged An editor note should explain what were the merged terms and the reason for the merge. terms merged term imported This is to be used when the original term has been replaced by a term imported from an other ontology. An editor note should indicate what is the URI of the new term to use. term imported term split This is to be used when a term has been split in two or more new terms. An editor note should indicate the reason for the split and indicate the URIs of the new terms created. term split universal Hard to give a definition for. Intuitively a "natural kind" rather than a collection of any old things, which a class is able to be, formally. At the meta level, universals are defined as positives, are disjoint with their siblings, have single asserted parents. Alan Ruttenberg A Formal Theory of Substances, Qualities, and Universals, http://ontology.buffalo.edu/bfo/SQU.pdf universal defined class A defined class is a class that is defined by a set of logically necessary and sufficient conditions but is not a universal "definitions", in some readings, always are given by necessary and sufficient conditions. So one must be careful (and this is difficult sometimes) to distinguish between defined classes and universal. Alan Ruttenberg defined class named class expression A named class expression is a logical expression that is given a name. The name can be used in place of the expression. named class expressions are used in order to have more concise logical definition but their extensions may not be interesting classes on their own. In languages such as OWL, with no provisions for macros, these show up as actuall classes. Tools may with to not show them as such, and to replace uses of the macros with their expansions Alan Ruttenberg named class expression to be replaced with external ontology term Terms with this status should eventually replaced with a term from another ontology. Alan Ruttenberg group:OBI to be replaced with external ontology term requires discussion A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues. Alan Ruttenberg group:OBI requires discussion The term was added to the ontology on the assumption it was in scope, but it turned out later that it was not. This obsolesence reason should be used conservatively. Typical valid examples are: un-necessary grouping classes in disease ontologies, a phenotype term added on the assumption it was a disease. https://github.com/information-artifact-ontology/ontology-metadata/issues/77 https://orcid.org/0000-0001-5208-3432 out of scope Jie Zheng Xingxian Li Organon Teknika Corp., LLC